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ABSTRACT
Two separate bioanalytical methods were developed, validated and applied to determine
agricultural exposure to organochlorine and organophosphorus pesticides using different biological
matrices as reference sources.
The method that was validated for the quantification of the organochlorine compounds was used to
simultaneously determine β-endosulfan [6, 7, 8, 9, 10, 10- hexacloro-1, 5, 5a, 6, 9, 9a- hexahydro-
6, 9-methano-2, 4, 3-benzodioxathiepin-3- oxide] and one of its main metabolites, endosulfan
sulfate, in human serum. In a second bioanalytical method, urinary dialkylphosphate metabolites
have been assessed as markers to estimate the exposure to organophosphorus pesticides, focusing
on three of the six organophosphorus urinary metabolites, namely dimethyl phosphate, dimethyl
thiophosphate and diethyl phosphate.
For both the bioanalytical methods, liquid-liquid extraction was used for sample preparation and
high performance liquid chromatography with tandem mass spectrometry as detection method due
to its high sensitivity and selectivity.
Chromatographic separation for both bioanalytical methods was achieved by performing reverse
phase chromatography on C18 analytical columns. Isocratic elution with a mobile phase composed
of acetonitrile, methanol and water was employed for the analysis of the organochlorine
compounds while the organophosphorus compounds were eluted using gradient elution with a
mobile phase consisting of acetonitrile and 20 mM ammonium acetate.
A triple quadrupole mass spectrometer equipped with an electrospray ionization source operating
in the negative ionization mode was used for mass detection of all the analytes, employing multiple
reaction monitoring as scan mode.
Calibration standards and quality control samples for both analyses were prepared in the biological
matrix in which the samples for each determination were collected, i.e. serum for the determination
of the organochlorine compounds and stripped urine for the organophosphorus compounds.
Deuterated internal standards were used in the bioanalytical method for the determination of the
organophosphorus compounds whereas the organochlorine compounds were determined without
the use of an internal standard due to unavailability of suitable internal standards.
The calibration ranges for the determination of β-endosulfan and endosulfan sulfate were 0.8 ng/ml 
to 200 ng/ml and 0.117 ng/ml to 30 ng/ml, respectively, and 1.0 ng/ml to 30 ng/ml for the
dialkylphosphate metabolites of the organophosphorus compounds.
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These sensitive and robust quantitation methods were successfully applied to quantify 219 serum
and 187 urine samples that were collected from agricultural workers with the purpose to determine
whether they were exposed to any of the investigated organochlorine or organophosphorus
compounds.
No traces of β-endosulfan and endosulfan sulfate were found in any of the serum samples that were 
analyzed, however, significant amounts of the three organophosphorus compounds dimethyl
phosphate, dimethyl thiophosphate and diethyl phosphate were present in the urine samples.
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CHAPTER 1
INTRODUCTION
1.1 STUDY RATIONALE
Pesticides are used worldwide in the agriculture industry against pests that can damage crops, in
order to avoid or reduce losses and improve product quality. However, with this extensive use of
pesticides, human health has become a major concern as these chemicals are designed to have
adverse biological effect on a variety of organisms. Pesticides are organic pollutants and are the
only toxic substance released on an international scale into the environment to kill living organisms
[1].
Based on their functional groups and toxicity, pesticides are generally divided into five categories
namely organophosphorus pesticides, organochlorine pesticides, carbamate pesticides, pyrethroids
and herbicides [2] [3].
Many contemporary agricultural pesticides are hormonally active [4] with the potential to cause
male reproductive health effects in exposed persons. The Clinical Study Protocol titled “Male
reproductive health effects due to pesticides among farm residents in the Western Cape” was
approved by the Human Research Ethics Committee of the Faculty of Health Sciences, University
of Cape Town in 2005 (REC REF: 279/2005) and proposed the investigation of the effects of
exposure to pesticides on male subjects in the target area. A clinical trial was conducted in
compliance with this Clinical Study Protocol and ethical principles that have their origins in the
Declaration of Helsinki of the 25th World Medical Assembly [5].
South Africa is the principal user of pesticides in Southern Africa and previous investigations
indicated pesticide use in the Western Cape agricultural areas to be substantial [6] [7]. Some of the
most commonly used pesticides in the Western Cape, identified in previous surveys [6] [7] [8],
were reported to have the potential to adversely affect the male reproductive systems of laboratory
animals, and/or wildlife, or have been related to adverse male reproductive outcomes in humans.
Candidate pesticides included chlorpyrifos, cypermethrin, deltamethrin, dichlorvos, dinitro-ortho-
cresol (DNOC), endosulfan, fenarimol, fenvelerate, glyphosate, iprodione, parathion, procloraz,
vinclozolin, linuron and procymidon.
Previous studies reported the detection of endosulfan, chlorpyrifos, fenarimol, deltamethrin and
iprodione in Western Cape rural surface and groundwater, including drinking water [8] [9] [10].
Endosulfan and chlorpyrifos concentrations exceeding the World Health Organization (WHO)
drinking water standard of 0.1 µg/l were reported in about a third of the samples tested.
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The proposed study based on the above-mentioned Clinical Study Protocol was aimed at
monitoring exposure to organochlorine or organophosphate pesticides in biological samples
collected from rural residents in the Western Cape. Therefore, serum and urine samples from such
subjects were collected and analytical methods were developed to determine the levels of the
pesticides and/or the metabolites thereof in the biological matrix. The samples were obtained from
male farm workers and farm residents, including children, adolescents and adults from four rural
areas in the Western Cape. Three of these areas are agriculturally intensive where pesticides have
previously been detected in water supplies [8] [9] [10], including the Hex River Valley where
grape farming is practiced, Grabouw where pome fruit farming is predominant and Piketberg
where wheat and fruit farming is practiced. Controls were collected from similar male subjects
residing in neighboring non-agricultural areas.
Venous blood samples, 10 ml, for the determination of the organochlorine pesticides and first
morning void urine samples for the determination of organophosphates were collected into labeled
tubes. The blood samples were allowed to clot and serum was prepared from the clotted blood.
Urine samples were collected in plastic containers topped with a plastic cap. The urine and serum
samples were stored frozen at ~ -20°C in solvent pre-cleaned containers.
Occupational effects were investigated amongst adults from all four areas using both years of
exposure as calculated using a questionnaire to describe the application status. A physical
examination of the reproductive system was performed by a professional health practitioner,
recording height, weight, secondary sexual characteristics and sexual maturity rating according to
the Tanner score [11].
1.1.1 Endosulfan
Endosulfan, the common name for 6, 7, 8, 9, 10, 10- hexacloro-1, 5, 5a, 6, 9, 9a- hexahydro-6, 9-
methano-2, 4, 3-benzodioxathiepin-3- oxide (see Table 1.1), is an organochlorine insecticide [12]
developed and introduced by Farbwerke-Hoechst A.G under the registered trademark “Thiodan”
[13], and was first registered for use in the United States of America in 1954 [14]. Chemically
similar to dichlorodiphenyltrichloroethane (DDT), the agricultural industry uses this insecticide to
protect a variety of crops against several species of pests [15]. Although most organochlorine
pesticides have been forbidden in most parts of the world, the compounds and their metabolites are
still in existence in biological matrices due to their high lipophilic properties [16]. Manual and
aerial spray used for agricultural purposes are the major contributors of endosulfan residue in soil
and water.
Contact with this insecticide is common, especially for agricultural workers, as well as for
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consumers buying the food products from crops on which the pesticides are used [17]. Degradation
of endosulfan in soil is affected by environmental conditions, and studies have shown that
degradation is reduced at lower temperatures and lower water content [18].
Endosulfan is a solid substance that ranges from brown to cream colored. It has been reported to be
light sensitive and therefore it is recommended that samples containing endosulfan be prepared,
stored and analyzed under protected lighting condition [19]. Technical endosulfan consists of two
stereoisomers that differ in the configuration of the 7-member dioxothiepin-oxide ring. The two
isomers are known as the alpha-isomer (α-isomer) and beta-isomer (β-isomer) and are present in 
the ratio of 2:1 to 7:3, depending on the mixture applied [14] [20] [21]. Schmidt et al. indicated
that the α-isomer is more toxic than the β-isomer and that conversion of the β-isomer to the 
α-isomer can occur, which may be irreversible [22]. Significant conversion of the β-isomer to the 
α-isomer has been reported, but only one instance of the conversion from the α-isomer to the 
β-isomer has been described. The conversion quantities of the α-isomer was insignificant (less than 
1% conversion), and additional work would be required to confirm this reported conversion
process [22] [23] [24].
Similar to other chlorinated pesticides, the isomers of endosulfans are semi-volatile and have
similar vapour pressures causing volatilization into the atmosphere and allowing subsequent
atmospheric transport and deposition. The vapour pressures of the α- and β-isomers are similar, but 
the aqueous solubility of the β-isomer is much greater than that of the α-isomer allowing the 
β-isomer to have a lower Henry's Law constant (H) and will therefore more readily partition to 
aqueous phases [18].
The chemical properties of endosulfan, α-endosulfan and β-endosulfan, are listed in Tables 1-1, 1-2 
and 1-3, respectively.
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Table 1.1 Chemical properties of endosulfan
Chemical Structure
O
S
O
O
Cl
Cl
Cl
Cl
Cl
Cl
Chemical name Endosulfan
Chemical name Synonyms
6,7,8,9,10,10-Hexachloro-1,5,5a,6,9,9a-hexahydro-6,9-methano-2,4,3-
benzodioxathiepine-3-oxide;Endosulfan technical; 5-Norbornene-2,3-
dimethanol1,4,5,6,7,7-hexachlorocyclic sulfit
Registered trade names Thiodan; Thionex; Thionate Malix; HOE 2671; FMC 5462; Cyclodan;Thifor; Beosit; Chlorthiepin; Endosulphanb
Chemical formula C9H6Cl6O3S
Molecular weight: 406.95Da
Monoisotopic mass: 403.816Da
Table 1-2 Chemical properties of α- endosulfan 
Chemical Structure
O
S
O
O
Cl
Cl
Cl
Cl
Cl
Cl
Chemical name α- Endosulfan
Chemical name Synonyms
Endosulfan I; Endosulfan A, 6,9-Methano2,4,3- benzodioxathiepin,
6,7,8,9,10,10-hexachloro1,5,5a,6,9,9a- hexahydro-, 3-oxide (3α, 5a β, 6α, 
9a α, 9β)-; 5- Norbornene-2,3-dimethanol, 1,4,5,6,7,7-hexachloro-, cyclic 
sulfite, endo-
b
Registered trade name(s) α-Benzoepin; α-Thiodan; α -Thionex
c
Chemical formula C9H6Cl6O3S
Molecular weight: 406.95Da
Monoisotopic mass: 403.816Da
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Table 1-3 Chemical properties of β-endosulfan 
Chemical Structure
O
S
O
O
Cl
Cl
Cl
Cl
Cl
Cl
Chemical name β-Endosulfan 
Chemical name Synonyms
EndosulfanII; Endosulfan B,6,7,9,10,10-- Hexachloro1,5,5a,6,9,9a-
hexahydro-6,9-methano-2,4,3- benzodiozathiepin3-oxide, (3α, 5aα, 6β, 9β,
9aα)-; 5 Norbornene-2,3-dimethanol, 1,4,5,6,7,7-hexachloro-,  cyclic 
sulfite, endo-
b
Registered trade name(s) β-Benzoepin; β-Thiodan; β -Thionex
c
Chemical formula C9H6Cl6O3S
Molecular weight: 406.95Da
Monoisotopic mass: 403.816Da
Exposure to endosulfan is not only determined by the presence of the two intact isomers in
biological matrices, but also by the presence of its metabolites. In humans, endosulfan is known to
be metabolized to endosulfan sulfate, endosulfan diol, endosulfan ether, endosulfan hydroxy-ether
and endosulfan lactone [16]. Endosulfan sulfate, formed metabolically from both the α-isomer and 
β-isomer, is equally toxic and is more persistent in the environment than both of its parent 
compounds [18] [25]. The chemical properties of endosulfan metabolites are listed in Tables 1-4,
1-5, 1-6, 1-7 and 1-8.
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Table 1-4 Chemical properties of endosulfan sulfate
Chemical Structure
O
S
O
OCl
Cl
Cl
Cl
Cl
Cl
O
Chemical name Endosulfan sulfate
Chemical formula C9H6Cl6O4S
Molecular weight: 422.924Da
Monoisotopic mass: 419.811Da
Table 1-5 Chemical properties of endosulfan ether
Chemical Structure
O
Cl
Cl
Cl
Cl
Cl
Cl
Chemical name Endosulfan ether
Chemical formula C9H6Cl6O
Molecular weight: 342.861Da
Monoisotopic mass: 339.854Da
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Table 1-6 Chemical properties of endosulfan hydroxy ether
Chemical Structure
O
Cl
Cl
Cl
Cl
Cl
Cl
OH
Chemical name Endosulfan hydroxyl ether
Chemical formula C9H6Cl6O2
Molecular weight: 358.860Da
Monoisotopic mass: 355.849Da
Table 1-7 Chemical properties of endosulfan diol
Chemical Structure
OH
Cl
Cl
Cl
Cl
Cl
Cl
OH
Chemical name Endosulfan diol
Chemical formula C9H8Cl6O2
Molecular weight: 360.876Da
Monoisotopic mass: 357.865Da
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Table 1-8 Chemical properties of endosulfan lactone
Chemical Structure
O
Cl
Cl
Cl
Cl
Cl
Cl
O
Chemical name Endosulfan lactone
Chemical formula C9H4Cl6O2
Molecular weight: 356.844Da
Monoisotopic mass: 353.834Da
Endosulfan can enter the body through the skin, by inhalation and by drinking and/or eating
contaminated products [26]. Once absorbed, endosulfan accumulates in fatty tissues and affects the
nervous system to cause headaches, nausea, seizures and in extreme cases can lead to death [27].
Additionally, various studies have shown that pesticides such as endosulfan causes male
reproductive organ abnormalities [14] due to its anti-androgenic and estrogenic capabilities
demonstrated in vitro [28]. Endosulfan is also extremely toxic to fish and is implicated in
genotoxicity and neurotoxicity in mammal species [29].
The most widely published analytical method for the determination of organochlorine pesticides is
gas chromatography (GC) with electron capture detection [16] [26] [30] [20]. In this study the
emphasis was however on the employment of the fast developing technology of high performance
liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) to detect and quantify
these molecules in biological matrices. This very well developed technology, focused on sensitive
and highly specific detection, is now commonly available in most bioanalytical laboratories. The
development of an LC-MS/MS assay to analyze organochlorine pesticides is therefore considered
as a worthy pursuit.
1.1.2 Organophosphates
Organophosphate pesticides are also widely used in developed and developing countries, both in
agricultural and residential applications and these compounds have the same adverse effects on
human health than that indicated for the organochlorine pesticides [31] [32]. Because of the
widespread use of organophosphate pesticides, well documented studies have shown that exposure
to these pesticides are almost impossible to avoid [33].
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Most organophosphates are metabolised in humans to six common dialkylphosphate (DAP)
metabolites, namely dimethyl phosphate (DMP), dimethyl thiophosphate (DMTP), dimethyl-
dithiophosphate (DMDTP), diethyl phosphate (DEP), diethyl thiophosphate (DETP) and diethyl
dithiophosphate (DEDTP) [34] [35] [36] [37], which are detectable in urine. The presence of these
metabolites in urine is used as markers for exposure to organophosphates [32] [34].
The chemical structures of the six dialkylphosphate metabolites are listed in Tables 1-9, 1-10, 1-11,
1-12, 1-13 and 1-14.
Table 1-9 Chemical properties of dimethylphosphate
Chemical Structure
Chemical name Dimethylphosphate
Chemical formula C2H7O4P
Molecular weight: 126.048Da
Monoisotopic mass: 126.008Da
Table 1-10 Chemical Identity of Dimethyl thiophosphate
Chemical Structure
Chemical name Dimethyl thiophosphate
Chemical formula C2H7O3PS
Molecular weight: 142.113Da
Monoisotopic mass: 141.985Da
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Table 1-11 Chemical properties of dimethyl dithiophosphate
Chemical Structure
Chemical name Dimethyl-dithiophosphate
Chemical formula C2H7O2PS2
Molecular weight: 158.179Da
Monoisotopic mass: 157.962Da
Table 1-12 Chemical properties of diethyl phosphate
Chemical Structure
Chemical name Diethyl phosphate
Chemical formula C4H11O4P
Molecular weight: 154.101Da
Monoisotopic mass: 154.039Da
Table 1-13 Chemical Identity of diethyl thiophosphate
Chemical Structure
Chemical name Diethyl thiophosphate
Chemical formula C4H11O3PS
Molecular weight: 170.167Da
Monoisotopic mass: 170.016Da
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Table 1-14 Chemical properties of diethyl dithiophosphate
Chemical Structure
Chemical name Diethyl dithiophosphate
Chemical formula C4H11O2PS2
Molecular weight: 186.232Da
Monoisotopic mass: 185.993Da
Analytical methods for the determination of DAP metabolites described in the literature mainly
involve gas chromatography coupled to tandem mass spectrometry (GC-MS/MS) [33] [38] [32].
This study describes a sensitive bioanalytical method based on LC-MS/MS, which was used to
screen urine samples of agricultural workers exposed to organophosphate pesticides.
1.2 INTRODUCTION TO BIOANALYTICAL METHODS
In the modern era, bioanalytical methods are mainly used to generate quantitative concentration
data to establish bioavailability, bioequivalence, pharmacokinetic and toxicokinetic parameters of
bio-active exogenous molecules administered to humans and other mammals [39].
To obtain knowledge regarding these parameters, measurable concentrations in different biological
matrices such as plasma, serum, blood, urine and saliva are determined. For acceptance, such data
needs to meet strict criteria set by the regulatory authorities and therefore a bioanalytical method
which is the basis for obtaining the data, also needs to conform to strict criteria [40] [41]. A well-
defined work-flow is used to establish an acceptable analytical method, starting with literature
research to obtain as much as possible available information, followed by method development to
establish an acceptable, well performing analytical method, which is then validated before it can be
used for the measurement of study samples.
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1.3 BIOANALYTICAL METHOD DEVELOPMENT
1.3.1 Method development
During method development, different experiments are conducted to ascertain the optimal
techniques with which an analyte can be determined and measured in a biological matrix.
Development of an analytical method is complex and expensive and involves many considerations
such as concentration levels, biological matrix of a sample, chemical properties of the analyte and
speed of the analyses [40]. Method development consists of three essential parts: sample
preparation and extraction of the analyte from the biological matrix, chromatographic separation of
the analyte from extracted matrix components and detection of the analyte by a sensitive and
specific detection method [41].
A literature survey of published analytical methods supplies useful information to set up a strategic
action plan for method development. Such a survey should be as specific as possible, focused on
the specific analyte detected in the specific biological matrix [42] [43]. The strategic plan for
method development should include steps to optimize the method concerning aspects such as
selectivity, accuracy, precision, recovery, sensitivity, reproducibility and stability of the analyte in
spiked biological matrices [42] [44]. An example of the work-flow involved in such a plan is
depicted in Figure 1.1.
Figure 1.1 Strategic plan for bioanalytical method development [45]
Since a bioanalytical method will be used for the creation of important data which may eventually
be employed by the Toxicology industry in the development of vital medicinal preparations, strict
rules are applied to this scientific field and the foundation of adherence to these rules is a well-
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developed robust and reliable analytical method. Much attention should therefore be given to the
development thereof and the major points of interest in method development are briefly discussed
in the following sections [42] [43].
1.3.2 Analyte
The analyte is the specific chemical moiety being measured, which can be an intact drug, a
biomolecule or its derivative, metabolite and/or degradation product present in the biologic matrix
[42] [43]. This compound has to be acquired as a pure reference standard which is usually
commercially available.
1.3.3 Internal Standard
The use of an internal standard is common practice in bioanalysis and involves the addition of a
compound which is similar to the analyte, to each sample being analyzed, in order to compensate
for variations in the analytical procedure. Each sample being analyzed should therefore contain the
same amount of the internal standard, added as soon as possible during sample preparation. The
similarity to the analyte depends on the nature of the detection method. If mass spectrometry is
used to detect the analyte, the preferred internal standard would be a stable isotope-labeled
molecule of the analyte, which means that the internal standard has the same chemical
characteristics as the analyte, but can be separately detected based on the different mass properties
of the two molecules. Alternatively, a molecule which is structurally and chemically similar, but
not identical to the analyte may be used as internal standard. It is important to assure that the
difference between the analyte and the internal standard is maintained throughout the analytical
process and also that the internal standard is not intrinsically present in the biological matrix, such
as for instance a metabolite or break-down product of the analyte. When acquiring an internal
standard it is also important to assure that the preparation used does not contain the analyte as an
impurity, such as the non-labeled analyte being present in a preparation of the stable isotope-
labeled compound used as an internal standard [43] [46].
1.3.4 Biological matrix
In bioanalysis, the matrix is the medium in which the analyte has to be measured and which can be
defined as a discrete material of biological origin that can be sampled and processed in a
reproducible manner. These discrete materials can be blood or its separable components such as
serum and plasma, or other body fluids such as urine, sputum, saliva, cerebrospinal fluid etc. [43].
The analytical method will be developed to specifically analyze the analyte in the biological matrix
and therefore an appropriate volume of the biological matrix, devoid of the analyte (blank matrix),
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has to be available for the development of the method. This blank matrix will have to be available
later on as well, during method validation and also for the routine analysis of study samples, in
order to prepare calibration standards (STDs) and quality control samples (QCs). The blank matrix
is normally collected from voluntary donors who give consent to the use of the matrix [46].
1.3.5 Sample preparation and extraction procedures
General considerations such as the environment and management of a sample must be considered
during sample preparation and extraction. The suitability of sample containers needs to be explored
as some analytes may adsorb onto plastic and/or glass surfaces and certain solvent mixtures may
dissolve molecular components from the container material, increasing the complexity of the
sample. The thermal stability and photo stability of the analyte must also be taken into account,
necessitating the preparation being performed at lower or higher temperatures and/or the use of
light protected containers [45]. Once the appropriate containers and handling conditions have been
established, such measures can be applied to the sample collection process.
The study samples per se are usually not suitable for analysis since the matrix may be too complex,
too dilute for direct sample injection, or incompatible with the mobile phase. In such instances,
some sample cleanup procedures such as extraction must be investigated and evaluated.
Sample extraction techniques are the processes whereby biological samples are subjected to
procedures that would transfer the analyte from the aqueous biological matrix into a suitable
solvent. During this process, background components in the biological matrix, which may interfere
with the detection and measurements of the analyte, can be removed. The sensitivity of the method
may also be increased due to the concentrating effect that can be applied during extraction. The end
product of extraction should thus be focused on the reconstitution of the analyte in a solvent in
which it is optimally detectable. [47].
Frequently used sample preparation techniques include protein precipitation, liquid-liquid
extraction and solid phase extraction.
1.3.5.1 Protein precipitation
Protein precipitation is used to remove proteins from the biological matrix resulting in a relatively
clean preparation containing the analyte. This technique is thus relevant to samples in which the
matrix contains proteins, such as plasma and/or serum.
Proteins can be precipitated by the addition of solvents that render the proteins insoluble, upon
which it can be removed by centrifugation, resulting in the analyte being present in the supernatant.
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For this purpose, water soluble organic solvents such as acetonitrile, methanol or ethanol can be
used. Proteins will also precipitate due to the addition of certain salts, such as ammonium sulfate or
by drastically adjusting the pH by the addition of strong organic acids such as trichloroacetic acid
(TCA) to the biological sample [45].
The protein-free supernatant can either be analyzed directly or evaporated to dryness and thereafter
reconstituted in a more suitable injection solvent prior to analysis. Protein precipitation is a simple
and less time consuming technique when compared to liquid-liquid extraction (LLE) and solid-
phase extraction (SPE). The disadvantage of protein precipitation is however that it is relatively
non-selective and many endogenous compounds that can interfere during analysis may still be
present in the supernatant [48].
1.3.5.2 Liquid-liquid extraction
This sample preparation technique is based on the partitioning of an analyte between two
immiscible solvents and entails the addition of an organic solvent to the sample which is in an
aqueous solution. The purpose is to optimally displace the analyte into the organic phase. To
achieve this, the polarity of the analyte can be manipulated by adjustment of the pH of the sample
(aqueous phase) to render the analyte as non-polar as possible. The required pH will depend on the
pKa of the analyte and in general, basic analyte molecules will optimally transfer to the organic
phase at high pH (where they are less protonated), whereas acidic molecules will optimally transfer
to the organic phase at low pH (where they will be protonated). A series of experiments assessing
the recovery of the analyte in the organic phase at different pH values is therefore always necessary
as part of the method development process [49].
Although the adjustment of the sample pH can manipulate the polarity of the analyte by controlling
ionization of basic and acidic groups, each molecule has an intrinsic polarity even when not
ionized, based on the functional groups within the molecule. An intrinsically polar molecule will
therefore not optimally transfer to an organic phase that is too non-polar and a highly non-polar
molecule will not transfer to a high degree to an intrinsically polar organic solvent. Because there
are differences in the polarity of different water-immiscible solvents, the extraction can be
optimized by choosing an organic solvent with the correct polarity. The different polarity indexes
of some commonly used organic solvents are indicated in Table 1.15 where the most non-polar
solvent, pentane, has a polarity index of 0.0 as compared to water with a polarity index of 10.2. To
obtain the optimal polarity of the organic solvent, mixtures of solvents can also be used and the
adjustment of this should also be an important part of the method development process.
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Table 1-15 Polarity indexes of commonly used organic solvents [50]
Solvent Polarity Index (P’)
Pentane 0.0
Hexane 0.1
Cyclohexane 0.2
Toluene 2.4
Methyl t-Butyl Ether 2.5
Ethyl Ether 2.8
Dichloromethane 3.1
Chloroform 4.1
Ethyl Acetate 4.4
Water 10.2
Liquid-liquid extraction is practically executed by adding an appropriate volume of a suitable
organic solvent to the sample, usually three times that of the volume of the sample, followed by
thorough mixing for an appropriate period to allow optimal transfer of the analyte. After the
mixing process, the separation of the phases is allowed to take place (can be expedited by low-g
centrifugation). The organic phase, containing the analyte, is then separated from the aqueous
phase by decanting the organic phase to a clean container. The volatile organic solvent is then
removed by evaporation and the residue reconstituted in a solvent in which the analyte is soluble
and ready for analysis.
Liquid-liquid extraction is often preferred over sample preparation by simple protein precipitation
as it results in a “cleaner” preparation of the analyte in which most of the unwanted, mostly more
polar compounds, have been removed. Liquid-liquid extraction also allows for the enrichment of
the analyte, because the final reconstitution of the sample can be done in a lower volume than that
of the initial sample volume.
1.3.5.3 Solid-phase extraction (SPE)
This preparation technique can be used to establish three important prerequisites during sample
preparation, namely removal of interfering matrix components, changing the solvent from matrix
to an appropriate reconstitution solution for subsequent analysis, and enrichment of the analyte
[51].
Similar to liquid-liquid extraction, the analyte is partitioned between two immiscible phases during
SPE. Instead of using a liquid organic phase, the second phase is a stationary phase bonded to
insoluble, solid particles (the solid phase). Depending on the chemical character of the analyte, a
bonded phase will be selected that has an affinity for the analyte. The aqueous sample containing
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the analyte is then passed through a column packed with the bonded phase resulting in the analyte
associating with the bonded phase and therefore being retained in the column. In this way
unwanted compounds in the sample pass through the column and are washed out of the column.
The analyte can then be eluted from the column by passing a liquid phase through the column for
which the analyte has a higher affinity than the bonded phase. Alternatively, the bonded phase and
the condition of the sample can be selected so that unwanted compounds in the sample are retained
on the bonded phase and the analyte pass through, devoid of the unwanted material [51] [52].
The principle by which association between the analyte and the bonded phase takes place is
normally based on either hydrophobic or ionic interactions. Similar to liquid-liquid extraction, the
pH of the sample can be adjusted so as to render the analyte in the most favorable polarity
condition to induce the desired interaction. The work-flow by which SPE is accomplished is
explained graphically in Figure 1.2.
Figure 1.2 Schematic representation of a solid phase extraction process [45]
1.3.6 Separation by Liquid Chromatography
Following sample preparation as described in the previous sections, the sample is usually not ready
for analysis on the detection system, since there are still biological components present that may
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interfere with the detection of the analyte which could lead to incorrect results during quantitative
or qualitative analysis. The final preparative step for the introduction of the analyte into the
detection system is therefore usually a chromatographic procedure that would separate the analyte
from most of the matrix components. The most commonly used chromatographic technique for the
determination of small molecules in extracts of biological matrices is high performance liquid
chromatography (HPLC) [53].
A typical HPLC chromatograph consists of a solvent delivery system comprising a solvent
degasser and a high pressure pump that delivers the mobile phase to a packed column. Between the
pump and the column, an automated injector introduces the sample into the solvent flow.
Separation takes place in the column which is packed with a stationary phase and the separation
process depends on the chemical nature of the analyte which will allow it to associate to a specific
degree with the packing material within the column. This association will then retard the flow of
the analyte through the column and under the ideal conditions of packing material and mobile
phase, the analyte will separate from other compounds still in the sample extract, so that only the
analyte will flow from the column into the detection system at a given time (the retention time)
[54].
The principles controlling the association of the analyte with the material in the column is the same
as that employed during SPE, therefore relying on the polarity of the analyte and the material in the
column. The most widely used association is that of hydrophobic interaction resulting in reverse
phase chromatography during which hydrophobic groups on the packing material in the column
will associate with hydrophobic groups in the analyte molecule, therefore retaining it in the column
and allowing more polar compounds to elute from the column before the analyte. By adjusting the
organic content in the column, the retention time of the analyte in the column can be controlled
[54] [55] [56].
Because HPLC can employ volatile mobile phases, this separation technique can readily be
connected directly to mass spectrometry in order to create a very versatile and specific detection
technique widely used in the bioanalytical field, termed LC-MS or LC-MS/MS [57]. Both
quantitative and qualitative analyses are accomplished using this methodology.
1.3.7 Mass spectrometry
Mass spectrometry is an analytical technique that can be used selectively to detect and determine
the presence and amount of many biological relevant compounds in biological matrices. With this
powerful technique, one can quantify known compounds, identify unknown compounds and reveal
the chemical properties of different compounds [58]. By mass spectrometry the mass to charge
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ratio (m/z) of ions is determined providing information regarding the molecular mass of a molecule
as well as information as to its structural composition through fragmentation of the ion and
analysis of the mass of its fragments [54] [59].
A mass spectrometer can be divided into three basic components, namely an ionization source, a
mass analyzer, and an ion detector. The analyzer and detector of the mass spectrometer, and often
the ionization source too, are maintained under high vacuum inside the instrument (vacuum
chamber), enabling the ions to travel from one end of the instrument to the other without any
interruption from air molecules [54].
Mass spectrometers used as detectors for HPLC during bioanalysis should be selective and
sensitive, and characterized by a linear response for concentrations over a wide dynamic range.
The detector should be reliable with good reproducibility and stability, and have a fast response
time [60]. Quadrupole mass spectrometers, mostly employed as tandem instruments, provide the
combination of an effective and sensitive mass analyzer with versatile analytical possibilities based
on fragmentation analysis of solute molecules [51]. These instruments were used for the study
described here and will therefore be discussed in more detail.
A schematic representation of a triple quadrupole mass analyzer is shown in figure 1.3.
Figure 1.3 Components and schematic view of a triple quadrupole mass spectrometer [58]
1.3.8 The ionization source and ionization techniques relevant to bioanalysis
Triple quadrupole mass spectrometers used during bioanalysis mostly employ atmospheric
pressure ionization (API) to accomplish three basic tasks, namely conversion of solutes to gaseous
phase while performing ionization, separation of ions according to their m/z ratio and then
detecting the separated ions [52] [54]. The API techniques most commonly employed in current
LC-MC interphases are electrospray ionization (ESI), atmospheric pressure chemical ionization
(APCI) and atmospheric pressure photo ionization (APPI). These techniques allow the ionization
of various polar and non-polar compounds at trace level concentrations.
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1.3.8.1 Electrospray ionizaion (ESI)
In an electrospray ionization (ESI) interface, the inflow of solvent containing the sample is coupled
to a metal capillary on which a high direct current (DC) charge (about 4000V) is applied, either
positive or negative. The charge is transferred to the surface of the solvent which cause the solvent
stream to break up in a spray of small droplets, all of which are covered with the same charge so
that they repel each other, giving rise to the typical electrospray [59].
The charged capillary is usually situated within another capillary through which a flow of nitrogen
gas is applied. The source is also heated and the combination of these two factors causes
evaporation of the solvent from the charged droplets, resulting in ever decreasing sizes of the
droplets. Surface charges will therefore be compressed until the repulsion of like charges overcome
the surface tension of the droplets, at which stage the droplets will break apart in a process termed
Coulombic explosion. Except for the solvent, the droplets will also contain ions of the same charge
than that on the surface of the droplets. These ions will also be subjected to the increasing
Coulombic forces until they escape the droplets and thus enter the gas phase. Finally, the total
dissolution of the droplets will result in total desolvation with the ions left in the gas phase. Ions
will then be drawn into the analyzer section of the instrument while uncharged particles can be
excluded by applying an orthogonal flow of gas [51] [59]. The electrospray process is graphically
demonstrated in figure 1.4.
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Figure 1.4 Electrospray interface and schematic ESI process [61]
Electrospray ionization is considered a mild ionization process, since the ionization of the analyte
molecules already takes place to a large extent in the solvent before the electrospray process.
Cations are mostly formed by protonation resulting in pseudo-molecular cations with m/z of one
mass unit more than the monoisotopic mass of the molecules. An anion is formed from a molecule
that more readily deprotonates resulting in a pseudo-molecular anion which will have a m/z value
of one mass unit lower than the monoisotopic mass of the molecule. Due to the mildness of the
ionization process, adducts of the molecular ions with other cations or anions present in the source
can also be created, these then having m/z values equal to the sum of the monoisotopic masses of
the molecule and the specific cation or anion [59]. These ionization mechanisms are summarized in
Scheme 1.
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Scheme 1: Mechanisms of ionization during electrospray ionization
1.3.8.2 Atmospheric pressure chemical ionization (APCI)
In an APCI source the capillary through which the solvent is delivered ends in a short ceramic tube
which can be heated to high temperatures. Heated nitrogen acting as a nebulizing gas also flows
through the tube unidirectional to the flow of the solvent. The combination of heat and gas rapidly
vaporizes the solvent so that dry vapor exits in the tube. In front of the opening a metal pin is
situated to which as high voltage is applied causing a corona discharge at the tip of the pin. The
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vaporized solvent molecules entering this area of corona discharge are then ionized. As for
electrospray ionization, APCI can be either in the positive or the negative mode. Due to the
presence of water in the solvent, the primary ion species formed during positive ionization is
oxonium (H3O+). Organic solvents in the mobile phase can result in the formation of for instance
protonated methyloxonium ions (CH3OH2+) if methanol is present or methylidyne ammonium
(CHNH+) if acetonitrile is present. In the negative mode, mainly hydroxide (OH-) ions result from
the deprotonation of water while the presence of methanol or acetonitrile can give rise to
methanolate ions (CH3O-) or cyanide ions (CN-), respectively. If an analyte is present in the
solvent, it will thus also be transformed to the gas phase and enter the corona discharge. Direct
ionization of the analyte may occur, but mostly, chemical ionization will occur by transfer of the
charge from the solvent ions to the analyte molecules, forming protonated pseudo-molecular ions
in the positive mode or deprotonated pseudo-molecular ions in the negative mode. Analyte ions
formed during this process will then be extracted and transferred to the rest of the instrument as
explained above for ESI [51] [54] [59].
The elevated temperature and more robust vaporization functionality during APCI allow the use of
higher solvent flow rates from the HPLC than is possible with electrospray ionization. The process
is graphically demonstrated in figure 1.5.
Figure 1.5 Atmospheric pressure chemical ionization interface and schematic APCI process [61]
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Atmospheric pressure chemical ionization is typically used for less polar compounds which may
not readily be ionized by the milder electrospray ionization process. The ionization mechanisms
relevant to APCI are summarized in Scheme 2.
Scheme 2: Mechanisms of ionization during atmospheric pressure chemical ionization
1.3.8.3 Atmospheric pressure photo ionization (APPI)
Atmospheric pressure photo ionization (APPI) technology is an evolution of APCI. Vaporization in
an APPI source is identical to that in the APCI source. However, instead of creating ions with a
corona discharge needle, an ultraviolet (UV) light source is situated in front of the outflow from
the vaporization tube.
Ionization depends on the action of high energy photons emitted by the UV source. Although direct
ionization of the vaporized solvent molecules is possible, a dopant solvent is normally added to
promote ionization by UV radiation. Due to their intrinsic photo-reactivity, the most common
dopants are toluene and acetone, which would absorb the high energy photons causing ionization
of the dopant which further leads to a cascade of ion-molecule reactions involving solvent
molecules introduced by the mobile phase. If vaporized analyte molecules are present, ionization
may occur directly if the molecule is photo-reactive. Most commonly however, ionization will
occur by either proton transfer or by charge exchange between the solvent or dopant ions and the
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analyte molecules. In the positive ion mode, both [M+H] + as well as [M] + ions can be formed
depending on the molecule and whether the ions were created by proton transfer or charge transfer.
In the negative ion mode, [M-H]- ions are predominantly formed by deprotonation [54] [62].
A schematic representation of an APPI source is shown in figure 1.6, while ionization mechanisms
during APPI are summarized in Scheme 3.
Figure 1.6 Atmospheric pressure photo ionization interface and schematic APPI process [61]
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Scheme 3: Mechanisms for ionization in the positive mode during atmospheric pressure
photo ionization
1.3.9 Mass analyzers: the quadrupole analyzer
As mentioned before, the instruments relevant to this study employ quadrupoles as mass analyzers.
These are structures within the vacuum chamber, consisting of four separate metal rods arranged so
that a channel is formed between them. Ions formed in the ionization source are focused by
electrostatic lenses and drawn into the vacuum compartment by the opposing electrostatic force of
the ion lenses. The quadrupoles are aligned in such a way that the ions will move through the
channel formed by the four rods of the quadrupole. Opposing direct current (DC) and alternating
radio frequencies (RF) voltages are applied to the rods which create electrostatic forces on the
surfaces of the rods. By keeping the frequency of the applied RF voltages constant and increasing
the amplitude thereof, only ions of a specified mass-to-charge ratio (m/z) will follow a stable
oscillation path and thus pass through the quadrupole analyzer and impinge on the detector at a
given instance. Quadrupole analyzers are therefore also termed mass filters. Collision of ions on
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the surface of the detector will cause an increasing cascade of electrons, multiplying the signal
strength to a level where the event can be detected as an electronic signal which can then be
recorded and integrated so that the signal strength is proportional to the abundance of ions. This
then forms the basis by which the quantity of an analyte extracted from a matrix and subjected to
LC/MS analysis, can be measured [54] [59].
To increase the specificity and sensitivity by which analytes can be measured, the more advanced
instruments used for quantitative analysis employ two quadrupole mass analyzers in tandem,
separated in space by a non-analyzing quadrupole in which ions can be fragmented. This
fragmentation process is termed collision induced dissociation (CID) and will be further discussed
in section 1.3.9.2 below.
The tandem array of quadrupoles resulted in these instruments being termed triple quadrupole mass
spectrometers and the arrangement of major components therein is graphically demonstrated in
figure 1.7.
Figure 1.7. Main components of a triple quadrupole mass spectrometer [63]
The tandem array of quadrupole mass analyzers in the triple quadrupole mass spectrometer allows
for a range of scan types possible with this instrument. The three scan types applicable to this
study, precursor ion scans, product ion scans and multiple reaction monitoring will be briefly
discussed in the following sections [59] [63].
1.3.9.1 Precursor ion scans (Q1 scan)
The m/z values of all ions produced in the ionization source can be determined by continuous
scanning of a pre-set m/z range using Q1. The data will then be in the form of a mass spectrum,
indicating the m/z value of all ions detectable and their relative abundance. This data is valuable to
ascertain the presence of a particular ion, and also to adjust the settings of the ionization source to
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obtain the optimal intensity of the expected ion. Such settings will include the flow rate by which
the solvent is delivered into the ionization source, the flow of nebulizing gas and the control of the
temperature of the ionization source. For ESI, the voltage of the capillary can also be adjusted,
while for APCI the charge on the corona discharge pin can be optimized. Furthermore, the energy
by which the ions are extracted into the instrument can be adjusted, so that unwanted clusters of the
analyte and other ions such as solvent ions can be prevented. If this energy setting (termed the
declustering voltage in some instruments) is however set too high, the increase in kinetic energy
can cause collisions between the analyte ions and residual atmospheric gas ions, resulting in
unwanted fragmentation of the analyte ions and thus reduction in the intensity thereof.
1.3.9.2 Product ion scans
The first quadrupole (Q1) can be set to pass ions of only one specific m/z value. Such ions will then
be directed into the fragmentation cell (Q2). Introduction of an inert gas into Q2 will result in
collisions between the gas molecules and the introduced ions. The energy of this collisions can be
controlled by adjustment of the kinetic energy of the ions (collision energy) producing fragment
ions of the specific ion. Such fragment ions (also termed product ions) are characteristic to the
structure of the introduced ion (termed the precursor ion) and the m/z values of the product ions
can be determined by introducing it into the second analyzing quadrupole (Q3) and scanning the
m/z range through set values. The product of such a scan is a mass spectrum in which the m/z
values of the product ions are indicated. The mass spectrum is thus valuable for the interpretation
of the molecular structure of the precursor ion.
1.3.9.3 Multiple reaction monitoring (MRM)
Product ions produced during fragmentation are characteristic and unique to the precursor ion and
can therefore be used to represent the precursor ion. If Q1 is therefore set to select and introduce
only the specific precursor ion into Q2 where fragmentation occurs, Q3 can be set to allow only
one of the product ions to pass through and impinge on the detector. The transition of the precursor
ion to a characteristic product ion therefore produces a very selective mechanism for detection of
the specific precursor ion. Because the abundance of the product ion will depend on the
concentration of the introduced precursor ion, this scanning mode, termed multiple reaction
monitoring (MRM), can also be used in a quantitative detection mechanism. The result of MRM
scan mode is a chromatogram, indicating the exit of the precursor ion from a chromatographic
system such as HPLC, with the area of the representative chromatographic peak as indication of
the concentration of the selected precursor ion. Since the transition from precursor to product ion is
relatively unique, the specificity of MRM detection is superior to many other detection methods
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and this uniqueness also renders it very sensitive because it excludes most non-specific background
detection, therefore resulting in a very low baseline for the chromatogram.
MRM detection was the scanning mode used for the determination of specific compounds in
biological matrices in this study.
1.3.10 Optimization of chromatographic and detection conditions
The optimization of chromatagraphic conditions for sufficient separation of the analyte and settings
for optimal detection thereof on the mass spectrometer are of the most important criteria to be
considered when developing an analytical method based on LC-MS/MS. Mass spectrometric
optimization is performed by optimizing the specific source and compound dependent parameters
to achieve maximum sensitivity, whilst the chromatographic optimization involves optimization of
the physical separation technique. The following three steps summarize the normal procedures
involved to achieve an optimized analytical method.
Step 1: A primary stock solution of the analyte is prepared at a high concentration, typically 1
mg/ml, usually in a volatile solvent such as methanol. A working solution containing a relatively
low concentration of the analyte, typically about 200 ng/ml, is prepared from the primary stock
solution and is infused into the mass spectrometer at a continuous low flow rate (typically 10
µl/min) using a syringe pump. The pseudomolecular ion of the analyte can then be observed in the
mass spectrum if a Q1 scan is performed. Fragmentation of the pseudomolecular ion (the precursor
ion) can be monitored by performing a product ion scan and the most abundant ion is then selected
to set up an MRM method, representing the presence of the analyte as a peak in a chromatographic
run [62]. Once the combination of precursor ion and product ion m/z values are selected (termed
the transition), optimization of the sensitivity of detection can be done by tuning of the compound
dependent parameters, including ionization settings such as the capillary voltage and the
declustering potential (DP), as well as settings within the analyzers such as the collision energy
(CE) and collision cell entrance and exit potentials.
Step 2: Chromatography optimization during method development is a critical factor to establish a
robust analytical method since it affects both the sensitivity and the selectivity of the method.
Careful consideration should therefore be given to all aspects of the chromatography process.
The most commonly used chromatographic separation technique is reverse phase chromatography.
Optimal chromatography, resulting in symmetric peak shapes at short run times, is achieved by
selecting the correct combination of mobile phase pH, composition and flow-rate, and the correct
analytical column at the optimal column temperature. The flow-rate should be acceptable for
optimal ionization in the ionization source of the mass spectrometer and volatile pH modifiers
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should be used. Acetic acid, formic acid and buffer salts such as ammonium acetate and
ammonium formate are the most common additives used. The flow of the mobile phase can be
either isocratic (the same ratio of aqueous and organic phases throughout the run) or by applying a
gradient, therefore linearly increasing the ratio of organic to aqueous phases throughout the run.
A final aspect to consider during the optimization of the chromatographic method is the injection
volume and composition of the injection solution used to apply the sample to the column. The
injection volume should be as small as possible and as a rule the injection solution should have the
same or slightly higher polarity than the mobile phase, to assure that the sample is applied as a
narrow band on the column [45].
Step 3: Once satisfactory chromatographic conditions have been determined, the ionization source
parameters are adjusted and optimized to accommodate the flow-rate and composition of the
mobile phase which will be used for sample analysis. Repeated injections are performed during
which source settings such as temperatures, gasses and voltages are optimized. This is usually
performed automatically during the process termed flow injection analysis [45].
1.4 METHOD VALIDATION
The measurements of drug concentration in biological matrices such as blood, serum, plasma, urine
and saliva are a vital aspect in product development [42]. The validation of the bioanalytical
method used to perform such measurements includes processes and procedures that generate
quantitative concentration data of an analyte in a given biological matrix to prove that the method
is accurate, precise, repeatable and robust and that the integrity of the analyte is maintained
throughout the quantification process to yield reliable and reproducible results [42] [64].
According to international standards as outlined in the Food and Drug Administration (FDA) and
European Medicines Agency (EMA) guidelines for bioanalytical method validation, different types
and levels of method validation are required depending on the application of the bioanalytical
method.
• A full validation must be performed when a newly developed bioanalytical method is used
for the first time.
• A full validation must be performed when an existing validated method is altered by
adding metabolites for quantification or for the addition of a new analyte entity to the
method.
• A partial validation is performed when minor changes or modifications are made to a
bioanalytical method that has previously been validated. Changes that require a partial
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validation include transfer of a bioanalytical method to another analyst or laboratory,
change in detection equipment, another biological fluid, concentration range, sample
processing and storage conditions, etc.
• Cross validations are performed when different bioanalytical methods are used to generate
data across different studies or within the same study. Data obtained from cross validations
are used to compare results between newly validated methods and results obtained from
previously validated methods.
To fulfill validation requirements, fundamental parameters such as selectivity and specificity,
accuracy and precision, recovery, reproducibility, sensitivity, stability and suitability has to be
demonstrated.
1.4.1 Selectivity/specificity
Selectivity is the ability of the analytical method to secure the quantification of an analyte in the
presence of other endogenous components in the sample whilst specificity is the ability to observe
solely the analyte rather than the unknown or interfering components. For selectivity/specificity,
analysis of blank samples of the appropriate biological matrix such as blood, urine, serum and
plasma should first be tested for interfering/endogenous components which may consist of a
variety of impurities, metabolites, matrix components or even concomitantly administered
medication [42] [43].
1.4.1.1 Blanks samples
At least 6 blank samples from different individual sources are assessed to determine if endogenous
matrix components will interfere with the detection of the analyte. If the intended use of the
method is for more than one analyte, each analyte should be tested to ensure that there is no
interference. Interference by components in the blank matrix should be less than 20% of the lower
limit of quantification (LLOQ; see section 1.4.3) of the analyte and less than 5% of the LLOQ
when such interference originate from the internal standard [42].
1.4.1.2 Matrix effects
Matrix components can have a negative effect on the analytical process since they can cause
suppression or enhancement of the ionization of the analyte. Therefore, when performing
quantitative analysis using LC-MS/MS, matrix effects should be tested using blank matrix from six
individual donors. Pooled matrix should not be used.
The assessment of matrix effects can typically be determined by calculating the internal standard
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normalised matrix factor or alternatively by using Matuszewski’s approach as described below [65]
[66].
The matrix factor (MF) for the analyte and the internal standard (IS) should be determined for each
individual source of blank matrix by calculating the ratio of the peak area in the presence of matrix
to the peak area in the absence of matrix. The data is acquired by analysing a blank sample to
which the analyte is added after extraction and comparing it to the analysis of a pure solution of the
analyte. The internal standard normalised MF takes the internal standard (IS) into account and is
calculated by dividing the MF of the analyte by the MF of the internal standard. The percentage
coefficient of variation (% CV) of the IS-normalised matrix factors is calculated and should be less
than 15%. This determination should be done at low and high levels of concentrations of the
analyte and at one concentration of the internal standard.
When assessing the matrix effects according to the Matuszewski approach, six individual blank
sources, spiked with the analyte at a low and at a high concentration level and the internal standard
at one concentration, are analyzed separately to determine the variability of the response from
source to source. The peak responses of the analyte and of the IS are documented for each
individual sample and the % CV calculated for the peak responses should be smaller than 15% [42]
[43].
When performing matrix effects, it is recommended to investigate other possible sources of
potential interference such as haemolysed and lipidaemic samples and the presence of relevant
concomitantly administered drugs, to ensure that the selectivity and precision are not compromised
by such components within the matrix [65] [66] [67].
1.4.2 Accuracy, precision and recovery
The reliability of an analytical method is determined by its precision and accuracy, which is
demonstrated by the analysis of quality control samples.
Accuracy of an analytical method, expressed as percentage nominal (% Nom), can be described as
the closeness of the measured concentration obtained by the analytical method to the nominal
concentration of the analyte. The accuracy of a method is calculated using the following formula:
100
ionconcentratNominal
ionconcentratmeasuredMeanNominal% ×=
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Accuracy determination is done by performing replicate analysis of quality control samples
containing known amounts of the analyte. A minimum of five determinations should be done of
QC’s at each of three concentration levels, namely at low, medium and high concentration levels. It
is recommended that the low QC should be within three times the LLOQ, the medium QC at
approximately the 50% mark of the calibration curve series and the high QC at 75% of the
concentration of the upper limit of quantification (ULOQ). Deviation from the mean value (CV %)
should be within 15% of the actual value except at LLOQ, where it should not be more than 20%.
Precision of an analytical method can be described as the closeness of repeated individual
measurements of the analyte when the procedure was repeated with multiple aliquots of a single
homogeneous volume of biological matrix containing a certain concentration of the analyte.
As for accuracy assessment, precision is assessed by performing at least five determinations of
QC’s at each of the three concentration levels used for accuracy determination. Using the formula
indicated below, the precision should not exceed 15% of the coefficient of variation (CV), except
for the LLOQ, for which it should not exceed 20%.
Accuracy and precision assessments are performed during two sub categories of the validation
process, enabling evaluation based on within-batch and between-batch calculations, respectively.
Within-batch accuracy and precision calculations are performed within in a single validation batch,
analyzing a minimum of five samples per level at a minimum of four concentration levels that
covers the calibration ranges. Between-batch accuracy and precision calculations must include data
from QC samples from three separately analyzed validation batches over a period of two days. This
includes the LLOQ, low, medium and high QC samples from the individual batches.
Assessment of the recovery of an analyte measures the efficiency by which the analyte is extracted
from the matrix. Therefore recovery assessment is performed by comparing the instrument
response of a blank matrix sample spiked with analyte and undergoing the extraction process (test
sample), with the response of a blank matrix sample first undergoing extraction and then being
spiked with analyte to contain the same concentration as the test sample (theoretical sample). This
comparative assessment is done at three different concentrations for the analyte (low, medium and
high) and for the internal standard at the concentration at which it will be used.
The recovery of the analyte does not have to be 100%, but the degree of recovery of an analyte and
of the internal standard should be precise, consistent and reproducible. It is calculated using the
X 100% CV = Standard deviation
Mean
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
34
following formula:
1.4.3 Sensitivity and the Lower Limit of Quantification (LLOQ)
The sensitivity of an analytical method is determined by the lowest concentration of analyte that
can measurably be detected in the biological matrix. For quantitative analysis, this concentration is
termed the lower limit of quantification (LLOQ) and defined as the lowest concentration that can
be distinguished from the background noise. If an adequately signal to noise ratio is calculated, the
LLOQ is suitable for quantification of the samples. Therefore the LLOQ should meet the following
criteria:
• The analyte peak should be at least 5 times more compared to the response of a blank
sample similarly analyzed.
• The analyte peak should be detectable, distinct, and reproducible with accuracy between
80-120% and a precision of 20%.
1.4.4 Calibration curve
A calibration curve is used to define the relationship between the instrument response and the
known concentration of the analyte over the specified calibration range [42] [68]. A calibration
curve should be generated for each analyte in the same blank matrix as the intended study samples.
Blank matrix is spiked with a known concentration of the analyte to define an analyte
concentration to instrument response relationship.
Concentrations of calibration standards should be selected on the basis of the range expected for a
particular study, covering the calibration range from the lowest calibration standard (LLOQ) up to
the highest calibration standard (ULOQ), for each analyte.
After defining the expected concentration range of the analyte involved, a calibration curve must
be evaluated. A calibration curve must consist of a minimum of six calibration standards including
a blank sample and a zero sample. The blank and the zero samples are not taken into consideration
when calculating the calibration parameters. Each calibration standard is analyzed in duplicate [42]
[43].
Calibration standards should be evaluated against different regression models. The simplest model
that adequately describes the concentration-response relationship should be chosen. The
% Recovery = Mean response of the test samples X 100
Mean response of the theoretical samples
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relationship between the response and the concentration should be continuous and reproducible.
A standard curve should meet the following criteria:
• At least 75% of the calibration standards must have an accuracy within 15% of the nominal
value, except for the LLOQ which should be within 20%
• At least one of the duplicate calibration standards at each concentration level must have an
accuracy of 15% of the nominal value (20% at the LLOQ)
1.4.4.1 Carry-over
Carry-over is defined as residue of an analyte that is carried over from a previous injected sample
to a subsequent injected sample. It can affect the accuracy and precision of study samples during
analysis and should be addressed and minimised during method development. The primary causes
of carry-over can be ascribed to column carry-over, when residues of the analyte are retained on
the analytical column and auto sampler carry-over where the analyte is trapped within the injection
port. During validation, carry-over should be assessed by including a blank sample after a high
concentration sample, usually at the upper limit of quantification (ULOQ). Carry-over measured in
the blank sample following the high concentration sample should be less than 20% of the LLOQ,
and 5% or for the internal standard [69] and can be calculated using the following formula:
1.4.4.2 Dilution integrity
Accuracy and precision of a sample is set within specified criteria and dilution of a sample should
not affect this, however the dilution integrity should cover the dilution applied to the entire range
of study samples.
Dilution integrity should be performed by spiking the matrix with an analyte at a concentration
above the highest calibration standard concentration (ULOQ), and diluting this sample with blank
matrix, performing at least five determinations per dilution factor.
1.4.5 Reproducibility
Reproducibility of a method represents the precision of a method under the same operating
condition over a short period of time. It can also represent the precision between two different
laboratories [43].
% Carry-over = X 100
Peak area of analyte in LLOQ
Peak area of analyte in blank sample after ULOQ
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When reinjection reproducibility has been demonstrated an analytical batch can be reanalyzed
(reinjected) in the case of instrument interruptions or failures.
1.4.6 Stability
The stability of a chemical compound in a given biological matrix must be evaluated under specific
conditions for given time periods at low and high concentration levels during method validation.
The parameters of stability that should be evaluated are the storage condition, the matrix and the
container system. The condition used in stability experiments should reflect situations likely to be
encountered during routine analysis [43].
Assessment of analyte stability under the following conditions is required by the FDA and EMA:
• Freeze and thaw stability
• Short-term matrix temperature stability (on-bench stability)
• Long term matrix stability
• Stock solution stability
• Post preparative stability (on-instrument stability)
1.4.6.1 Freeze and thaw stability
Analyte stability should be determined after three freeze and thaw cycles, using at least three
aliquots at both low and high concentrations. These aliquots must be stored frozen at the intended
temperature for a period of at least 24 hours and then thawed unassisted at room temperature.
When completely thawed, samples must be frozen again at the same temperatures for a period of
12-24 hours and the thawing process repeated under the same conditions. After the third thawing
cycle the samples are analyzed using freshly prepared calibration standards. Stability sample
results should be within 15% of the nominal concentrations [43].
1.4.6.2 Stock solution stability
Stability of the analyte and internal standard in a stock solution should be evaluated to determine
their stability under different storage conditions in the solvent used to prepare the stock solutions.
The storage conditions used in the assessment should reflect those used for normal storage of such
solutions, thus at room temperature, refrigerated in a fridge (approximately 5ºC) and in a freezer
(approximately -20ºC). The time of storage should not be less than 6 hours. The stored stocks
solutions should be tested by comparing the instrument response thereof to that of freshly prepared
stock solutions at the same concentration [43].
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1.4.6.3 Short term stability
Short-term matrix stability (on-bench stability) assesses the stability of the analyte in the biological
matrix if left standing under laboratory conditions for an extended period. Therefore at least three
samples at both low and high concentrations in a biological matrix is thawed at room temperature
and kept at these conditions for a period of 4 to 24 hours before analysis using freshly prepared
calibration standards. Stability sample results should be within 15% of the nominal concentrations
[43].
1.4.6.4 Long term stability
Long term stabilities of an analyte should be determined by storing at least three aliquots at low
and high concentrations of the analyte in the biological matrix under the same conditions as the
intended study samples. The time of storage for the assessment must exceed the period for which
the study samples will be stored, therefore from the date of the first sample collection until the last
day of analysis [43]. Stability assessment samples can be retrieved and analyzed at different times
during this period of long term storage as long as it is analyzed using freshly prepared calibration
standards. Stability sample results should be within 15% of the nominal concentrations.
1.4.6.5 Post-preparative stability
Post-preparative stability (on-instrument stability) of the analyte indicates the stability of the
analyte in processed format, in other words following extraction and awaiting injection for analysis
on the analytical instrument. The storage condition will thus be that of the conditions within the
analytical instrument, which is normally the auto sampler of the HPLC. The period of storage
should cover the time resident on the instrument from submitting the samples of an analytical batch
for injection until completion of injection. As for the other stability assessments, this assessment
should also be performed using samples at low and high concentration. The concentration of the
samples should be calculated against freshly prepared or freshly extracted calibration standards.
Stability sample results should be within 15% of the nominal concentrations [42].
1.4.7 Suitability
Suitability can be subdivided in to two categories, the first being the suitability of an analytical
method and the second the suitability of the system (instrumentation) used for analysis.
Suitability of an analytical method indicates that validation requirements have been met and that
the method is suitable for the quantification of a compound in the biological matrix of choice.
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System suitability is determined by scientifically qualified and properly maintained instruments for
conducting of the analytical methods ensuring that the system operates properly during time of use.
Suitability checks are conducted during each batch by ten injections (five at the beginning of the
batch and five at the end of the batch) of a sample at a suitable concentration of the analyte and
containing the internal standard, if one is used, to evaluate instrument performance during an
analytical batch. The responses obtained from the injections at the beginning of the batch are
compared with the responses obtained at the end of the batch [42] [43]. Any erratic changes or
upward or downward trends in peak responses are an indication of possible problems with the
instrument assembly and are investigated and resolved.
1.5 ACCEPTANCE CRITERIA OF AN ANALYTICAL AND VALIDATION BATCH
Acceptance criteria of an analytical batch are based on guidelines set by regulatory authorities such
as the FDA and EMA. Evaluation of these criteria confirms acceptance of a validation batch,
analytical batch and subsequently the analytical method.
A validation batch consists of a minimum of six STDs. All the calibration standards from ULOQ to
LLOQ must be analyzed in duplicate. A minimum of three concentration levels of QCs at low,
medium and high concentration and at the LLOQ are included. Additional QC’s can be added at
the medium level if the calibration range is judged too wide. QCs in six fold at each concentration
level are spread throughout the batch but placed so as to control the analysis appropriately and
detect possible carry-over. If an internal standard is used, a zero sample, containing neither analyte
nor internal standard, should be included as well as blank samples, which contain only the internal
standard to confirm that there is no interference from the internal standard on analyte analysis.
Blank samples should be placed following high concentration calibration standards or QCs to
assess carry-over. In an analytical batch, the sequence is constructed similar to a validation batch
accept that the study samples are included.
1.5.1 Acceptance criteria of a validation and analytical batch
A validation batch and an analytical batch are accepted based on the performance of the calibration
curve and the quality control samples.
Acceptance criteria for the calibration curve (applicable to a validation and analytical batch):
• The calibration curve, including the ULOQ and LLOQ, must consist of a minimum of six
calibration standard levels and the calculated regression line should have a coefficient of
determination (r2) not less than 0.990.
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• At least 75% of the calibration standard concentrations must be within 15% of the nominal
concentrations, except at LLOQ where it should be within 20% of the nominal
concentration. One of each (50%) of the duplicates per concentration level should meet
this criterion.
• If one of the calibration standards does not meet the above criterion, it should be rejected,
and the calibration curve without this calibration standard must be re-evaluated. This
includes re-calculating the regression line of the regression model used.
• The batch should be rejected in the event that both the duplicates of the ULOQ or the
LLOQ are not within the acceptance criteria.
Acceptance criteria for the quality control samples (applicable to a validation batch):
• At least four of the six QC samples of each level included in a validation batch must be
within 15% of their individual nominal concentrations and within 20% of the nominal
concentration at LLOQ. The mean within-batch accuracy of each QC level included in a
validation batch must be within 15% for each QC and 20% at the LLOQ. The within-batch
precision of each QC level included in a validation batch must be equal to, or less than
15% and equal to, or less than 20% at LLOQ. This last criterion is not applicable to
batches with only two QC samples per concentration level.
Acceptance criteria for the quality control samples (applicable to an analytical batch, as well a
validation batch that contains only two QCs per concentration level):
• At least 67% of the total number of QC samples must be within 15% and within 20% at
LLOQ of their respective nominal concentrations. At least one (50%) QC sample per
concentration level must be within its individual nominal concentration.
1.5.2 Acceptance criteria for an analytical method
In addition, the following acceptance criteria must be met for an analytical method:
• Between-batch accuracy, expressed as % Bias, must be within 15% over the range and
within 20% at the LLOQ, calculated over all three successive validation batches.
• Between-batch precision, expressed as % CV, must be equal to or less than 15% or equal
to or less than 20% at the LLOQ, calculated over all three successive validation batches.
• Selectivity, stability and recovery criteria as detailed under the relevant headings in section
1.4 must be met.
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1.6 ROBUSTNESS OF AN ANALYTICAL METHOD
Robustness of an analytical method is the ability to reproduce the method in different laboratories,
under different circumstances without the occurrence of unexpected variances in the obtained
result(s). A robustness test is an experimental set-up to evaluate the robustness of a method by
performing validation batches on separate days and not on the same day. This robustness test can
also be verified by using different instrumentation of the same type. If the results remain
unaffected by these small, but deliberate procedures, the method reliability is proven for routine
analysis.
1.7 STUDY OBJECTIVES
The aim of the development and validation for the quantitative determination of endosulfan in
serum was to obtain data that would correlate exposure and possible levels in the biological matrix
and to compare this to published results.
Similarly, the use of the validated method obtained from UCT to study levels of organophosphate
metabolites in urine of exposed subjects provided data that can be used to monitor such exposure
and correlate it with similar data in the literature.
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CHAPTER 2
DEVELOPMENT AND VALIDATION OF A BIOANALYTICAL
METHOD FOR THE DETERMINATION OF β-ENDOSULFAN AND
ENDOSULFAN SULFATE IN HUMAN SERUM PREPARED FROM
BLOOD COLLECTED FROM AGRICULTURAL WORKERS
2.1 INTRODUCTION
Analytical methods for the determination of the organochlorine pesticide endosulfan and its
metabolites in biological matrices described in the literature mainly employed gas chromatography
coupled to tandem mass spectrometry (GC-MS/MS) [16] [20] [26]. This was also the prescribe
method of choice in the Clinical Study Protocol on which this study is based (REC REF:
279/2005). The superior versatility of LC-MS/MS was however demonstrated in this study by the
application of this technology to develop and validated a sensitive bioanalytical method to
quantitatively determine β-endosulfan and its major metabolite, endosulfan sulfate, in human 
serum.
Although protein precipitation and solid phase extraction were also investigated, the best sample
preparation procedure proofed to be liquid-liquid extraction. Chromatographic separation was
optimized using a Supelco® Discovery C18 (2.1mm x 150 mm, 5 μm) analytical column fitted
with a Phenomenex® Security Guard™ system with a C18, 4 x 2 mm precolumn and applying an
isocratic mobile phase consisting of acetonitrile, methanol and water (80:80:40 v/v/v).
Mass spectrometer detection was done by MRM scanning using negative mode electrospray for
both β-endosulfan and endosulfan sulfate. Although a second metabolite, endosulfan lactone could 
also be detected, this metabolite could only be observed in the positive mode and since polarity
switching could not be achieved on the available instrument, the quantification of this metabolite
was not performed in this study. The literature also indicates that the most abundant metabolite is
the sulfate [12], and since the aim of the project was the optimal detection of endosulfan and its
metabolites to proof exposure of human subjects to the pesticide, it was decided to concentrate on
the most abundant species. For this reason, α-endosulfan was also excluded since the lower level of 
quantification achieved was much higher than that of β-endosulfan. 
The lower level of quantifications were 1 ng/ml and 0.1 ng/ml for β-endosulfan and endosulfan 
sulfate, respectively, and was applied to analyze individual serum samples collected from healthy
workers reported to have been exposed to agricultural pesticides in the Western Cape. Although
the sensitivity of the method was deemed adequate to be able to detect these compounds [20] [16],
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no indication of the presence of any of the two tested compounds could be found in any of the
samples. However, previous studies reported the detection of endosulfan, chlorpyrifos, fenarimol,
deltamethrin and iprodione in Western Cape rural surface and groundwater, including drinking
water [8] [9] [10]. Endosulfan and chlorpyrifos concentrations exceeding the WHO drinking water
standard of 0.1 µg/l as reported in about a third of the samples tested.
2.2 METHOD DEVELOPMENT PROCEDURE
2.2.1 Chemicals and reagents
Analytical reference standards of α-endosulfan, β-endosulfan, endosulfan sulfate and endosulfan 
lactone, with purities higher than 99% were obtained from Sigma Aldrich. Internal standards tested
during method development were sourced from a suitable supplier. All chemicals and reagents
used in this study were of analytical grade, as indicated in the Table 2.1.
Table 2.1 Chemicals and reagents
Reagents Grade Supplier
Acetonitrile High Purity Honeywell
Ammonium formate Reagent Sigma-Aldrich
Ammonium acetate High Purity Honeywell
Dichloromethane High Purity Honeywell
Dimethyl sulfoxide High Purity Radchem
Ethanol High Purity Honeywell
Formic acid 99% Radchem
Hexane High Purity Honeywell
Isoamyl alcohol High Purity Sigma-Aldrich
Methanol High Purity Honeywell
Ultrapure water used to prepare solutions was prepared by a Millipore Elix 10 reverse osmosis and
Milli-Q® (Millipore, USA) Advantage A 10® polishing system.
2.2.2 Preparation of stock solutions
Separate primary stock solutions for α-endosulfan, β-endosulfan, endosulfan sulfate and 
endosulfan lactone were prepared in methanol, each at a concentration of 100 µg/ml as indicated in
table 2.2. The stock solutions were stored at approximately -20ºC and were used to prepare
secondary reference solutions (10 ng/ml) of each analyte.
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Table 2.2 Preparation of primary stock solutions
Analyte Solventused
Solvent
density
Mass
analyte
(mg)
Mass
solvent
(g)
Volume
solvent
(ml)
Concentration
analyte
(µg/ml)
α-endosulfan Methanol 0.791 1.00 7.91 10 100
β-endosulfan Methanol 0.791 1.00 7.91 10 100
Endosulfan lactone Methanol 0.791 1.00 7.91 10 100
Endosulfan sulfate Methanol 0.791 1.00 7.91 10 100
2.2.3 LC-MS/MS optimization for endosulfan and its metabolites
2.2.3.1 Infusion (Spectral Analysis)
Spectra of the different compounds were obtained from direct infusion of the reference solutions
(10 ng/ml), prepared from the primary stock solutions, by using a Harvard syringe pump at a
constant flow rate of 10 µl/min. During this process compound parameters are optimized including
the declustering potential (DP), entrance potential (EP), collision energy (CE) and collision exit
potential (CXP).
Detection was performed on an AB Sciex API 4000 mass spectrometer and the ionization
intensities of three different atmospheric pressure ionization techniques namely electrospray
ionization (ESI), atmospheric pressure chemical ionization (APCI) and atmospheric pressure
photoionization (APPI) were evaluated for both positive and negative polarity scan types, using the
principles as described in Chapter 1, section 1.3.8.
ESI was found to be the best ionization technique. α-endosulfan, β-endosulfan and endosulfan 
sulfate were successfully ionized in the negative ion mode forming the respective deprotonated
pseudo molecular ions, while endosulfan lactone could only be observed as the protonated pseudo
molecular ion in the positive mode.
The presence of six chlorine atoms in each of these molecules resulted in complex mass spectra
indicating the patterns expected due to the stable chlorine isotopes (see figure 2.1). Ions at the
following m/z values were selected to act as precursor ions for the creation of MRM detection
methods for the four compounds:
α-endosulfan: m/z = 405
β-endosulfan: m/z = 405
Endosulfan sulfate: m/z = 421
Endosulfan lactone: m/z = 357
Figure 2.2 indicates the mass spectra of the fragments ions obtained when the precursor ions of the
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four molecules are subjected to collision induced dissociation. The proposed structures of the
prominent fragment ions selected as transition for the detection of each compound are also
indicated in figure 2.2, and therefore the transition settings on the instrument were as follows:
α-Endosulfan: 405→287 
β-Endosulfan: 405→305 
Endosulfan sulfate: 421→97 
Endosulfan lactone: 357→85 
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2.2.3.2 Flow Injection Analysis
Following infusion and the establishment of transitions for the detection of the analytes, flow
injection analyses (FIA) was performed automatically to optimize individual parameters. The FIA
optimization process was conducted by injecting multiple samples of endosulfan and its
metabolites onto a Discovery C18 (2.1 mm x 150 mm, 5 μm) analytical column with a constant
flow rate of 200 µl/min. Based on the evaluated chromatographic conditions; acetonitrile, methanol
and water (80:80:40 v/v/v) were used as the mobile phase and acetonitrile and methanol (50:50
v/v) as the injection solution.
During the FIA process the optimum source temperature, nebulizing and auxiliary gas flows, as
well as ionization voltage settings were obtained, by ramping the various parameters. Each
parameter was evaluated in triplicate and based on average results the parameter with the highest
average intensity was logged for each compound. Examples of source parameters settings are
present in figure 2.3.
Figure 2.3 Source parameter settings during FIA
2.2.4 Chromatographic development
Chromatographic conditions were optimized using combinations of mobile phases, various types of
reverse phase analytical columns, different flow rates, injection volumes and injection solutions.
For the selection of mobile phases, various mixtures of solvents such as acetonitrile, methanol,
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acetonitrile and methanol (50:50 v/v), acetonitrile, methanol and water (80:80:40 v/v/v) were tested
to achieve efficient separation, good peak shapes and optimal ionization. Small percentages of
volatile organic acids such as formic acid and acetic acid, ranging from 0.1 to 0.5%, and volatile
buffers such as ammonium acetate and ammonium formate, ranging from 5 mM to 20 mM, were
added to the mobile phase solutions to improve ionization and gain maximum sensitivity. All
solvents were degassed by sparging with helium gas for 3-5 minutes depending on the volume of
the mobile phase.
The injection solvent was optimized by testing the various combinations of mobile phases as
injection solutions. The optimum injection volume was assessed by injecting different volumes of
the various injection solutions by increments of 3 µl, starting from 2 µl up to 20 µl.
Various types of reverse phase analytical columns, namely Kinetex® EVO C18 (2.1 mm x 150
mm, 5 μm), Discovery® C18 (2.1 mm x 150 mm, 5 μm), Discovery® C8 (2.1 mm x 150 mm, 5
μm), Discovery® Cyano (2.1 mm x 150 mm, 5 μm), Agilent® Poroshell C18 (2.1 mm × 150 mm,
5 μm), Luna C18 (2.0 mm x 150 mm, 5 μm), Luna C8 (2.0 mm x 150 mm, 5 μm), and Luna Phenyl
Hexyl (2.0 mm x 150 mm, 5 μm) were tested. Different flow rates were applied to separate
columns ranging from 150 µl/min up to 1 ml/min, to achieve a short but stable retention time.
Chromatographic parameters such as stable retention time, highest peak intensities good
symmetrical peak shapes were optimised.
2.2.5 Procedures for the selection of a sample extraction method
Serum samples were submitted to a series of sample preparation techniques such as protein
precipitation, liquid-liquid extraction (LLE) and solid phase extraction (SPE). The recoveries and
sensitivities of detection of each compound was determined and compared to select the ideal
extraction procedure. A stock solution of each compound was prepared at a concentration of 100
µg/ml in methanol. Pooled blank serum donated by healthy volunteers was spiked with 180 µl of
each stock solution to obtain a serum sample at a concentration of 30 ng/ml of each analyte. This
was used to assess the different extraction procedures as summarised below.
2.2.5.1 Protein precipitation
Protein precipitation was evaluated by using solvents or solvent mixtures as precipitation solution.
The following precipitation solutions were evaluated: acetonitrile; methanol; acetonitrile :
methanol (50 : 50 v/v); acetonitrile : 0.1% formic acid in water (50 : 50, v/v); methanol : 0.1%
formic acid in water (50 : 50, v/v); acetonitrile : methanol : 0.1% formic acid: (50:50 v/v 0.1%
formic acid).
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This following procedure was performed for each of the precipitation solutions mentioned above.
• Aliquot 200 µl of the serum sample into a 2 ml microfuge tube.
• Add 500 μl precipitation solution.
• Vortex the samples for 30 seconds.
• Place the sample on ice for approximately 15 minutes.
• Centrifuge at 3000 x g for 5 minutes.
• Transfer the supernatants to 96-well collection plates for injection onto the
chromatographic system.
2.2.5.2 Liquid-liquid extraction (LLE)
The organic solvents evaluated for liquid-liquid extraction were hexane : ethyl acetate (50 : 50,
v/v), hexane : dichloromethane (60 : 40, v/v), hexane : iso-amyl alcohol (98 : 2, v/v) and tert-butyl
methyl ether (TBME). Each of these solvents was tested separately with and without the universal
Britton Robinson buffers at various pH values, ranging from 2.5 up to 12. The following procedure
was applied:
• Aliquot 200 µl of the serum sample into a 10 ml amber glass ampoule.
• Add 200 μl of each of the buffer, if applicable.
• Add 5 ml of the applicable organic solvents.
• Vortex the samples for 90 seconds.
• Centrifuge at 1300 x g for 5 minutes.
• Freeze the aqueous phase in an alcohol freezing bath at approximately -30°C.
• Decant the organic phase into a 5 ml amber glass ampoule.
• Evaporate the solvent under a gentle stream of nitrogen at 40°C until completely dry.
• Add 200 μl reconstitution solution (acetonitrile : methanol [50 : 50 v/v]).
• Vortex for 30 seconds.
• Transfer the extracts to 96-well collection plates for injection onto the chromatographic
system.
This procedure was performed for the entire buffer range at various pH levels (bullet 2), for each of
the above mentioned organic solvents (bullet 3).
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2.2.5.3 Solid phase extraction (SPE)
Solid phase extraction was performed using Waters Sep-Pak®Vac 100 mg tC18® SPE columns
with a SPEEDISK® 48 place positive pressure system. Different organic solvents such as
acetonitrile, hexane and methanol were tested as elution solvents. Each of the organic solvents was
tested separately with and without buffers at various pH values, ranging from 2.5 up to 12.
• Activate the solid phase cartridges by adding 1 ml of organic solvent (SPE Conditioning).
• Wash the column with 1 ml buffer.
• Aliquot 200 µl of the serum sample (with and without water dilution) onto the activated
solid phase cartridge.
• Perform a wash step with 1 ml of buffer.
• Elute with 200 μl organic buffer into polypropylene tubes.
• Evaporate the samples under a gentle stream of nitrogen at 40°C until completely dry.
• Add 200 μl of reconstitution solution (acetonitrile : methanol [50 : 50 v/v]).
• Vortex briefly for 30 seconds.
• Transfer the reconstitute to 96-well collection plates for injection onto the chromatographic
system.
2.3 DESCRIPTION OF THE OPTIMIZED ANALYTICAL PROCEDURE
2.3.1 Optimization of the sample preparation
Amongst all the extraction procedures that were evaluated, liquid-liquid extraction proved to be the
best and therefore it was applied for the extraction of α-endosulfan, β-endosulfan, endosulfan 
sulfate, and endosulfan lactone from serum.
The optimal pH of extraction and the choice of solvent were made based on the data depicted in
figures 2.4 and 2.5, respectively. At a pH of 9, the recovery of α-endosulfan, β-endosulfan and 
endosulfan sulfate was consistently approximately 82%, while that of endosulfan lactone was
approximately 50%. As all the compounds were extracted simultaneously from the same serum
sample, the lower recovery of endosulfan was regarded as acceptable.
The organic solvent of choice for the extraction of α-endosulfan, β-endosulfan, endosulfan sulfate, 
and endosulfan lactone from serum was hexane : dichloromethane (60 : 40, v/v) as it resulted in the
highest extraction efficiency of approximately 80% for all the compounds.
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Figure 2.4 The influence of pH on sample on extraction efficiency of α-endosulfan, 
β-endosulfan, endosulfan sulfate, and endosulfan lactone from serum 
Figure 2.5 Organic solvent extract efficiency of, α-endosulfan, β-endosulfan, endosulfan 
sulfate, and endosulfan lactone from serum
The final extraction procedure can be summarized as follows:
• Thaw the serum samples unassisted at room temperature (~ 23 oC).
• Vortex briefly for 10 seconds.
• Aliquot serum (200 µl) into a 10 ml amber glass ampoule.
• Add 200 µl of a Britton Robinson buffer at pH 9.
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• Add 5 ml hexane : dichloromethane (60 : 40, v/v).
• Vortex the samples for 90 seconds.
• Centrifuge for 5 minutes at 1300 x g (~ 5 oC).
• Freeze the aqueous phase in an alcohol freezing bath (~ -30 oC).
• Decant the organic phase into a clean 5 ml amber glass ampoule and discard the aqueous
phase left in the 10 ml amber glass ampoule.
• Evaporate the organic solvent in the 5 ml amber glass ampoule under a gentle stream of
nitrogen at ~ 40°C until completely dry (approximately 25 minutes).
• Add 200 μl reconstitution solution into the 5 ml amber glass ampules (acetonitrile :
methanol (50 : 50 v/v)).
• Vortex for 30 seconds.
• Transfer the extracts to 96 well plates.
• Inject 10 µl onto the HPLC column.
2.3.2 Chromatographic separation and detection of the analytes
HPLC analysis and detection were performed using the following instruments and conditions:
2.3.2.1 Chromatography
For the analysis of α-endosulfan, β-endosulfan and endosulfan sulfate, which was detected by 
negative mode electrospray ionization, the best analytical column was a Supelco® Discovery C18
(2.1 mm x 150 mm, 5 μm) fitted with a Phenomenex® Security Guard™ system with a C18, 4 x 2
mm precolumn. Endosulfan lactone was detected in the positive mode and the column of choice for
its analysis was a Phenomenex® Kinetex C18 (2.1 mm x 100 mm, 2.6 μm). The columns were
kept at 40°C in an Agilent 1200 series column compartment.
Acetonitrile : methanol : water (80 : 80 : 40, v/v/v) was used as the isocratic mobile phase to
perform analysis in the negative ionization mode for the detection of α-endosulfan, β-endosulfan 
and endosulfan sulfate, and acetonitrile : 0.1 % formic acid (80 : 20, v/v) was used (also
isocratically) for the detection of endosulfan lactone in the positive ionization mode. The
respective mobile phases were used as reconstitution and injection solutions.
An Agilent 1200 series binary pump, combined with a degasser, was used to deliver the mobile
phase at a constant flow rate of 200 μl/min.
An Agilent 1200 series auto sampler, equipped with an Agilent cooling device (sample cooler) set
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at 5oC, was used to inject 10 µl sample onto the HPLC column. The auto sampler was equipped
with a flush port with needle wash for 20 seconds.
2.3.2.2 Detection
Detection was performed on an AB SCIEX API 4000 triple quadrupole mass spectrometer (AB
SCIEX Toronto Canada) equipped with an electrospray ionization (ESI) source operating in the
positive or negative ion mode as applicable. Settings used for the detection of α-endosulfan, β- 
endosulfan, endosulfan sulfate are indicated in Tables 2.3 to 2.5 and for endosulfan lactone as
listed in Tables 2.6 to 2.8.
Table 2.3 Source parameter settings for α-endosulfan, β-endosulfan and endosulfan sulfate
Electrospray Ionization Settings Value
Nebulizer gas (Gas 1) 30
Turbo gas (Gas 2) 50
CUR (curtain gas) 20
CAD (collision gas) 12
TEM (source temperature) (°C) 450
IS ( Ion Spray Voltage) (V) -4500
Table 2.4 MS/MS parameter settings for α-endosulfan, β-endosulfan and endosulfan sulfate
MS/MS Settings α-Endosulfan Β-Endosulfan Endosulfan sulfate
Monoisotopic mass* 403.816 403.813 419.811
Deprotonated isotope used ( m/z) 405 405 421
Product ion ( m/z) 287 305 97
Dwell time (ms) 150 150 150
DP (declustering potential) (V) -30 -30 -40
EP (entrance potential) (V) -10 -10 -10
CE (collision energy) (eV) -15 -15 -5
CXP (collision cell exit potential) (V) -12 -15 -10
*As calculated using Analyst® software
Table 2.5 Scan description for α-endosulfan, β-endosulfan and endosulfan sulfate
Scan Description
Scan type MRM
Polarity Negative
Pause time 5 ms
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Table 2.6 Source parameter settings for endosulfan lactone
Electrospray Ionization Settings Value
Nebulizer gas (Gas 1) 45
Turbo gas (Gas 2) 55
CUR (curtain gas) 15
CAD (collision gas) 12
TEM (source temperature) (°C) 450
IS ( Ion Spray Voltage) (V) 5000
Table 2.7 MS/MS parameter settings for endosulfan lactone
MS/MS Settings Endosulfan lactone
Monoisotopic mass* 353.834
Protonated isotope used ( m/z) 357
Product ion ( m/z) 85
Dwell time (ms) 150
DP (declustering potential) (V) 40
EP (entrance potential) (V) 12
CE (collision energy) (eV) 30
CXP (collision cell exit potential) (V) 5
*As calculated using the Analyst® software
Table 2.8 Scan description for endosulfan lactone
Scan Description
Scan type MRM
Polarity Positive
Pause time 5 ms
2.3.3 Chromatographic results
The total runtime for each sample was 4.5 minutes. A representative chromatogram of an extracted
serum sample containing α-endosulfan (300 ng/ml), β-endosulfan (200 ng/ml) and endosulfan 
sulfate (30 ng/ml), in the negative ionization mode, is present in figure 2.6 and that for endosulfan
lactone (100 ng/ml) analyzed in positive ionization mode is present in figure 2.7.
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Figure 2.6 A Representative Chromatogram of α-endosulfan, β-endosulfan and endosulfan 
sulfate
Figure 2.7 A Representative Chromatogram of endosulfan lactone
2.3.3.1 Limit of Detection
According to literature, gas chromatography coupled to tandem mass spectrometry (GC-MS/MS)
was mostly employed to determine endosulfan and its metabolites in biological matrices such as
serum and urine [20] [26].
Arrebola et al. [20] reported limits of detection of 0.014 ng/ml, 0.015 ng/ml, 0.01 ng/ml and 0.019
ng/ml for α-endosulfan, β-endosulfan, endosulfan sulfate and endosulfan lactone, respectively, 
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using human serum as matrix. Limits of quantification were however 0.051 ng/ml for
α-endosulfan, 0.055 ng/ml for β-endosulfan, 0.034 ng/ml for endosulfan sulfate and 0.068 ng/ml 
for endosulfan lactone. The method was applied to nine serum samples from agricultural workers,
eight males and one female that were occupationally and non-occupationally exposed. The α and β-
isomers were found in all the samples with concentration levels between 3.88 ng/ml and 12.84
ng/ml for α-endosulfan and 1.68 ng/ml and 6.86 ng/ml for β-endosulfan  with no traces of 
endosulfan sulfate or endosulfan lactone in any of the samples. The levels of β-endosulfan that can 
be observed with the method reported in this study, therefore falls within the expected range
following exposure as indicated by Arrebola et al. [20].
Vidal et al. [26] performed a similar GC-MS/MS-based study in human urine and reported limits
of detection at 0.009 ng/ml for α-endosulfan, 0.018 ng/ml for β-endosulfan, 0.013 ng/ml for 
endosulfan sulfate and 0.009 ng/ml for endosulfan lactone. However, the limits of quantification
were 0.031 ng/ml for α-endosulfan, 0.060 ng/ml for β-endosulfan, 0.044 ng/ml for endosulfan 
sulfate and 0.031 ng/ml for endosulfan lactone.
The electrospray ionization technique employed in this study successfully ionized β-endosulfan in 
the negative mode. Under the same conditions, the ionization intensity of α-endosulfan was much 
lower so that the quantification limit thereof was not comparable to that of the β-isomer. For this 
reason, α-endosulfan was omitted from the study. The sulfate metabolite ionized stronger than the 
parent compounds and the anion was formed under the same conditions as applied for the
ionization of the β-isomer. These two analytes could also be successfully extracted and 
chromatographically separated from the matrix components using the same column.
The lactone metabolite did not ionize in the negative mode but formed a strong cation during
electrospray ionization. The extraction and chromatographic characteristics of the lactone also
significantly differed from that of β-endosulfan and the sulfate metabolite, to such a degree that the 
lactone had to be analyzed in a separate run, including a separate extraction procedure. The
available sample volume was not enough to allow two separate analytical procedures per sample
and therefore β-endosulfan and the sulfate metabolite were used as markers for the exposure to the 
pesticide.
2.3.3.2 Repeatability
Repeatability of an analytical method should be proven during the method development process.
This is evaluated by performing 100 injections in pure solution (sample prepared in reconstitution
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solution) followed by 100 injection of an extracted sample. As indicated in figure 2.8 and 2.9, the
instrument response was stable and the % CV of β-endosulfan and endosulfan sulfate were 5.39 
and 2.28 in pure solution, and 6.25 and 3.14 in the extracted sample.
Figure 2.8 Repeatability of β-endosulfan and endosulfan sulfate in pure solution 
Figure 2.9 Repeatability of β-endosulfan and endosulfan sulfate after extraction 
The results prove that the instrument response and retention times are consistent during sample
injection.
2.3.4. Choice of internal standard
Both β-endosulfan and endosulfan sulfate contain six chlorine atoms which results in multiple 
isotope peaks representing the molecular ions as presented in figures 2.10 and 2.11 [70]. The
complexity of the mass spectrometric characteristics prevents the use of deuterated molecules of
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these compounds as internal standards. Such material is also not commercially available.
Figure 2.10 Q1 mass spectrum of β-endosulfan indicating the chlorine isotope peaks 
Figure 2.11 Q1 mass spectrum of endosulfan sulfate indicating the chlorine isotope peaks
Other chlorinated pesticides such as dieldrin and dichlorodiphenyltrichloroethane (DDT) were
considered as internal standards, but due to their chemical characteristics and lack of ionisable
functional groups, could not be ionized under the same conditions as for the endosulfans.
Chlorinated compounds containing ionisable functional groups such as diclofenac and
dichorophenol were evaluated but their chemical characteristics were found to be too diverse to the
endosulfans so that they could not compensate during ionization and extraction. It was therefore
decided to perform the detection of β-endosulfan and endosulfan sulfate without an internal 
-Q1: 5.143 to 5.884 min from Sample 1 (Endosulfan Beta) of Beta Neg.wiff (Turbo Spray), Smoothed Max. 6.4e5 cps.
392 394 396 398 400 402 404 406 408 410 412 414 416 418 420 422 424 426
m/z, Da
0.0
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.5e5
5.0e5
5.4e5
In
te
ns
ity
,c
ps
402.8
404.7
406.7
408.6
406.1
410.8
403.6
410.1
425.3397.3 421.4
419.3395.0 398.6 412.9411.9393.5 426.6393.0 423.3415.4399.4 422.5 424.5396.2 417.4
-Q1: 3.241 to 4.369 min from Sample 1 (Endosalfan Sulfate ) of Sulfate Neg.wiff (Turbo Spray), Smoothed Max. 2.3e6 cps.
410 412 414 416 418 420 422 424 426 428 430 432 434 436 438 440 442
m/z, Da
0.0
1.0e5
2.0e5
3.0e5
4.0e5
5.0e5
6.0e5
7.0e5
8.0e5
9.0e5
1.0e6
1.1e6
1.2e6
1.3e6
1.4e6
1.5e6
1.6e6
1.7e6
1.8e6
1.9e6
2.0e6
2.1e6
2.2e6
2.3e6
In
te
ns
ity
,c
ps
421.0
422.8
419.0
425.0
426.7
425.9
429.0427.7 441.6
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
59
standard.
2.3.5 Method conclusion and application
Both β-endosulfan and endosulfan sulfate are to be determined simultaneously from the same 
sample if the acceptance criteria are met for both calibration ranges. Having two different
calibration ranges also implies that calibration standards and quality control samples would each
contain the two compounds at different concentrations. All analysis performed on the instrument
was interfaced to a DELL® work station running Analyst® software version 1.5.2, and all data
generated was captured and stored on this workstation. Watson™ LIMS software version 7.1 was
used to process the raw data.
2.4 INTRODUCTION TO THE VALIDATION PROCESS
Before subject samples can be analyzed with the developed analytical method, the reliability and
reproducibility of the method have to be confirmed by performing a validation. This is done in a
complete and well defined understandable format, proving accurate determination of β-endosulfan 
and endosulfan sulfate in human serum over a suitable concentration range. A complete validation
includes three validation batches consisting of repeated analysis of calibration standards and
quality control samples in three successive batches, each analyzed on different occurrences.
2.4.1 Calibration range
The calibration range of β-endosulfan was within 1 % from 0.800 ng/ml to 200 ng/ml and 0.117 
ng/ml to 30.0 ng/ml for endosulfan sulfate.
2.4.1.1 Preparation of calibration standards (STDs)
Primary stock solutions of each analyte were prepared in HPLC grade methanol to a final
concentration as indicated in Table 2.2. The primary stock solutions were used to spike an accurate
volume of pooled normal blank serum so that the ULOQ of each analyte is reached. This serves as
the highest concentration calibration standard (identified in this case as STD J). Serial dilutions of
STD J were then performed gravimetrically (1:1 dilutions), using the same blank pool of serum,
until the full range from ULOQ to LLOQ is achieved, i.e. in this case STD J - STD B (see Table
2.9). The individual calibration standards were divided into aliquots of 1 ml into three individual
sets of polypropylene tubes. A set of aliquots were used after preparation for the first validation
batch and the rest of the aliquots were stored at approximately -20°C to be used in validation
batches 2 and 3 and for the analysis of the study samples. The storage conditions of the prepared
calibration standards were the same as applied to the storage of the subject samples.
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Table 2.9 Preparation of calibration standards
Sample Source A B C D
Identification Solution (g) (g) (ng/ml) (ng/ml)
STD J Stock solution 30.029 204 30.0
STD I STD J 7.000 14.000 102 15.0
STD H STD I 7.000 14.001 51.1 7.49
STD G STD H 7.001 14.007 25.6 3.75
STD F STD G 6.999 14.002 12.8 1.87
STD E STD F 7.001 14.001 6.39 0.937
STD D STD E 7.000 14.001 3.20 0.468
STD C STD D 7.002 14.004 1.60 0.234
STD B STD C 4.999 10.003 0.799 0.117
A = Mass of container + normal blank serum
B = Total mass of container + normal blank serum + spiked serum
C = Concentration of β-endosulfan 
D = Concentration of endosulfan sulfate
Note: Density of human serum is 1.0269kg/l
2.4.2 Preparation of quality controls (QCs)
Quality control samples were similarly prepared gravimetrically in pooled blank serum by using
the primary stock solutions of β-endosulfan and endosulfan sulfate prepared for the calibration 
standards. An accurate volume of normal blank serum was spiked to the highest concentration of
each individual analyte (QC H). QC H was then serially diluted with normal blank serum to
achieve the desired concentrations (QC H - QC A; see Table 2.10). The quality control samples
were aliquoted into three individual sets of polypropylene tubes. A set of aliquots were used after
preparation for the first validation batch and the rest of the aliquots were stored at approximately -
20°C to be used in validation batches 2 and 3 and for the analysis of the study samples. The
prepared quality control samples were stored under the same conditions as the subject samples.
Table 2.10 Preparation of quality control samples
Sample Source A B C D
Code & No. Solution (g) (g) (ng/ml) (ng/ml)
QC H Stock solution 30.021 323 48.0
QC G QC H 8.002 15.998 162 24.0
QC F QC G 8.001 15.999 80.8 12.0
QC E QC F 8.001 16.000 40.4 6.00
QC D QC E 8.002 16.001 20.2 3.00
QC C QC D 7.998 16.002 10.10 1.15
QC B QC C 10.000 12.399 1.95 0.230
QC A QC B 5.000 8.500 0.805 0.117
A = Mass of container + normal blank serum
B = Total mass of container + normal blank serum + spiked serum
C = Concentration of β-endosulfan 
D = Concentration of endosulfan sulfate
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Note: Density of human serum is 1.0269kg/l
2.4.3 Preparation of stability samples
Quality Control samples prepared for the validation batches were used as stability samples. The
concentration of the sample must be determined immediately after preparation by using freshly
prepared calibration standards. The stability assessments were performed during the analysis of the
first validation batch.
2.4.4 Calibration curve
To test the acceptability of the calibration standards, duplicates of a set of the calibration standards
were analyzed using the validated analytical method. The responses were plotted against the
known nominal concentrations of these calibration standards. The calibration curves for
β-endosulfan and endosulfan sulfate, obtained using Watson™ LIMS version 7.1 software, covers 
the concentration ranges of 0.800 ng/ml to 200 ng/ml and 0.117 ng/ml to 30 ng/ml. See figures
2.12 and 2.13 and Tables 2.11 and 2.12.
Figure 2.12 Calibration curve of β-endosulfan
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Table 2.11 Results of the analysis of the calibration standards for β-endosulfan
Sample Replicates Calibration Concentration
ID Concentration(ng/ml) Found (ng/ml)
STD B 1 0.781 0.719
STD B 2 0.781 *0.368
STD C 1 1.56 1.69
STD C 2 1.56 1.66
STD D 1 3.13 *3.83
STD D 2 3.13 3.08
STD E 1 6.25 6.00
STD E 2 6.25 6.22
STD F 1 12.5 12.4
STD F 2 12.5 13.1
STD G 1 25.0 *20.1
STD G 2 25.0 24.0
STD H 1 50.0 49.9
STD H 2 50.0 47.3
STD I 1 100.0 109
STD I 2 100.0 98.6
STD J 1 200.0 180
STD J 2 200.0 219
Code: * = Deactivated calibration standard (% Dev > 15%)
Results %Dev Response per ng/ml
Mean 4.9 521.744
S.D 3.5 46.174
Calibration curve parameters
Regression method WAGNER
R-Squared 0.998
ULOQ 200 ng/ml
LLOQ 0.781 ng/ml
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Figure 2.13 Calibration curve of endosulfan sulfate
Table 2.12 Results of the analysis of the calibration standards for endosulfan sulfate
Sample Replicates Calibration Concentration
ID Concentration (ng/ml) Found (ng/ml)
STD B 1 0.117 0.130
STD B 2 0.117 0.103
STD C 1 0.234 0.247
STD C 2 0.234 0.207
STD D 1 0.469 0.536
STD D 2 0.469 0.448
STD E 1 0.938 0.944
STD E 2 0.938 0.996
STD F 1 1.88 1.86
STD F 2 1.88 2.03
STD G 1 3.75 3.35
STD G 2 3.75 3.69
STD H 1 7.50 7.43
STD H 2 7.50 7.35
STD I 1 15.0 15.9
STD I 2 15.0 15.3
STD J 1 30.0 27.0
STD J 2 30.0 30.1
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
64
Results %Dev Response per ng/ml
Mean 6.0 71757.200
S.D 4.7 5865.730
Calibration curve parameters
Regression method LINEAR (1/X**2)
R-Squared 0.991
ULOQ 30 ng/ml
LLOQ 0.117 ng/ml
2.5 RECOVERY
The absolute recovery of the extraction procedure was assessed by comparing the responses
measured for samples spiked with β-endosulfan and endosulfan sulfate post-extraction (reference 
samples) to responses measured for extracted quality controls. Six samples of each were injected at
high, medium and low concentrations. Recovery was determined (expressed as a percentage) by
calculating the ratio of the β-endosulfan and endosulfan sulfate peak areas after extraction to the 
reference samples peak areas. The precision of the measured recovery expressed as percentage
coefficient of variation should not exceed 15%. See tables 2.13 and 2.14 for the recovery
assessment results for β-endosulfan and endosulfan sulfate, respectively. 
Table 2.13 Recovery of β-endosulfan
Injection
No.
β-Endosulfan extract Β-Endosulfan reference
(Peak areas) (Peak areas)
High Conc. Medium Conc. Low Conc. High Conc. Medium Conc. Low Conc.
1 145300 26590 1447 128800 28200 1519
2 108700 33910 1326 125200 32800 1413
3 125500 33410 1255 129800 31200 1509
4 127100 30350 1746 115100 32060 1901
5 122800 29830 1775 112600 32190 1692
6 119100 26600 1487 109400 33200 1371
Average 124750 30115 1506 12150 31608 1567.5
% CV 9.6 10.5 14.2 7.4 5.7 12.6
Recovery High Concentration(159.6 ng/ml)
Medium Concentration
(40.7 ng/ml)
Low Concentration
(2.3 ng/ml)
103.8 95.3 96.1
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Table 2.14 Recovery of endosulfan sulfate
Injection No.
Endosulfan-sulfate extract Endosulfan-sulfate reference
(Peak areas) (Peak areas)
High Conc. MediumConc. Low Conc. High Conc.
Medium
Conc. Low Conc.
1 2117000 508500 29130 2278000 553600 32020
2 1757000 641600 27850 2240000 606600 29800
3 1950000 620100 27870 2171000 590300 31660
4 2150000 562000 30070 2111000 588300 32450
5 2140000 524200 34110 2048000 617900 32620
6 2061000 486600 31010 2095000 621200 32770
Average 2029166.67 557166.67 30006.67 2157166.67 596313.67 31886.67
% CV 7.5 11.2 7.9 4.1 4.2 3.5
Recovery High Concentration(24.1 ng/ml)
Medium Concentration
(6.2 ng/ml)
Low Concentration
(0.3 ng/ml)
94.1 93.4 94.1
β-endosulfan and endosulfan sulfate at high (159.6 ng/ml and 24.1 ng/ml, respectively), medium 
(40.7 ng/ml and 6.2 ng/ml, respectively) and low (2.8 ng/ml and 0.3 ng/ml, respectively)
concentrations were used to determine the recovery of the analytes. Results obtained from the
samples peak areas after extraction compared to the reference samples peak areas indicated an
extraction efficiency of 103.8%, 95.3% and 96.1% for β-endosulfan and an extraction efficiency of 
94.1%, 93.4% and 94.1% for endosulfan sulfate.
2.6 SELECTIVITY ASSESMENT
Using the quality control samples, several assessments were performed to prove the selectivity of
the analytical method for the specific analytes. It is important to establish selectivity since the
biological matrix is a complex mixture of components with the potential for interfering with the
analytical process which may lead to aberrant conclusions regarding the quantification of the
analytes in the matrix.
2.6.1 Blank selectivity
Blank serum samples from six different sources were analyzed by the developed method for the
determination of β-endosulfan and endosulfan sulfate to prove analytical specificity. Figure 2.14 
depicts a chromatogram resulting from this analysis showing that no interfering chromatographic
peaks were found at the expected retention times of 3.25 minutes for β-endosulfan and 2.38 
minutes for endosulfan sulfate. The detection of either of the analytes in serum samples can
therefore not be ascribed to interfering components extracted from the serum.
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Figure 2.14 A Representative chromatogram of a blank serum extract
2.6.2 Matrix Effects
The effect of matrix components on the ionization of β-endosulfan and endosulfan sulfate was 
assessed at high and low concentration levels, by comparing the peak areas of two sets of samples.
The first set of samples contained no matrix ions, but consisted of β-endosulfan and endosulfan 
sulfate in the reconstitution solution (reference samples). For the second set of samples containing
matrix ions, six different lots of blank serum samples were extracted. The extracted samples (test
samples) were reconstituted with the reconstitution solution containing β-endosulfan and 
endosulfan sulfate at the same concentrations as that of the reference samples. The reference and
test samples were analyzed together.
This assessment was performed at high (160 ng/ml and 24.0 ng/ml) and low (3 ng/ml and 0.3
ng/ml) concentrations of β-endosulfan and endosulfan sulfate, respectively.  
As described before, the analyte matrix factor (MF) is determined by dividing the analyte peak
areas in presence of matrix (test samples) by the corresponding analyte peak area in the absence of
matrix (reference samples). An absolute MF value of 1.00 indicates no matrix effect, while a
matrix factor of greater than one indicates ionization enhancement and a matrix factor less than one
indicates ionization suppression. The relative matrix effect is expressed as the coefficient of
variation (% CV) and is acceptable when it has a value equal or less than 15%.
XIC of -MRM (2 pairs): 421.000/97.000 Da ID: Endosalfan Sulfate from Sample 1 (19 007 LCMS VAL298/01-CVC BLANK 1) of V19CVC007.wiff (T... Max. 746.7 cps.
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Tables 2.15 and 2.16 indicate that matrix components had a slight effect, especially at low
concentration of both the analytes. The % CV in both cases is however low, indicating the
constancy of this effect and making it acceptable.
Table 2.15 Assessment of the influence of matrix components on the analysis of β-endosulfan 
at high and low concentrations
Matrix
Identification
High Concentration Relative to
Calibration Curve
Low Concentration Relative to
Calibration Curve
(160 ng/ml) (3 ng/ml)
Analyte Peak
Area in
Presence of
Matrix Ions
Analyte Peak
Area in
Absence of
Matrix Ions
Analyte
Matrix
Factor
Analyte Peak
Area in
Presence of
Matrix Ions
Analyte Peak
Area in
Absence of
Matrix Ions
Analyte
Matrix
Factor
Matrix 1 131100 104900 1.08 1200 819.2 1.263
Matrix 2 138700 111400 1.15 1237 761.4 1.30
Matrix 3 130600 119800 1.08 945.2 1029 0.99
Matrix 4 114200 128400 0.94 1200 971 1.26
Matrix 5 127600 131700 1.06 1151 1051 1.21
Matrix 6 135700 129300 1.12 1081 1068 1.14
Average 120917 1.07 Average 950 1.20
% CV of Matrix Factors 6.6 % CV of Matrix Factors 9.5
Table 2.16 Assessment of the influence of matrix components on the analysis of endosulfan
sulfate at high and low concentrations
Matrix
Identification
High Concentration Relative to
Calibration Curve
Low Concentration Relative to Calibration
Curve
(24.0 ng/ml) (0.3 ng/ml)
Analyte Peak
Area in
Presence of
Matrix Ions
Analyte Peak
Area in
Absence of
Matrix Ions
Analyte
Matrix
Factor
Analyte Peak
Area in
Presence of
Matrix Ions
Analyte Peak
Area in
Absence of
Matrix Ions
Analyte
Matrix Factor
Matrix 1 1775000 1426000 1.231 18960 12240 1.419
Matrix 2 1715000 1418000 1.19 17750 12660 1.33
Matrix 3 1583000 1449000 1.10 14740 13690 1.10
Matrix 4 1374000 1445000 0.953 18720 13570 1.401
Matrix 5 1621000 1442000 1.12 16880 13900 1.26
Matrix 6 1781000 1468000 1.24 16440 14100 1.23
Average 1441333 1.14 Average 13360 1.29
% CV of Matrix Factors 9.4 % CV of Matrix Factors 9.1
2.6.3 Effect of haemolysis
Serum prepared from haemolysis blood contains higher concentrations of the ingredients of red
blood cells, such as heme, the presence of which may have an effect on the ionization and the
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analysis of analytes in such a matrix. To assess such a possibility, haemolyzed serum was
artificially prepared by the addition of haemolysed blood to normal serum and comparing the
responses of samples prepared in this matrix to the responses obtained from samples prepared in
normal serum.
A set of samples containing the analyte at concentrations equal to that of the high and low QCs was
prepared in severely haemolysed drug-free serum (about 5% haemolysis). The estimated QClow was
2 - 3 times that of the LLOQ and estimated QChigh were about 80% of the ULOQ.
A second set of samples were prepared similarly in normal (not haemolysed) drug-free serum to
the same concentration levels. Both sets of samples were analyzed in six-fold at each concentration
level. The analyte peaks areas obtained by the analysis of the haemolysed matrix samples were
compared with that of the normal matrix samples.
For both β-endosulfan and endosulfan sulfate, the % difference (which should not be exceeding 
15%) between the mean peak areas observed for the haemolysed samples and normal samples
indicates a negligible effect due to the presence of haemolysis components. The precision,
indicated as % CV of the peak areas of both the haemolysed and normal samples, was within 15%,
which demonstrates acceptable reproducibility of analysis (see Tables 2.17 and 2.18).
Table 2.17 Assessment of the influence of a matrix containing components from haemolysed
blood on the analysis of β-endosulfan at high and low concentrations
Replicate
β-Endosulfan Peak Area
High Analyte Concentration Low Analyte Concentration
Haemolysis Matrix Normal Matrix Haemolysis Matix Normal Matrix
(160 ng/ml) (160 ng/ml) (0.3 ng/ml) (0.3 ng/ml)
1 197400 177600 3711 3482
2 193300 195600 3045 3272
3 200200 179600 3075 3248
4 199700 195300 3269 3824
5 184200 207100 3408 3329
6 211900 193300 3053 3345
Average 197783 191417 3260 3417
% Diff 3.3 N/A -4.6 N/A
% CV 4.6 5.8 8.1 6.3
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Table 2.18 Assessment of the influence of a matrix containing components from haemolysed
blood on the analysis of endosulfan sulfate at high and low concentrations
Replicate
Endosulfan sulfate Peak Area
High Analyte Concentration Low Analyte Concentration
Haemolysis Matrix Normal Matrix Haemolysis Matix Normal Matrix
(24.0 ng/ml) (24.0 ng/ml) (0.3 ng/ml) (0.3 ng/ml)
1 3264000 2762000 55130 48830
2 3221000 2782000 54890 47590
3 3234000 2766000 51650 47830
4 3186000 2895000 51480 50070
5 3103000 2985000 50570 49780
6 3406000 2859000 49350 47930
Average 3235667 2841500 52178 48672
% Diff 13.9 N/A 7.2 N/A
% CV 3.1 3.1 4.5 2.2
The results meet the required acceptance criteria, indicating that haemolysis had no significant
effect on the analysis of β-endosulfan and endosulfan sulfate at high and low concentrations, and 
hence β-endosulfan and endosulfan sulfate can be accurately quantified in the presence of severe 
hemolysis.
2.6.4 Effect of Lipemia
Due to physiological conditions, serum prepared from the blood of individual donors/study
subjects may contain high levels of lipids. Such samples are judged to be lipemic and because
some of these endogenous lipids can also interfere with the analytical method, an assessment of
such a possibility is usually performed similar to that performed to assess the effect of haemolysis.
A set of samples at both high and low concentrations of the analytes are therefore prepared in
lipemic matrix and analytically compared to a similar set of samples prepared in normal (non
lipemic) drug-free matrix at the same concentration levels. These samples were analyzed in
six-fold at each concentration level according to the prescribed analysis procedure.
The acceptance criteria, similar to the haemolysis assessment, state that no effect is observed if
both the mean % difference and % of coefficient of variation do not exceed 15%. Table 2.19 and
2.20 however, clearly indicates that both parameters are noticeably affected by lipemic serum. This
was also noted at both high and low concentration of both analytes.
The results of this assessment therefore indicate that both β-endosulfan and endosulfan sulfate 
cannot accurately be quantified in lipemic samples, and should be excluded from the analysis and
reported as such.
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Table 2.19 Assessment of the influence of a matrix containing components from lipemic
serum on the analysis of β-endosulfan at high and low concentrations  
Replicate
β-endosulfan Peak Area
High Analyte Concentration Low Analyte Concentration
Lipemic Matrix Normal Matrix Lipemic Matix Normal Matrix
(160 ng/ml) (160 ng/ml) (3 ng/ml) (3 ng/ml)
1 197500 77060 3622 1326
2 139000 86720 1978 1804
3 80710 193500 1563 3547
4 76670 194000 1077 3801
5 74310 208200 1526 3280
6 83630 200000 1384 3143
Average 108637 159913 1858 2817
% Diff -32.1 N/A -34.0 N/A
% CV 45.9 38.0 49.1 35.8
Table 2.20 Assessment of the influence of a matrix containing components from lipemic
serum on the analysis of endosulfan sulfate at high and low concentrations
Replicate
Endosulfan sulfate Peak Area
High Analyte Concentration Low Analyte Concentration
Lipemic Matrix Normal Matrix Lipemic Matix Normal Matrix
(24.0 ng/ml) (24.0 ng/ml) (0.3 ng/ml) (0.3 ng/ml)
1 3053000 1927000 50820 33790
2 2551000 2091000 38730 36710
3 2161000 2549000 31480 42590
4 2060000 2800000 30940 47070
5 2011000 2932000 32850 46160
6 2066000 2846000 31790 47670
Average 2317000 2524167 36102 42332
% Diff -8.2 N/A -14.7 N/A
% CV 17.7 16.7 21.5 13.8
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2.7 VALIDATION PERFORMANCE
The validation of an analytical method is defined as a process by which the accuracy, precision and
repeatability of an analytical method is proven. It is performed by analyzing the calibration
standards in three batches of which two are done on one day and the third on a consecutive day.
For this study, calibration standards (STD’s) were analyzed in duplicate ranging from 0.780 ng/ml
to 200 ng/ml and 0.117 ng/ml to 30 ng/ml for β-endosulfan and endosulfan sulfate, respectively. 
Since no internal standards were employed, the instrument response expressed as the integral of the
chromatographic peaks, was proportionally equated to the concentration of the analytes in the
sample, according to the regression function used.
Quality control samples (QC’s) were analyzed for each validation batch by extracting 6 replicates
to cover the range of each concentration level (QC H – QC A), to determine the accuracy and
precision of the method.
Within-batch accuracy and precision were assessed for each of the three consecutive validation
batches that were successfully completed. A Wagner calibration curve weighted by 1 and a Linear
1/concentration2 were selected for β-endosulfan and endosulfan sulfate, respectively. 
The accuracy of the method was determined by comparing the analytically acquired concentrations
of the quality control samples to the nominal (theoretical) concentrations and expressed as a
percentage (% nom). The precision of the method was determined by calculating the percentage
relative standard deviation (% RSD) determined between the concentrations obtained from quality
control samples at the same concentration level.
Each validation batch consisted of:
• Ten System Suitability Samples (SYS)
• Calibration standards (STDs) in duplicate
• Blank samples and zero samples
• Quality control samples (QCs) in six fold
The results of each of the three individual validation batches are displayed in section 2.7.1 to 2.7.4.
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2.7.1 Intra-batch accuracy and precision for validation batch 1
Figure 2.15 Calibration curve constructed by analysis of the STD’s in validation batch 1,
indicating the β-endosulfan concentration in each 
Table 2.21 Back- calculated STD concentrations in ng/ml (Validation 1)
Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.800 1.60 3.19 6.39 12.8 25.6 51.1 102 204
1 0.884 1.36 3.26 7.07 13.0 25.3 51.3 101 213
% Bias 10.5 -15 2.2 10.6 1.6 -1.2 0.4 -1.0 4.4
2 0.823 1.46 3.27 6.67 12.8 26.0 50.2 -94.3 207
% Bias 2.9 -8.8 -0.6 4.4 0.0 1.6 -1.8 -7.5 1.5
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Table 2.22 Quality control samples summary in ng/ml (Validation 1)
Replicates
QC A QC B QC C QC D QC E QC F QC G QC H(Dil)
0.805 1.95 10.1 20.2 40.4 80.8 162 323
1 0.716 2.02 9.90 20.5 42.2 85.1 165 304
2 0.800 2.11 10.3 21.6 44.1 84.6 167 346
3 0.785 1.95 10.9 19.7 36.8 77.5 160 324
4 0.671 1.90 10.5 19.5 39.6 87.5 179 334
5 0.824 1.92 9.86 19.6 37.8 84.7 159 287
6 0.818 #1.53 9.18 18.6 38.1 73.5 152 307
Average 0.769 1.98 10.1 19.9 39.8 82.2 164 317
% CV 8.0 4.3 5.9 5.1 7.1 6.6 5.6 6.8
% Bias -4.5 1.5 0.0 -1.5 -1.5 1.7 1.2 -1.9
N 6 5 6 6 6 6 6 6
Code: # = % Dev > 15%
Figure 2.16 Calibration curve constructed by analysis of the STD’s in validation batch 1,
indicating the endosulfan sulfate concentration in each
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Table 2.23 Back- calculated STD concentrations in ng/ml (Validation 1)
Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.117 0.234 0.468 0.936 1.87 3.74 7.49 15.0 30.0
1 0.119 0.221 0.457 0.955 1.93 3.71 7.63 14.9 30.0
% Bias 1.7 -5.6 -2.4 2.0 3.2 -0.8 1.9 -0.7 0.0
2 0.119 0.230 0.490 0.942 1.80 3.76 7.60 17.1 30.8
% Bias 1.7 -1.7 4.7 0.6 -3.7 0.5 1.5 -6.0 2.7
Table 2.24 Quality control samples summary in ng/ml (Validation 1)
Replicates
QC A QC B QC C QC D QC E QC F QC G QC H (Dil)
0.121 0.294 1.52 3.04 6.07 12.1 24.3 48.6
1 0.130 0.311 1.53 3.14 6.50 12.9 24.7 46.8
2 0.130 0.302 1.53 3.12 6.50 12.6 25.4 51.0
3 0.129 0.293 1.63 3.09 5.94 12.6 25.0 50.1
4 0.114 0.306 1.61 3.12 6.26 13.4 26.4 51.8
5 0.119 0.284 1.48 3.00 5.69 12.6 24.7 47.1
6 0.130 0.291 1.47 3.02 6.19 12.1 23.0 47.3
Average 0.125 0.298 1.54 3.08 6.18 12.7 24.9 49.0
% CV 5.6 3.4 4.3 1.9 5.2 3.4 4.5 4.5
% Bias 3.3 1.4 1.3 1.3 1.8 5.0 2.5 0.8
N 6 6 6 6 6 6 6 6
The results obtained from validation batch one met all validation criteria for β-endosulfan and 
endosulfan sulfate analyzed in serum.
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2.7.2 Intra-batch accuracy and precision for validation batch 2
Figure 2.17 Calibration curve constructed by analysis of the STD’s in validation batch 2,
indicating the β-endosulfan concentration in each 
Table 2.25 Back- calculated STD concentrations in ng/ml (Validation 2)
Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.800 1.60 3.19 6.39 12.8 25.6 51.1 102 204
1 0.822 1.57 3.30 6.38 *10.3 25.5 *36.2 100 208
% Bias 2.8 -1.9 3.4 -0.2 -19.5 -0.4 -29.2 -2.0 2.0
2 0.803 1.57 3.16 6.07 13.4 25.3 50.9 110 192
% Bias 0.4 -1.9 -0.9 -5.0 4.7 -1.2 -0.4 7.8 -5.9
Code: * = Deactivated calibration standard (% Dev > 15%)
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
76
Table 2.26 Quality control samples summary in ng/ml (Validation 2)
Replicates
QC A QC B QC C QC D QC E QC F QC G
0.805 1.95 10.1 20.2 40.4 80.8 162.0
1 0.663 1.96 10.8 19.8 #32.9 74.0 150
2 0.719 #1.57 10.6 20.5 42.0 78.9 148
3 0.825 1.99 9.94 #15.7 36.9 86.4 159
4 0.770 2.01 11.1 23.2 43.1 83.2 160
5 ##0.992 2.09 #11.7 #7.31 39.8 82.2 161
6 ##0.609 2.00 10.5 21.3 37.8 76.0 156
Average 0.763 1.93 10.8 20.10 38.8 80.1 156
% CV 17.8 9.5 5.5 13.8 9.6 5.8 3.5
% Bias -5.2 -1.0 6.9 -0.5 -4.0 -0.9 -2.7
N 6 6 6 5 6 6 6
Code: # = % Dev > 15%
## = % Dev 20%
Figure 2.18 Calibration curve constructed by analysis of the STD’s in validation batch 2,
indicating the endosulfan sulfate concentration in each
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Table 2.27 Back- calculated STD concentrations in ng/ml (Validation 2)
Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.117 0.234 0.468 0.936 1.87 3.74 7.49 15.0 30.0
1 0.118 0.238 0.490 0.988 1.73 4.00 *5.84 15.0 30.2
% Bias 0.9 1.7 4.7 5.6 -7.5 7.0 -22.0 0.0 0.7
2 0.116 0.231 0.456 0.874 1.92 3.70 7.66 15.5 27.6
% Bias -0.9 -1.3 -2.6 -6.6 2.7 -1.1 2.3 3.3 -8.0
Code: * = Deactivated calibration standard (% Dev > 15%)
Table 2.28 Quality control samples summary in ng/ml (Validation 2)
Replicates
QC A QC B QC C QC D QC E QC F QC G
0.121 0.294 1.52 3.04 6.07 12.1 24.3
1 0.126 0.314 1.58 3.07 5.27 11.9 24.5
2 0.121 0.303 1.57 3.18 6.35 12.2 22.9
3 0.129 0.313 1.47 #2.48 5.55 12.6 23.8
4 0.121 0.289 1.60 3.23 6.12 11.8 23.0
5 0.125 0.299 1.53 #1.15 5.83 12.0 23.2
6 0.119 0.287 1.56 3.10 5.76 11.3 22.6
Average 0.124 0.301 1.55 3.01 5.81 12.0 23.3
% CV 3.0 3.8 3.0 10.1 6.7 3.6 3.0
% Bias 2.5 2.4 2.0 -0.9 -4.3 -0.8 -4.1
N 6 5 6 5 6 6 6
Code: # = % Dev > 15%
The results obtained from validation batch two met all the criteria for β-endosulfan and endosulfan 
sulfate analyzed in serum.
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2.7.3 Intra-batch accuracy and precision for validation batch 3
Figure 2.19 Calibration curve constructed by analysis of the STD’s in validation batch 3,
indicating the β-endosulfan concentration in each 
Table 2.29 Back- calculated STD concentrations in ng/ml (Validation 3)
Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.800 1.60 3.19 6.39 12.8 25.6 51.1 102 204
1 0.755 1.73 3.19 5.92 12.5 23.4 46.2 97.2 212
% Bias -5.6 8.1 0.0 -7.4 -2.3 -8.6 -9.6 -4.7 3.9
2 0.825 1.53 3.37 6.57 12.9 27.0 56.7 117 188
% Bias 3.19 -4.4 5.6 2.8 0.8 5.5 11.0 14.7 -7.8
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Table 2.30 Quality control samples summary in ng/ml (Validation 3)
Replicates
QC A QC B QC C QC D QC E QC F QC G
0.805 1.95 10.1 20.2 40.4 80.8 162
1 0.921 2.06 9.89 #16.7 37.0 79.2 164
2 0.737 1.89 9.90 18.9 40.1 86.2 168
3 0.757 2.08 10.9 19.6 40.5 85.0 176
4 0.780 2.21 11.1 19.9 43.4 90.2 185
5 0.886 2.06 11.1 21.9 42.5 #95.6 #187
6 0.951 #2.32 10.8 22.5 40.7 84.4 #188
Average 0.839 2.10 10.6 19.9 40.7 86.8 178
% CV 10.9 7.0 5.4 10.6 5.5 6.4 5.8
% Bias 4.2 7.7 5.0 -1.5 0.7 7.4 9.9
N 6 6 6 6 6 6 6
Code: # = % Dev > 15%
Figure 2.20 Calibration curve constructed by analysis of the STD’s in validation batch 3,
indicating the endosulfan sulfate concentration in each
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Table 2.31 Back- calculated STD concentrations in ng/ml (Validation 3)
Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.117 0.234 0.468 0.936 1.87 3.74 7.49 15.0 30.0
1 0.11 0.244 0.490 0.906 1.95 3.76 7.36 15.0 29.3
% Bias -5.1 4.3 4.7 -3.2 4.3 0.5 -1.7 0.00 -2.3
2 0.119 0.231 0.488 0.959 1.83 3.78 7.82 15.3 25.8
% Bias 1.7 -1.3 4.3 2.5 -2.1 1.1 4.4 2.0 -14.0
Table 2.32 Quality control samples summary in ng/ml (Validation 3)
Replicates
QC A QC B QC C QC D QC E QC F QC G
0.121 0.294 1.52 3.04 6.07 12.1 24.3
1 0.108 0.313 1.55 2.72 6.10 12.4 23.3
2 0.115 0.307 1.57 3.09 6.23 12.1 23.0
3 0.106 0.317 1.66 3.05 6.39 12.5 25.0
4 0.122 0.306 1.67 3.04 6.40 12.9 25.2
5 ##0.096 0.292 1.60 3.23 6.16 13.2 24.5
6 0.132 0.318 1.68 3.17 5.91 12.3 24.2
Average 0.113 0.309 1.62 3.05 6.20 12.6 24.2
% CV 11.2 3.1 3.4 5.8 3.0 3.2 3.7
% Bias -5.6 5.1 6.6 0.3 2.1 4.1 -0.4
N 6 6 6 6 6 6 6
Code: ## = % Dev > 20%
The results obtained from validation batch three met all the validation criteria for β-endosulfan and 
endosulfan sulfate analyzed in serum.
2.7.4 Intra-batch accuracy and precision for reinjection batch
To prove the robustness of the method, one of the validation batches was reinjected and the results
of the reinjected batch compared to those of the original batch. Validation batch 2 was chosen as
the reinjection validation batch and the results are indicated in figure 2.21 and 2.22 and in tables
2.33 to 2.36.
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Figure 2.21 Calibration curve constructed by analysis of the STD’s during the reinjection of
validation batch 2, indicating the β-endosulfan concentration in each 
Table 2.33 Back- calculated STD concentrations in ng/ml (Re-injection validation batch 2)
Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.800 1.60 3.19 6.39 12.8 25.6 51.1 102 204
1 0.811 1.62 3.22 6.00 13.0 22.7 *43.0 93.7 204
% Bias 1.4 1.3 0.9 -6.1 1.6 -11.3 -15.9 -8.1 0.0
2 0.763 1.62 3.38 6.69 12.4 25.6 55.5 117 197
% Bias -4.6 1.3 6.0 4.7 -3.1 0.0 8.6 14.7 -3.4
Code: * = Deactivated calibration standard (% Dev > 15%)
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
82
Table 2.34 Quality control samples summary in ng/ml (Re-injection validation batch 2)
Replicates
QC A QC B QC C QC D QC E QC F QC G
0.805 1.95 10.1 20.2 40.4 80.8 162.0
1 0.702 1.92 9.24 #16.8 36.8 89.6 163
2 ##0.630 2.02 10.4 20.4 39.3 80.5 184
3 0.721 2.17 10.6 19.8 40.5 86.2 185
4 0.840 2.03 10.5 18.9 42.9 91.4 #193
5 0.680 2.04 10.3 21.5 42.2 92.0 186
6 0.891 2.19 10.7 21.5 40.3 86.4 #194
Average 0.744 2.06 10.3 19.8 40.3 87.7 184
% CV 13.4 4.9 5.2 9.0 5.4 4.9 6.1
% Bias 7.6 -5.6 -2.0 2.0 0.2 -8.5 -13.6
N 6 6 6 6 6 6 6
Code: # = % Dev > 15%
## = % Dev 20%
Figure 2.22 Calibration curve constructed by analysis of the STD’s during the reinjection of
validation batch 2, indicating the endosulfan sulfate concentration in each
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Table 2.35 Back- calculated STD concentrations in ng/ml (Re-injection validation batch 2)
Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.117 0.234 0.468 0.936 1.87 3.74 7.49 15.0 30.0
1 0.0.106 0.239 0.468 0.921 1.94 3.68 6.99 14.8 29.3
% Bias -9.4 2.1 0.0 -1.6 3.7 -1.6 -6.7 -1.3 -2.3
2 0.124 0.236 0.493 0.962 1.82 3.76 7.64 15.3 25.1
% Bias 6.0 0.9 5.3 2.8 -2.7 0.5 2.0 2.0 -16.3
Table 2.36 Quality control samples summary in ng/ml (Re-injection validation batch 2)
Replicates
QC A QC B QC C QC D QC E QC F QC G
0.121 0.294 1.52 3.04 6.07 12.1 24.3
1 0.117 0.326 1.59 2.93 6.06 13.3 23.3
2 0.116 0.301 1.61 3.06 5.63 12.0 23.5
3 0.116 0.304 1.59 3.07 6.02 12.4 24.3
4 0.119 0.303 1.63 2.91 6.17 12.3 24.6
5 0.120 0.298 1.57 3.16 6.15 12.9 24.6
6 0.125 0.307 1.61 3.11 5.79 11.9 23.4
Average 0.119 0.307 1.60 3.04 5.97 12.5 24.0
% CV 2.9 3.3 1.3 3.3 3.6 4.3 2.6
% Bias -1.7 4.4 5.3 0.0 -1.6 3.3 -1.2
N 6 6 6 6 6 6 6
The results obtained from the reinjection of validation batch 2 compared well with the values
obtained for the original batch and therefore met all validation criteria set for this assessment
2.7.4.1 Summary of the intra-batch accuracy and precision
All results were calculated using the WATSON LIMS™ (Laboratory Information Management
System) data capturing software interfaces automatically with the Analyst 1.5.2 software used on
the instruments. Acquired data files are automatically analyzed and summarised and the data points
fitted to the pre-set regression model, calculating the concentrations of the injected samples by
comparison to the theoretical concentrations of the calibration standards.
The intra-batch accuracy and precision of each validation batch were evaluated separately by
calculation of the regression equation and constructing the calibration curve based on the best
results.
The results of the intra-batch validation are summarized in tables with the performance statistics
per batch as summarised in table 2.21 to table 2.36. All acceptance criteria for the intra-batch
validations were met.
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2.7.5 Inter-batch accuracy and precision for all the validation batches
2.7.5.1 Inter-batch accuracy and precision results
The between-batch accuracy and precision were evaluated by calculating the accuracy and
precision statistics over all three validation batches. Assessment of the β-endosulfan content was as 
follows:.
Table 2.37 Parameters of the calibration curves used for the analysis of β-endosulfan over the 
three validation batches (ln(Resp.) = A * (ln(Conc.))**2 + B * ln(Conc.) + C)
Validation batch
Calibration Curve Parameters (β-endosulfan)
A B C R-Squared (r2)
Validation 1 -0.01176 1.072 7.170 0.998752
Validation 2 0.005359 0.9621 7.255 0.999693
Validation 3 -0.005519 1.001 7.521 0.998591
Average -0.003973 1.012 7.315 0.999012
% CV -218.1 5.5 2.3 0.1
Table 2.38 Back-calculated calibration standard concentrations of β-endosulfan in ng/ml for 
the three validation batches
Validation
batch Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.800 1.60 3.19 6.39 12.8 25.6 51.1 102 204
Validation 1
1 0.884 1.36 3.26 7.07 13.0 25.3 51.3 101 213
2 0.823 1.46 3.17 6.67 12.8 26.0 50.2 94.3 207
Validation 2
1 0.822 1.57 3.30 6.38 *10.3 25.5 *36.2 100 208
2 0.803 1.57 3.16 6.07 13.4 25.3 50.9 110 192
Validation 3
1 0.755 1.73 3.19 5.92 12.5 23.4 46.2 97.2 212
2 0.825 1.53 3.37 6.57 12.9 27.0 56.7 117 188
Average 0.819 1.54 3.24 6.45 12.9 25.4 51.1 103 203
% CV 5.1 8.1 2.6 6.5 2.5 4.6 7.3 8.3 5.3
% Bias 2.4 -3.8 1.6 0.9 0.8 -0.8 0.0 1.0 -0.5
N 6 6 6 6 5 6 5 6 6
Code: * = Deactivated calibration standard (% Dev > 15%)
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Table 2.39 Statistics for the β-endosulfan contents of quality control samples for the three 
validation batches (concentration is in ng/ml)
Validation
Replicates
QC A QC B QC C QC D QC E QC F QC G
batch 0.805 1.95 10.1 20.2 40.4 80.8 162
Validation 1
1 0.716 2.02 9.90 20.5 42.2 85.1 165
2 0.800 2.11 10.3 21.6 44.1 84.6 167
3 0.785 1.95 10.9 19.7 36.8 77.5 160
4 0.671 1.90 10.5 19.5 39.6 87.5 179
5 0.824 1.92 9.86 19.6 37.8 84.7 159
6 0.818 #1.53 9.18 18.6 38.1 73.5 152
Validation 2
1 0.663 1.96 10.8 19.8 #32.9 74.0 150
2 0.719 #1.57 10.6 20.5 42.0 78.9 148
3 0.825 1.96 9.94 #15.7 36.9 86.4 159
4 0.770 2.01 11.1 23.2 43.1 83.2 160
5 ##0.992 2.09 #11.7 [7.31] 39.8 82.2 161
6 ##0.609 2.00 10.5 21.3 37.8 76.0 159
Validation 3
1 0.921 2.06 9.89 #16.7 37.0 79.2 164
2 0.737 1.89 9.90 18.9 40.1 86.2 168
3 0.757 2.08 10.9 19.6 40.5 85.0 176
4 0.780 2.21 11.1 19.9 43.4 90.2 185
5 0.886 2.06 11.1 21.9 42.5 #95.6 #187
6 0.951 #2.32 10.8 22.5 40.7 84.4 #188
Average 0.790 1.98 10.5 19.97 39.7 83.0 166
% CV 12.8 9.6 5.9 9.5 7.4 6.9 7.5
% Bias -1.9 1.5 4.0 -1.1 -1.7 2.7 2.5
N 18 18 18 17 18 18 18
Code: # = % Dev > 15%
## = % Dev 20%
[ ] = Outlier not included in statistics (MNR outlier test)
The inter-batch accuracy and precision for endosulfan sulfate over all three validation batches were
as follows:
Table 2.40 Parameters of the calibration curves used for the analysis of endosulfan sulfate
over the three validation batches (Resp. = Slope * Conc. + Intercept)
Validation batch
Calibration Curve Parameters (Sulfate)
Slope Intercept R-Squared (r2)
Validation 1 122100 930.7 0.998040
Validation 2 137800 233.8 0.997340
Validation 3 139300 2713 0.997032
Average 133100 1293 0.997471
% CV 7.2 98.9 0.1
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Table 2.41 Back-calculated calibration standard concentrations of endosulfan sulfate in
ng/ml for the three validation batches
Validation
batch Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.117 0.234 0.468 0.936 1.87 3.74 7.49 15.0 30.0
Validation 1
1 0.117 0.223 0.468 0.980 1.97 3.75 7.59 14.6 28.7
2 0.117 0.233 0.502 0.966 1.84 3.80 7.56 13.8 29.4
Validation 2
1 0.118 0.238 0.490 0.988 1.73 4.00 *5.84 15.0 30.2
2 0.116 0.231 0.456 0.874 1.92 3.70 7.66 15.5 27.6
Validation 3
1 0.111 0.244 0.490 0.906 1.95 3.76 7.36 15.0 29.3
2 0.19 0.231 0.488 0.959 1.83 3.78 7.82 15.3 25.8
Average 0.116 0.233 0.482 0.946 1.87 3.80 7.60 14.9 28.4
% CV 2.4 3.1 3.5 4.8 4.8 2.7 2.2 4.1 5.5
% Bias -0.9 -0.4 3.0 1.1 0.0 1.6 1.5 -0.7 -5.0
N 6 6 6 6 6 6 5 6 6
Code: * = Deactivated calibration standard (% Dev > 15%)
Table 2.42 Statistics for the endosulfan sulfate contents of quality control samples for the
three validation batches (concentration is in ng/ml)
Validation
Replicates
QC A QC B QC C QC D QC E QC F QC G
batch 0.121 0.294 1.52 3.04 6.07 12.1 24.3
Validation 1
1 0.128 0.316 1.57 3.18 6.49 12.6 23.7
2 0.129 0.307 1.57 3.16 6.48 12.4 24.3
3 0.128 0.299 1.66 3.13 5.94 12.3 24.0
4 0.111 0.311 1.65 3.16 6.25 13.1 25.3
5 0.117 0.289 1.51 3.04 5.70 12.4 23.8
6 0.129 0.296 1.50 3.06 6.19 11.9 22.2
Validation 2
1 0.126 0.314 1.58 3.07 5.27 11.9 24.5
2 0.121 0.303 1.57 3.18 6.35 12.2 22.9
3 0.129 0.313 1.47 #2.48 5.55 12.6 23.8
4 0.121 0.289 1.60 3.23 6.12 11.8 23.0
5 0.125 0.299 1.53 #[1.15] 5.83 12.0 23.2
6 0.199 0.287 1.56 3.10 5.76 11.3 22.6
Validation 3
1 0.108 0.313 1.55 2.72 6.10 12.4 23.3
2 0.115 0.307 1.57 3.09 6.23 12.1 23.0
3 0.106 0.317 1.66 3.05 6.39 12.5 25.0
4 0.122 0.306 1.67 3.04 6.40 12.9 25.2
5 ##0.0960 0.292 1.60 3.23 6.16 13.2 24.5
6 0.132 0.318 1.68 3.17 5.91 12.3 24.2
Average 0.12 0.30 1.58 3.01 6.06 12.30 23.80
% CV 8.1 3.4 3.9 6.2 5.6 3.8 5.2
% Bias -0.8 3.4 3.9 0.8 -0.2 1.7 -2.1
N 18 18 18 17 18 18 18
Code: # = % Dev > 15%
## = % Dev > 20%
[] = Outlier not included in statistics (MNR-ESD outlier test)
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The overall % CV of the quality control samples of endosulfan sulfate was 6.2 as indicated in the
appendix C3 with one QC D as an outlier in the second validation batch.
2.7.5.2 Summary of the inter-batch accuracy and precision
The evaluation of the inter-batch accuracy and precision was assessed by the overall performance
of the quality control in all three validation batches. The statistical outlier for endosulfan sulfate in
validation batch 2 (injection 5; see Table 2.42) influenced the analytical performance of quality
control standard levels. After the exclusion of this statistical outlier, the overall statistics for the
combined validation batches were again evaluated and found to be within the acceptance criteria.
The decision that this one value can be interpreted as a statistical outlier is based on the MNR-ESD
outlier test being applied to QC level D and the results of this are included in the appendix section
of this dissertation.
The % CV (precision) of the quality control samples of β-endosulfan ranged from 5.9 % to 12.8 % 
and endosulfan sulfate ranged from 3.4 % to 8.1 %, respectively with one QC D as an outlier in the
second validation batch.
The % Bias (accuracy) of the quality control samples of β-endosulfan ranged from -1.9 % to 4.0 % 
and endosulfan sulfate ranged from -2.1 % to 3.9 %, respectively with one QC D as an outlier in
the second validation batch
The results confirmed that the % CV values for the intra- and inter-batch accuracy and precision
were less than 15% and less than 20% at the LLOQ making this a valid method.
2.7.6 Dilution integrity
The dilution integrity was assessed during the first validation batch by using the prepared quality
control sample (QC H) that was above the upper limit of quantification (ULOQ).
QC H was diluted (1:1) with normal blank serum and analyzed in order to validate the dilution of
unknown sample concentrations that does not fall within the validated range of the analysis.
Evaluated results confirmed that this dilution may be applied to β-endosulfan and endosulfan 
sulfate samples with concentration levels up to 323.0 ng/ml and 48.0 ng/ml, respectively.
2.7.7 Lower limit of quantification (LLOQ)
The lower limit of quantification was assessed with accuracy and precision of below 20%, and the
produced signal to noise ratio was indicated to be 8.9 and 22.6 for β-endosulfan and endosulfan 
sulfate, respectively. See figures 2.23 and 2.24.
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Figure 2.23 A representative chromatogram of β-endosulfan extracted from STD B (LLOQ). 
S/N ratio is 8.9
Figure 2.24 A representative chromatogram of endosulfan sulfate extracted from STD B
(LLOQ). S/N ratio is 22.5
XIC of -MRM (2 pairs): 405.000/305.000 Da ID: Endosulfan Beta from Sample 1 (10 041 LCMS VAL298/01-CVC STD B 1 1) of V10CVC041.wiff (T... Max. 203.8 cps.
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2.8 STABILITY ASSESMENTS
2.8.1 Short term stability (On bench)
Short-term matrix stability of β-endosulfan and endosulfan sulfate was determined in serum at high 
and low concentration levels. Serum samples were spiked with β-endosulfan and endosulfan 
sulfate at high concentration (162 ng/ml and 22.9 ng/ml, respectively), and low concentration (1.95
ng/ml and 0.308 ng/ml, respectively) and stored frozen at approximately -20°C until used.
Six aliquots of the stability samples at each concentration level were thawed and allowed to stand
at room temperature for approximately 8 hours. The stability samples were analyzed and the
concentrations were determined using a calibration curve derived from freshly prepared calibration
standards.
The means of the measured concentrations were compared with the nominal concentrations and
indicated that the % Bias and the % CV are within 15%, resulting in a reliable stability assessment
(see Table 2.43).
Table 2.43 Results of the short term stability assessment of β-endosulfan and endosulfan 
sulfate in human serum (concentration is in ng/ml)
Replicate
Short term stability
β-Endosulfan Endosulfan sulfate
High Concentration LowConcentration
High
Concentration
Low
Concentration
Nominal 162 1.95 22.9 0.308
1 164 2.02 23.1 0.296
2 164 2.09 23 0.341
3 158 2.35 22 0.311
4 155 2.04 23.4 0.327
5 156 2.43 23.3 0.316
6 160 2.33 21.8 0.312
Average 159.5 2.21 22.77 0.32
% Diff -1.5 13.3 -0.6 3.0
% CV 2.4 8.1 3.0 4.8
Results obtained from short-term stability met the required acceptance criteria for the compounds
left in the biological matrix for 8 hours at room temperature.
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2.8.2 Freeze-thaw stability
Freeze-thaw stability of β-endosulfan and endosulfan sulfate was determined in serum at high and 
low concentration levels, over three freeze-thaw cycles. The concentration levels were the same as
that used for short term stability assessment.
Six aliquots of the stability samples that have been frozen for 24 hours were thawed unassisted at
room temperature. When completely thawed, they were refrozen for at least 12 hours.
After a third freeze-thaw cycle, the samples were analyzed and the concentrations were determined
using a calibration curve derived from freshly prepared calibration standards.
As indicated in Table 2.44, the means of the measured concentrations were compared with the
nominal concentration that indicated that the % Bias and the % CV are within 15 %, resulting in a
reliable stability assessment.
Table 2.44 Results of the freeze-thaw stability assessment of β-endosulfan and endosulfan 
sulfate in human serum (concentration is in ng/ml)
Replicate
Freeze thaw stability
β-Endosulfan Endosulfan sulfate
High ConcentrationLow Concentration HighConcentration Low Concentration
Nominal 162 1.95 22.9 0.308
1 131 1.75 19.2 0.296
2 161 2.05 22.7 0.317
3 154 2.35 21.9 0.319
4 154 1.87 23.4 0.326
5 166 2.43 23.5 0.334
6 153 2.41 21.8 0.301
Average 153.17 2.14 22.08 0.32
% Diff -5.5 9.9 -3.6 2.4
% CV 7.8 13.8 7.2 4.6
Results obtained from freeze thaw stability met the required acceptance criteria for the compounds
over three freeze thaw cycles.
2.8.3 On-Instrument stability
On-instrument stability of β-endosulfan and endosulfan sulfate was assessed to demonstrate that 
the compounds are stable in the extract (after sample preparation) when stored on the instrument at
approximately +5°C.
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For the assessment of on-instrument stability, six individual aliquots of the stability samples at
high and low concentration levels of the two compounds, as used for the stability assessments
above, were extracted and the extracts were pooled. The pooled extracts were placed on the auto
sampler at 5°C and analysed after a period of 24 hours has elapsed, against a freshly prepared set
of calibration standards.
As indicated in Table 2.45, the % Bias and the % CV were within 15%, indicating reliable stability
of β-endosulfan and endosulfan sulfate left as extracts on instrument. 
Table 2.45 Results of the on instrument stability assessment of β-endosulfan and endosulfan 
sulfate in human serum (concentration is in ng/ml)
Replicate
On-Instrument stability
β-Endosulfan Endosulfan sulfate
High ConcentrationLow Concentration HighConcentration Low Concentration
Nominal 162 1.95 24.3 0.294
1 206 2.42 29.5 0.362
2 185 2.29 28 0.342
3 179 2.09 27.6 0.339
4 168 2.31 26.2 0.304
5 161 2.15 26.4 0.31
6 176 2.13 25.3 0.325
Average 179.17 2.23 27.17 0.33
% Diff 10.6 14.4 11.8 12.4
% CV 8.7 5.7 5.5 6.7
2.8.4 Stability of stock solutions
Separate stock solutions of β-endosulfan and endosulfan sulfate were prepared in methanol at 
concentrations of 100 µg/ml of β-endosulfan and 22 µg/ml of endosulfan sulfate. Aliquots of each 
solution were kept at room temperature for at least 8 hours and at approximately 5ºC and at
~ -20ºC, for up to 12 days. Just prior to analysis, the solutions were spiked into the reconstitution
solutions to achieve concentrations of 200 ng/ml for β-endosulfan and 30.0 ng/ml endosulfan 
sulfate. These solutions were then chromatographically analyzed together with freshly prepared
reference stock solutions of the compounds at the same concentrations and following the same
dilutions.
The peak areas of the stored stock solutions were compared to that of the freshly prepared stock
solutions and the % difference between the two preparations was found to be within 15%. The
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
92
precision, expressed as % CV, was also within 15% (see Tables 2.46 and 2.47 for β-endosulfan and 
endosulfan sulfate respectively).
Table 2.46 Stability assessment of β-endosulfan as a working solution in methanol, at 
200 ng/ml, kept at the temperature conditions indicated
Replicate
Working Solution Peak Area (β-Endosulfan) 
Room Temperature ~ 5°C ~ -20°C Fresh (Reference)
1 139000 139400 143800 148900
2 141000 139700 147200 148000
3 140500 140800 146700 151000
4 140000 140900 144900 150200
5 138100 138600 146800 147900
6 140000 144000 147600 149000
Average 139767 140567 146167 149167
% of Reference 93.7 94.2 98.0 N/A
% CV 0.8 1.3 1.0 0.8
Table 2.47 Stability assessment of endosulfan sulfate as a working solution in methanol, at
30 ng/ml, kept at the temperature conditions indicated
Working Solution Peak Area (Endosulfan sulfate)
Replicate Room Temperature ~ 5 °C ~ -20 °C Fresh (Reference)
1 4718000 4623000 5041000 4771000
2 4700000 4659000 5004000 4831000
3 4785000 4654000 4995000 4791000
4 4815000 4547000 5015000 4758000
5 4731000 4664000 4964000 4749000
6 4688000 4657000 4996000 4777000
Average 4739500 4634000 5002500 4779500
% of Reference 99.2 97.0 104.7 N/A
% CV 1.1 1.0 0.5 0.6
The results indicate that β-endosulfan and endosulfan sulfate are stable in methanol when stored at 
room temperature, at approximately 5ºC and at approximately - 20ºC for 12 days.
2.8.5 Long term stability
The storage period for long-term stability evaluation should exceed the time between the date of
first sample collection during the clinical trial and the date of last sample analysis. Long-term
stability was not determined during this study for the period that the study samples was stored due
to the fact that sample collection during the clinical trial was performed at least a year before the
start of the study and there was not enough time available to store QCs for the required time to
assess stability covering the full storage period.
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A long-term stability assessment was however performed for the period of 1 month, covering the
period from the first day of study sample analysis to the last day of study sample analysis, using
quality control samples (QC) that were stored from the date of preparation during method
development until completion of the analysis of the last study sample.
Quality control samples containing β-endosulfan and endosulfan sulfate at high concentration (162 
ng/ml and 22.9 ng/ml, respectively) and low concentration (1.95 ng/ml and 0.308 ng/ml,
respectively) were stored frozen at ~ -20°C for a period of 30 days. The samples were analyzed
against a calibration curve consisting of freshly prepared STDs and the measured concentrations
were compared to the nominal concentrations of the samples. The results obtained met the required
acceptance criteria for both compounds, proving stability in the matrix for at least 30 days (see
Table 2.48).
Table 2.48 Long term stability assessment of β-endosulfan and endosulfan sulfate in human 
serum stored at approximately -20°C for one month (concentration is in ng/ml)
Replicate
Long term stability
β-Endosulfan Endosulfan sulfate
High ConcentrationLow Concentration HighConcentration Low Concentration
Nominal 162 1.95 22.9 0.308
1 144 2.22 22.6 0.311
2 147 2.13 23.3 0.29
3 151 2.15 23.7 0.297
4 156 1.53 24.2 0.3
5 142 1.99 24 0.296
6 144 1.62 21.6 0.307
Average 147.33 1.92 23.23 0.300
% Diff -9.1 -1.7 1.5 -2.5
% CV 3.6 14.6 4.2 2.6
2.9 SAMPLE ANALYSIS RESULTS
2.9.1 β-Endosulfan and endosulfan sulfate 
A total of 219 serum samples which were collected during the clinical trial, were received for
analysis. The samples were divided into three equal quantities and analyzed in three separate
batches, referred to as production batches, to confirm the presence of β-endosulfan or endosulfan 
sulfate. The samples were collected from agricultural farm workers and other individuals reported
to have been exposed to endosulfan during treatment of fruit trees with the pesticide.
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The production batches each consisted of STDs that were extracted in duplicate, ranging from
0.800 ng/ml to 200 ng/ml and 0.117 ng/ml to 30 ng/ml for β-endosulfan and endosulfan sulfate, 
respectively. The sequence of the production batches was designed so that the STDs were placed in
decreasing order of concentration, starting from the highest STD (ULOQ) to the lowest standard
(LLOQ). The first replicate of the STDs was positioned in the first part of the batch and the second
replicate at the end of the batch.
Two replicates of the QCs at each concentration level (QC G – QC A), covering the entire
calibration range, were included in each production batch in order to determine the accuracy and
precision of the method. The QCs were distributed throughout each production batch in groups of
decreasing concentration order after a STD.
A Wagner calibration curve and a linear curve, weighted by 1/concentration2 were selected for
β-endosulfan and endosulfan sulfate, respectively. 
The production batch acceptance criteria are described in section 1.5 and were determined by using
the calculated concentration of the STDs and QC samples.
Each production batch contained ten system suitability samples (SYS) to evaluate the system
during the run. No upwards or downward trends in the responses of the SYS samples were noticed
in any of the production runs.
The performance of the STDs and QCs over the three production runs are displayed in tables 2.49
to 2.54.
Table 2.49 Back-calculated calibration standard concentrations of β-endosulfan in ng/ml for 
the three production batches
Production
batch Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.799 1.60 3.20 6.39 12.8 25.6 51.1 102 204
Production 1
1 0.748 *3.64 3.51 6.76 13.3 26.3 *38.1 104 194
2 0.901 1.4 3.05 *3.78 *16.3 25.2 44 108 215
Production 2
1 0.858 1.42 *2.24 6.81 13.4 *31.7 56.9 112 223
2 0.824 1.6 3.15 5.74 12.1 28.7 44.4 99.6 175
Production 3
1 0.794 1.48 3.09 6.72 13.1 26.8 45.1 103 197
2 0.804 1.41 3.17 6.15 12.4 25.4 47.6 105 204
Average 0.821 1.46 3.19 6.44 12.9 26.5 47.6 105 201
% CV 6.5 5.7 5.7 7.3 4.5 5.3 11.3 4.1 8.4
% Bias 2.8 -8.6 -0.1 0.7 0.4 3.4 -6.8 3.2 -1.3
N 6 5 5 5 5 5 5 6 6
Code: * = Deactivated calibration standard (% Dev > 15%)
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Table 2.50 Statistics for the β-endosulfan contents of quality control samples for the three 
production batches (concentration is in ng/ml)
Production
Replicates
QC A QC B QC C QC D QC E QC F
batch 1.95 10.1 20.2 40.4 80.8 162
Production 1
1 ##2.67 10.9 #23.9 43.3 83 159
2 2.1 #8.30 18.8 34.7 76.9 #212
Production 2
1 2.15 11 #23.9 #51.1 90.8 184
2 2.06 #8.29 23.2 41.2 82.2 165
Production 3
1 2.08 10.4 19.6 38.7 79.8 164
2 2.04 10.9 20.3 41.2 81.6 166
Average 2.08 10.8 20.47 39.82 82.38 167.6
% CV 2.0 2.5 9.4 8.3 5.7 5.7
% Bias 7.0 6.9 1.4 -1.4 2.0 3.5
N 6 6 6 6 6 6
Code: # = % Dev > 15%
## = % Dev > 20%
Table 2.51 Back-calculated calibration standard concentrations of endosulfan sulfate in
ng/ml for the three production batches
Production
batch Replicates
STD B STD C STD D STD E STD F STD G STD H STD I STD J
0.117 0.234 0.468 0.937 1.87 3.75 7.49 15.0 30.0
Production 1
1 0.111 0.239 0.507 1.03 2.01 3.98 7.14 14.6 26.5
2 0.115 0.249 0.446 0.889 1.98 4.02 7.62 13.6 26.8
Production 2
1 0.125 0.26 0.46 0.978 2.12 4.11 7.68 14.9 28.7
2 0.108 0.215 0.461 0.854 1.93 3.78 6.93 13.4 *22.0
Production 3
1 0.11 0.258 0.485 0.933 1.99 3.94 8.05 15.1 28.1
2 *0.0650 *0.190 *0.338 0.817 2.09 3.68 7.06 *12.1 26.2
Average 0.114 0.244 0.472 0.917 2.02 3.92 7.41 14.3 27.3
% CV 5.9 7.5 5.1 8.7 3.5 4.1 5.9 5.4 4
% Bias -2.6 4.3 0.9 -2.1 8 4.5 -1.1 -4.7 -9
N 5 5 5 6 6 6 6 5 5
Code: * = Deactivated calibration standard (% Dev > 15%)
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Table 2.52 Statistics for the endosulfan sulfate contents of quality control samples for the
three production batches (concentration is in ng/ml)
Production
Replicates
QC A QC B QC C QC D QC E QC F
batch 0.294 1.52 3.03 6.07 12.1 24.3
Production 1
1 0.33 #1.76 3.45 6.43 12.1 23
2 0.326 1.64 3.12 6.43 13.2 26.3
Production 2
1 0.318 1.49 3.23 6.72 12.1 26.4
2 0.25 #1.07 3.12 5.63 10.8 21.6
Production 3
1 0.306 1.56 2.71 6.37 13.3 23.8
2 ##0.219 #1.21 3.18 6.5 12.4 21.6
Average 0.292 1.45 3.14 6.35 12.3 23.8
% CV 15.8 17.9 7.7 5.9 7.4 9.1
% Bias -0.7 -4.6 3.6 4.6 1.7 -2.1
N 6 6 6 6 6 6
Code: # = % Dev > 15%
## = % Dev > 20%
Table 2.53 Summary of calibration curve parameters over the three production batches for
β-endosulfan (ln(Resp.) = A * (ln(Conc.))**2 + B * ln(Conc.) + C)) 
Production batch
Calibration Curve Parameters (β-endosulfan)
A B C R-Squared (r2)
Production 1 -0.003410 1.237 6.634 0.998752
Production 2 0.001017 1.016 6.634 0.999693
Production 3 -0.003550 1.110 6.730 0.998591
Average -0.00198 1.121 6.666 0.999012
% CV -131.1 9.9 0.8 0.1
Table 2.54 Summary of calibration curve parameters over the three production batches for
endosulfan sulfate (Resp. = Slope * Conc. + Intercept)
Production batch
Calibration Curve Parameters (Sulfate)
Slope Intercept R-Squared (r2)
Production 1 169100 1604 0.992944
Production 2 88790 31.25 0.992206
Production 3 111200 -628.9 0.992104
Mean 123030 335.45 0.992418
% CV 33.68 341.96 0.04
Evaluation of the % CV of the QC B’s of endosulfan sulfate across the three production batches
resulted in a value of 17.9%, which is outside of the accepted criteria. This was however accepted
due to the fact that these QCs passed within each batch and the similar values for the validation
batches were well within the acceptable range.
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Notwithstanding this good performance as judged by the acceptance criteria, the presence of
neither β-endosulfan nor endosulfan sulfate could be indicated in any of the subject samples. Due 
to the fact that each sample only contained about 200 µl of serum, no re-analysis of any of the
samples could be performed. Results obtained from each of the three individual production batches
are displayed in table 2.55 to 2.57.
Table 2.55 Results summary of production batch 1 for β–endosulfan and endosulfan sulfate 
Production batch 1 Production batch 1
Sample
Name
β-Endosulfan Endosulfan sulfate
Sample
Name
β-Endosulfan Endosulfan sulfate
Calc. Conc.
(ng/ml)
Calc. Conc.
(ng/ml)
Calc. Conc.
(ng/ml)
Calc. Conc.
(ng/ml)
Subject 1 BLQ BLQ Subject 54 BLQ BLQ
Subject 2 BLQ BLQ Subject 55 BLQ BLQ
Subject 3 BLQ BLQ Subject 56 BLQ BLQ
Subject 4 BLQ BLQ Subject 57 BLQ BLQ
Subject 5 BLQ BLQ Subject 59 BLQ BLQ
Subject 8 BLQ BLQ Subject 60 BLQ BLQ
Subject 9 BLQ BLQ Subject 61 BLQ BLQ
Subject 11 BLQ BLQ Subject 62 BLQ BLQ
Subject 13 BLQ BLQ Subject 64 BLQ BLQ
Subject 14 BLQ BLQ Subject 65 BLQ BLQ
Subject 15 BLQ BLQ Subject 67 BLQ BLQ
Subject 16 BLQ BLQ Subject 68 BLQ BLQ
Subject 17 BLQ BLQ Subject 69 BLQ BLQ
Subject 20 BLQ BLQ Subject 70 BLQ BLQ
Subject 22 BLQ BLQ Subject 71 BLQ BLQ
Subject 23 BLQ BLQ Subject 72 BLQ BLQ
Subject 25 BLQ BLQ Subject 73 BLQ BLQ
Subject 27 BLQ BLQ Subject 75 BLQ BLQ
Subject 28 BLQ BLQ Subject 76 BLQ BLQ
Subject 29 BLQ BLQ Subject 77 BLQ BLQ
Subject 31 BLQ BLQ Subject 78 BLQ BLQ
Subject 32 BLQ BLQ Subject 79 BLQ BLQ
Subject 33 BLQ BLQ Subject 80 BLQ BLQ
Subject 34 BLQ BLQ Subject 81 BLQ BLQ
Subject 35 BLQ BLQ Subject 82 BLQ BLQ
Subject 39 BLQ BLQ Subject 83 BLQ BLQ
Subject 40 BLQ BLQ Subject 84 BLQ BLQ
Subject 41 BLQ BLQ Subject 85 BLQ BLQ
Subject 42 BLQ BLQ Subject 86 BLQ BLQ
Subject 43 BLQ BLQ Subject 87 BLQ BLQ
Subject 44 BLQ BLQ Subject 88 BLQ BLQ
Subject 45 BLQ BLQ Subject 89 BLQ BLQ
Subject 46 BLQ BLQ Subject 91 BLQ BLQ
Subject 50 BLQ BLQ Subject 92 BLQ BLQ
Subject 52 BLQ BLQ Subject 93 BLQ BLQ
Subject 53 BLQ BLQ Subject 94 BLQ BLQ
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
98
Table 2.56 Results summary of production batch 2 for β–endosulfan and endosulfan sulfate 
Production batch 2 Production batch 2
Sample
Name
β-Endosulfan Endosulfan sulfate
Sample
Name
β-Endosulfan Endosulfan sulfate
Calc. Conc.
(ng/ml)
Calc. Conc.
(ng/ml)
Calc. Conc.
(ng/ml)
Calc. Conc.
(ng/ml)
Subject 95 BLQ BLQ Subject 135 BLQ BLQ
Subject 96 BLQ BLQ Subject 136 BLQ BLQ
Subject 97 BLQ BLQ Subject 137 BLQ BLQ
Subject 98 BLQ BLQ Subject 138 BLQ BLQ
Subject 99 BLQ BLQ Subject 139 BLQ BLQ
Subject 100 BLQ BLQ Subject 140 BLQ BLQ
Subject 101 BLQ BLQ Subject 141 BLQ BLQ
Subject 102 BLQ BLQ Subject 142 BLQ BLQ
Subject 103 BLQ BLQ Subject 143 BLQ BLQ
Subject 104 BLQ BLQ Subject 144 BLQ BLQ
Subject 105 BLQ BLQ Subject 145 BLQ BLQ
Subject 106 BLQ BLQ Subject 146 BLQ BLQ
Subject 107 BLQ BLQ Subject 147 BLQ BLQ
Subject 109 BLQ BLQ Subject 148 BLQ BLQ
Subject 110 BLQ BLQ Subject 149 BLQ BLQ
Subject 111 BLQ BLQ Subject 151 BLQ BLQ
Subject 112 BLQ BLQ Subject 154 BLQ BLQ
Subject 113 BLQ BLQ Subject 155 BLQ BLQ
Subject 114 BLQ BLQ Subject 156 BLQ BLQ
Subject 115 BLQ BLQ Subject 157 BLQ BLQ
Subject 116 BLQ BLQ Subject 158 BLQ BLQ
Subject 117 BLQ BLQ Subject 159 BLQ BLQ
Subject 118 BLQ BLQ Subject 160 BLQ BLQ
Subject 119 BLQ BLQ Subject 161 BLQ BLQ
Subject 121 BLQ BLQ Subject 162 BLQ BLQ
Subject 122 BLQ BLQ Subject 163 BLQ BLQ
Subject 123 BLQ BLQ Subject 164 BLQ BLQ
Subject 124 BLQ BLQ Subject 165 BLQ BLQ
Subject 125 BLQ BLQ Subject 166 BLQ BLQ
Subject 126 BLQ BLQ Subject 167 BLQ BLQ
Subject 127 BLQ BLQ Subject 168 BLQ BLQ
Subject 128 BLQ BLQ Subject 169 BLQ BLQ
Subject 129 BLQ BLQ Subject 170 BLQ BLQ
Subject 130 BLQ BLQ Subject 171 BLQ BLQ
Subject 131 BLQ BLQ Subject 172 BLQ BLQ
Subject 134 BLQ BLQ Subject 173 BLQ BLQ
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Table 2.57 Results summary of production batch 3 for β–endosulfan and endosulfan sulfate 
Production batch 3 Production batch 3
Sample
Name
β-endosulfan Endosulfan sulfate
Sample
Name
β-endosulfan Endosulfan sulfate
Calc. Conc.
(ng/ml)
Calc. Conc.
(ng/ml)
Calc. Conc.
(ng/ml)
Calc. Conc.
(ng/ml)
Subject 174 BLQ BLQ Subject 215 BLQ BLQ
Subject 176 BLQ BLQ Subject 216 BLQ BLQ
Subject 177 BLQ BLQ Subject 217 BLQ BLQ
Subject 178 BLQ BLQ Subject 218 BLQ BLQ
Subject 179 BLQ BLQ Subject 219 BLQ BLQ
Subject 180 BLQ BLQ Subject 220 BLQ BLQ
Subject 181 BLQ BLQ Subject 221 BLQ BLQ
Subject 182 BLQ BLQ Subject 222 BLQ BLQ
Subject 183 BLQ BLQ Subject 223 BLQ BLQ
Subject 184 BLQ BLQ Subject 224 BLQ BLQ
Subject 185 BLQ BLQ Subject 225 BLQ BLQ
Subject 186 BLQ BLQ Subject 226 BLQ BLQ
Subject 187 BLQ BLQ Subject 227 BLQ BLQ
Subject 188 BLQ BLQ Subject 228 BLQ BLQ
Subject 189 BLQ BLQ Subject 229 BLQ BLQ
Subject 190 BLQ BLQ Subject 230 BLQ BLQ
Subject 191 BLQ BLQ Subject 231 BLQ BLQ
Subject 192 BLQ BLQ Subject 232 BLQ BLQ
Subject 193 BLQ BLQ Subject 233 BLQ BLQ
Subject 194 BLQ BLQ Subject 235 BLQ BLQ
Subject 195 BLQ BLQ Subject 236 BLQ BLQ
Subject 196 BLQ BLQ Subject 237 BLQ BLQ
Subject 198 BLQ BLQ Subject 238 BLQ BLQ
Subject 199 BLQ BLQ Subject 239 BLQ BLQ
Subject 200 BLQ BLQ Subject 240 BLQ BLQ
Subject 201 BLQ BLQ Subject 241 BLQ BLQ
Subject 202 BLQ BLQ Subject 247 BLQ BLQ
Subject 203 BLQ BLQ Subject 248 BLQ BLQ
Subject 204 BLQ BLQ Subject 250 BLQ BLQ
Subject 205 BLQ BLQ Subject 257 BLQ BLQ
Subject 206 BLQ BLQ Subject 259 BLQ BLQ
Subject 207 BLQ BLQ Subject 260 BLQ BLQ
Subject 208 BLQ BLQ Subject 262 BLQ BLQ
Subject 209 BLQ BLQ Subject 263 BLQ BLQ
Subject 210 BLQ BLQ Subject 264 BLQ BLQ
Subject 211 BLQ BLQ Subject 265 BLQ BLQ
Subject 213 BLQ BLQ Subject 266 BLQ BLQ
Subject 214 BLQ BLQ
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2.10 CONCLUSION
A robust and accurate analytical method for the quantitative determination of β-endosulfan and 
endosulfan sulfate in human serum was developed and validated using LC-MS/MS with
electrospray ionization and MRM scanning in the negative mode.
During the validation, intra- and inter-batch accuracy and precision were demonstrated by
analyzing calibration standards (STDs) and quality control samples (QCs) in three consecutive
validation batches each containing the calibration standards (STD J – STD B) in duplicate to yield
one calibration curve and six replicates of quality control samples (QC H – QC A). The method
was shown to be specific and selective.
The selected regression models adequately described the concentration-response relationships for
each compound. Based on a range that consisted of nine calibration levels, a Wagner regression
equation provided the best fit for β-endosulfan, while a linear equation, weighted 
by1/concentration2 provided the best fit for endosulfan sulfate. The regression models selected
during the validation were used for the quantification of the study samples.
No suitable internal standards could be found for either of the compounds. Stable isotope-labeled
congeners of the compounds were not commercially available and would not have been
sufficiently specific to separate their m/z values from that of the complex isotope patterns of the
compounds that each contains six chlorine atoms. Furthermore, related chlorinated pesticide
molecules such as dichlorodiphenyltrichloroethane (DDT) and dieldrin are not ionizable with
electrospray and could therefore not been used as internal standards. These compounds were used
as internal standards in published studies based on GC-MS/MS in which electron ionization was
applied [20] [26]. The fact that good retention times of both compounds were achieved during
chromatography and that no significant effect from normal matrix components could be evidenced,
contributed to the satisfactory performance of the method without using internal standards.
Although the matrix effect assessment indicated no significant influence on the analysis by the
normal matrix components, it should be noted that lipemia in the serum had noticeable effects on
the analysis of both compounds. This can be ascribed to the fact that high concentrations of
phospholipids in lipemic serum can possibly influence the successful formation of cations of both
analytes during the negative ionization process [70].
During the first validation batch the QC at the highest concentration level (QC H) were diluted
(1:1) with blank normal serum to evaluate dilution integrity and the results demonstrated that
samples with concentration levels above the upper limit of quantification (ULOQ) (up to 323 ng/ml
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
101
and 48 ng/ml for β-endosulfan and endosulfan sulfate, respectively) can be accurately quantified 
with this method.
System suitability tests were performed during each validation batch to ensure that the instrument
did not lose response (sensitivity) during the validation batches. This was also performed for the
three production batches.
The lower limit of quantification (LLOQ) was confirmed and successfully quantified with a signal
to noise ratio of 8.9 and 22.6 for β-endosulfan and endosulfan sulfate, respectively. No carry-over 
was observed as assessed during the analysis of the three validation batches. Reinjection
reproducibility was demonstrated by reinjecting the second validation batch. Stability assessments
were performed during the validation and as summarized in section 2.8, no indication of instability
of either of the two compounds could be found during any of the assessments.
The validation results indicated that the performance of the analytical method met the acceptance
criteria as stipulated in the European Medical Agency (EMA) and Food and Drug Administration
(FDA) guidelines [42] [43]. The method is therefore regarded to be suitable for the quantification
of β-endosulfan and endosulfan sulfate in human serum samples over a concentration range of 
0.800 ng/ml to 200 ng/ml and 0.117 ng/ml to 30 ng/ml, respectively.
The applicable clinical protocol (REC REF: 279/2005) mentions the detection of endosulfan and
other pesticides in surface and groundwater of rural Western Cape areas [8] [9] [10]. The samples
analyzed in this study originated from farm workers active in the same area and therefore thought
to have been exposed to the pesticides. However, no evidence for the exposure to endosulfan
pesticides could be found in any of the serum samples. This was notwithstanding the fact that the
STDs and QCs in the production batches conformed to the same standards found during the
validation performance. The fact that none of the compounds could be observed could therefore
not be ascribed to poor performance of the analytical method. Furthermore, the signal to noise ratio
of the LLOQs for both compounds, especially for endosulfan sulfate, was high enough to still
observe sub-LLOQ concentrations of the compounds. No such observations were made. The
reasons for the negative results may reside in seasonal variation in the application of pesticides
used for pest control. This possibility can be explored by correlating the pesticide products used
during or before the period of sampling. However, it may indicate that the time of sampling was
too long after exposure or exposure was not high enough to result in levels of the compounds
within the calibration range.
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CHAPTER 3
DEVELOPMENT AND VALIDATION OF A BIOANALYTICAL
METHOD FOR THE DETERMINATION OF DIALKYLPHOSPHATE
METABOLITES IN HUMAN URINE BY LC-MS/MS
3.1 INTRODUCTION
As indicated in the rationale for the clinical trial (REC REF: 279/2005), South Africa is the highest
pesticide user in Southern Africa and exposure to these harmful pesticides needs to be determined
to incorporate protective practices. Pesticide exposure can occur through a number of sources as
indicated in Chapter 1 and the approach to biological monitoring for organophosphates is based on
the analysis of diakylphosphate metabolites in urine [71] [72] [73]. Organophosphates are rapidly
hydrolyzed to the diakylphosphate (DAP) metabolites detectable in urine, and can be measured
several days after exposure [74]. Identification of these metabolites can be used to monitor the
occasional exposure to organophosphate pesticides [75] and the non-invasive sampling procedure
is preferable [76].
Previous investigations have shown that the use of first morning void urine samples accurately
represent total daily exposure to organophosphates [77] although variable urine production may
influence the concentration levels [71]. The ubiquitous use of house-hold pesticides containing
organophosphates poses a further disadvantage when measuring the DAP metabolites as markers
for specific agricultural exposure [71]. Environmental routes of exposure to pesticides through
contaminated food, soil, water and spray drift in addition to occupational exposure might be
important for rural residents in the Western Cape. The use of a control group of subjects to act as a
“population background level” is therefore essential.
Due to the superior specificity and sensitivity that can be achieved with high performance liquid
chromatography with tandem mass spectrometer detection (LC-MS/MS), this technique was
applied in this study to quantitatively measure three of the DAP metabolites, dimethyl phosphate
(DMP), diethyl phosphate (DEP), and dimethyl thiophosphate (DMTP), using the corresponding
deuterated molecules as internal standards. One method was developed to extract the three
metabolites from urine and to determine the concentrations by LC-MS/MS. Although other known
metabolites could also be assessed, the lack of appropriate internal standards to accurately quantify
all of the molecules restricted the method to the three mentioned above.
The developed and partially validated method used for the quantitative determination of
dialkylphosphate (DAP) metabolites in urine was performed at the University of Cape Town. This
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method was used to investigate the possible correlation between exposure to the pesticides and
urinary levels of the metabolites, data which can also be compared to literature reports.
3.2 CHEMICALS AND MATERIALS USED
3.2.1 Chemicals and reagents
Analytical reference standards of the three DAP metabolites, with purities higher than 99%, as well
as the corresponding deuterated internal standards were obtained from Sigma Aldrich. All
chemicals and reagents used in this study were of analytical grade.
3.2.2 Preparation of stock solutions
Separate primary stock solutions for the three dialkylphosphate metabolites were prepared at a
concentration of 100 µg/ml in acetonitrile as indicated in Table 3.1.
Similarly, stock solutions of the internal standards were prepared in water as indicated in Table 3.2.
All stock solutions were stored at approximately -20ºC and were used to prepare secondary
reference solutions.
Table 3.1 Preparation of primary stock solutions
Analyte Solvent used Solventdensity
Mass analyte
(mg)
Mass solvent
(g)
Volume
Solvent (ml)
Concentration
analyte
(µg/ml)
Dimethyl phosphate
(DMP) Acetonitrile 0.791 1.00 7.91 10 100
Dimethyl thiophosphate
(DMTP) Acetonitrile 0.791 1.00 7.91 10 100
Diethyl phosphate (DEP) Acetonitrile 0.791 1.00 7.91 10 100
Table 3.2 Preparation of internal standard working solutions
Deuterated Internal standard Solvent used Solventdensity
Mass
analyte (mg)
Mass
solvent
(g)
Volume
Solvent (ml)
Concentration
analyte
(µg/ml)
Dimethyl phosphate (DMP)-D6 Water 1 1.00 10 10 100
Dimethyl thiophosphate
(DMTP)-D6 Water 1 1.00 10 10 100
Diethyl phosphate (DEP))-D5 Water 1 1.00 10 10 100
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3.2.3 Biological matrix
The biological matrix for this study was human urine and therefore it was used to prepare the
calibration standards (STD) and quality control (QC) samples. The acquisition of completely blank
(drug-free) urine was however problematic as exposure to even low levels of organophosphates
leads to the presence of the DAP metabolites in urine. Thus the urine which was used for the
preparation of STDs and QCs had to be treated to remove potential interfering molecules. Stripping
with activated charcoal is an acceptable method for removing unwanted molecules from biological
matrices and the following procedure was used in this case:
1. To a round bottom flask (volumetric), add 5 g of activated charcoal for every 50 ml of
urine.
2. Stopper the flask and incubate overnight at room temperature on an orbital shaker.
3. Transfer to 50 ml tubes and centrifuge at 13000 x g for 20 minutes.
4. Repeat the stripping procedure with the supernatant (steps 1 and 3), while discarding
the pellet.
5. After the final stripping, repeat the centrifugation at 13000 x g for 20 minutes.
6. Transfer the supernatant to a clean 50 ml tube.
7. Pre-filter the stripped urine using qualitative filter paper under vacuum to remove the
charcoal.
8. Finally, filter the stripped urine through a 0.45 µM filter under vacuum.
9. Store the stripped urine at ~ -20oC until required.
3.2.4 LC-MS/MS optimization by spectral analysis
Appropriate dilutions of the stock solutions were prepared for infusion to determine their mass
spectra of the analytes and the internal standards. The acidic nature of the phosphate groups
ensured successful ionization with electrospray in the negative mode. The molecular ions were
identified according to the expected molecular weights and fragment mass spectra were produced
by collision induced dissociation of the precursor ions. The product ion mass spectra and proposed
structures of selected fragment ions are depicted in figures 3.1 to 3.3 for DMP, DMTP and DEP,
and the internal standards d6-DMP, d6-DMTP and d10-DEP respectively.
Optimized compound parameters were obtained during infusion. The declustering potential (DP),
entrance potential (EP), collision energy (CE) and collision exit potential (CXP) were all adjusted
to achieve optimal signal intensity. The fragment ions indicated in figures 3.1 to 3.3 were selected
and the ion transitions indicated in Table 3.4 were selected for the detection of each individual
compound.
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Figure 3.1 The mass spectra of the fragment ions of deprotonated dimethyl phosphate (DMP)
and its deuterated internal standard, DMP-d6. The structures of the fragment ions based on
their m/z values are proposed.
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Figure 3.2 The mass spectra of the fragment ions of deprotonated dimethyl thiophosphate
(DMTP) and its deuterated internal standard, DMTP-d6. The structures of the fragment ions
based on their m/z values are proposed
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Figure 3.3 The mass spectra of the fragment ions of deprotonated diethyl phosphate (DEP)
and its deuterated internal standard, DEP-d10. The structures of the fragment ions based on
their m/z values are proposed.
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3.3 ANALYTICAL METHODOLOGY
3.3.1 Sample preparation
Urine samples, used for the determination of the DAP metabolites were processed as follows:
• Aliquot 1 ml urine into a 5 ml polypropylene tube.
• Add 20 µl of internal standard (5 µg/ml) to the tube.
• Vortex for 30 seconds.
• Freeze dry the sample overnight.
• Add 2 ml acetonitrile to the tube.
• Vortex for 30 seconds.
• Ultrasonicate for 10 minutes.
• Vortex briefly.
• Centrifuge for 10 minutes at 3800 x g (~ 5oC).
• Transfer the supernatant to a glass tube.
• Evaporate using a MiVac evaporator until completely dry (approximately 45 minutes).
• Add 200 μl injection solvent (20 mM ammonium acetate : acetonitrile [95:5, v/v]) to the
glass tube
• Vortex briefly.
• Transfer 150 µl of the extract to a 96-well plate.
• Inject 10 µl onto the HPLC column.
3.3.2 Chromatographic separation
Chromatography was performed on a Phenomenex Luna C18 (4.6 mm x 150 mm, 5 μm)
analytical column. The column was kept at 30°C in an Agilent 1200 series column compartment.
The mobile phase was pumped through the column by an Agilent 1200 binary pump at a constant
flow-rate of 600 µl/minute. A gradient was created by mixing solvent A (acetonitrile) and solvent
B (20 mM ammonium acetate prepared in water) according to table 3.3
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Table 3.3 Time table for gradient elution
Step Time (min) % A % B
0 0.00 98 2
1 3.00 2 98
2 3.10 98 2
3 7.50 98 2
A volume of 10 µl of each sample was injected onto the column by an Agilent 1200 auto sampler,
equipped with an Agilent cooling device (sample cooler) set at 5oC. The auto sampler was
equipped with a flush port to enable a needle wash cycle of 20 seconds before each injection.
3.3.3 Detection
Tandem mass spectrometric analysis was performed on an AB SCIEX API 5500QTRAP triple
quadrupole mass spectrometer (AB SCIEX Toronto Canada) equipped with an electrospray
ionization (ESI) source operating in the negative ion mode. Mass spectrometer settings used for the
detection of DMP, DMTP and DEP, together with their respective internal standards, are indicated
in Table 3.4 to 3.7. These settings were selected from data acquired by the infusion of each
compound (see figures 3.1 to 3.3).
Table 3.4 Source parameter settings for the optimal detection of the dialkylphosphate (DAP)
metabolites and their internal standards
Electrospray Ionization Settings Value
Nebulizer gas (Gas 1) (arbitrary unit) 65
Turbo gas (Gas 2) (arbitrary unit) 35
CUR (curtain gas) (arbitrary unit) 30
CAD (collision gas) (arbitrary unit) Medium
TEM (source temperature) (°C) 500
IS ( Ion Spray Voltage) (V) -3500
Table 3.5 MS/MS settings for the optimal detection of the dialkylphosphate (DAP)
metabolites
MS/MS Settings Dimethyl phosphate(DMP)
Dimethyl thiophosphate
(DMTP)
Diethyl phosphate
(DEP)
Monoisotopic mass 126.008 141.985 154.039
Deprotonated monoisotopic mass (m/z) 125 141 153
Product ion monoisotopic mass (m/z) 79 126 79
Dwell time (ms) 150 150 150
DP (declustering potential) (V) -85 -195 -55
EP (entrance potential) (V) -10 -10 -10
CE (collision energy) (eV) -32 -16 -26
CXP (collision cell exit potential) (V) -7 -11 -9
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Table 3.6 MS/MS settings for the optimal detection of the dialkylphosphate (DAP)
metabolites internal standards
MS/MS Settings DMP-d6 DMTP-d6 DEP-d10
Monoisotopic mass 132.000 148.000 164.000
Deprotonated monoisotopic mass (m/z) 131 147 163
Product ion monoisotopic mass (m/z) 79 97 131
Dwell time (ms) 150 150 150
DP (declustering potential) (V) -85 -120 -120
EP (entrance potential) (V) -10 -10 -10
CE (collision energy) (eV) -32 -30 -16
CXP (collision cell exit potential) (V) -7 -5 -15
Table 3.7 Scan description for the optimal detection of the dialkylphosphate (DAP)
metabolites and their internal standards
Scan Description
Scan type MRM
Polarity Negative
Pause time 5 ms
3.3.4 Chromatographic results
The total runtime for each sample was 7.5 minutes. A representative chromatogram of an extracted
urine sample containing 25 ng/ml of each of DMP, DMTP and DEP together with the internal
standards (at 20 ng/ml) is presented in figure 4.9.
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Figure 3.4 A representative chromatogram of dialkylphosphate (DAP) metabolites and their
deuterated internal standards extracted from stripped human urine.
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3.3.5 Blank selectivity
Blank stripped urine samples from six different sources were analyzed and no interfering
components were evident at the retention times of the compounds as indicated in the representative
chromatogram of one of the sources shown in figure 3.5.
Figure 3.5 A representative chromatogram of a blank urine extract
3.3.6 Marix effects and selectivity
The matrix effects were assessed by comparing six different urine sources, spiked with each of the
compounds at three concentration levels (25 ng/ml, 12.5 ng/ml and 2 ng/ml) and at one
concentration with each of the internal standards. Employing the analytical method, the peak areas
of each of the compounds and each of the internal standards were determined for each sample. The
peak area ratios were then calculated for each compound by dividing the analyte peak areas by that
of the internal standards peak areas. By graphically plotting the concentration versus the peak area
ratio, a regression line for each urine pool was obtained. The slopes of these regression lines should
be similar between the different urine pools (% CV ≤15%) if matrix components do not influence 
the analysis.
Selectivity is indicated when the % CV of the area ratios of the six pools at a certain concentration
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is less than or equal to 15%. .
The results of these assessments for each analyte are depicted in Tables 3.8, 3.9 and 3.10 for DMP,
DMTP and DEP respectively.
Table 3.8 Peak area ratios of DMP at low, medium and high concentrations in six different
stripped urine pools
Stripped Urine
Peak Area Ratio
High Conc.
25.0 ng/ml
Peak Area Ratio
Medium Conc.
12.5 ng/ml
Peak Area Ratio
Low Conc.
2.00 ng/ml
Slope of Regression
Line
Area Ratio vs
Conc.
Pool 1 60.8 36.6 5.84 2.38
Pool 2 66.9 40.0 7.07 2.59
Pool 3 72.0 36.3 7.65 2.80
Pool 4 75.6 41.2 6.98 2.98
Pool 5 68.7 41.2 7.95 2.63
Pool 6 69.3 40.5 10.0 2.57
Average 68.9 39.3 7.58 2.66
STDEV 4.99 2.27 1.39 0.207
% CV 7.2b 5.8b 18.3b 7.8a
a Matrix effects are measured by the % CV of the slopes of the regression lines obtained by plotting
the peak area ratios against the concentration.
b Selectivity is measured by the % CV of the peak area ratios at each concentration level.
Table 3.9 Peak area ratios of DMTP at low, medium and high concentrations in six different
stripped urine pools
Stripped Urine
High Conc.
25.0 ng/ml
Peak Area Ratio
Medium Conc.
12.5 ng/ml
Peak Area Ratio
Low Conc.
2.00 ng/ml
Peak Area Ratio
Slope of Regression
Line
Area Ratio vs
Conc.
Pool 1 26.4 16.4 2.62 1.03
Pool 2 28.1 14.3 1.86 1.14
Pool 3 24.8 13.2 2.57 0.96
Pool 4 24.4 14.5 2.19 0.96
Pool 5 27.6 12.8 2.48 1.10
Pool 6 30.5 13.3 2.10 1.24
Average 27.0 14.10 2.30 1.07
STDEV 2.29 1.31 0.304 0.110
% CV 8.5b 9.3b 13.0b 10.2a
a Matrix effects are measured by the % CV of the slopes of the regression lines obtained by plotting
the peak area ratios against the concentration.
b Selectivity is measured by the % CV of the peak area ratios at each concentration level.
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Table 3.10 Peak area ratios of DEP at low, medium and high concentrations in six different
stripped urine pools
Stripped Urine
High Conc.
25.0 ng/ml
Peak Area Ratio
Medium Conc.
12.5 ng/ml
Peak Area Ratio
Low Conc.
2.00 ng/ml
Peak Area Ratio
Slope of Regression
Line
Area Ratio vs
Conc.
Pool 1 225 110 15.1 9.15
Pool 2 221 99.3 14.9 8.99
Pool 3 237 122 17.5 9.55
Pool 4 266 124 17.2 10.8
Pool 5 211 116 15.9 8.46
Pool 6 294 109 16.6 12.1
Average 243 113 16.2 9.85
STDEV 31.4 9.31 1.08 1.37
% CV 13.0b 8.2b 6.6b 13.9a
a Matrix effects are measured by the % CV of the slopes of the regression lines obtained by plotting
the peak area ratios against the concentration.
b Selectivity is measured by the % CV of the peak area ratios at each concentration level.
The assessment of matrix effects indicates that matrix components in stripped urine do not
significantly influence the analysis of the DAP metabolites.
The selectivity of the method is also acceptable, although it was observed that the % CV of the
peak area ratios at low concentration of DMP did not meet the acceptance criteria (% CV > 15).
This was most probably due to a too high value incurred from the last injection and this point can
probably be regarded as a statistical outlier.
3.4 VALIDATION
The method was partially validated at the University of Cape Town as indicated in the following
paragraphs.
3.4.1 Accuracy and precision
Accuracy and precision were assessed by analyzing three consecutive, independent validation
batches. The calibration curves fit quadratic regressions, weighted by 1/concentration, for all three
DAP metabolites across the concentration range of 1 – 32 ng/ml. No indications of carry over or
interfering peaks were observed during the analysis of the validation batches and no analyte peaks
were observed in chromatograms of the blank samples.
The results are expressed as those for the three independent validation (intra-batch accuracy and
precision) and then a statistical comparison is made between the three batches (inter-batch
accuracy and precision). Lastly, validation batch two was re-injected to prove acceptability of the
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re-injection of a complete validation batch.
3.4.1.1 Intra-batch accuracy and precision
3.4.1.1.1 Validation batch 1
The calculation of the concentrations of DMP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure 3.6),
resulted in the values for the calibration standards and quality control standards as indicated in
tables 3.11 and 3.12 respectively.
Figure 3.6 Calibration curve constructed by analysis of the STDs in validation batch 1,
indicating the DMP concentration in each.
14July15_OP curve.rdb (DMP-1): "Quadratic" Regression ("1 / x" weighting): y = -0.000167 x 2^ + 0.0556 x + 0.106 (r = 0.9984)
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Table 3.11 Summary of the performance of the calibration standards of DMP of validation
batch 1
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 0.967 2.10 4.14 7.73 16.1 32.0
Standard Deviation 0.122 N/A 0.369 1.204 0.770 0.774
% CV 12.6 N/A 8.9 15.6 4.8 2.4
% Accuracy 96.7 104.7 103.6 96.6 100.8 99.9
N 2 of 2 1 of 2 2 of 2 2 of 2 2 of 2 2 of 2
Table 3.12 Summary of the accuracy and precision of the quality control standards of DMP
of validation batch 1
Nominal
Concentrations(ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 0.992 1.89 3.41 12.7 23.9
Standard Deviation 0.139 0.152 0.238 0.079 1.16
% CV 14.1 8.1 7.0 8.5 4.9
% Accuracy 99.3 94.4 97.5 101.2 95.6
N 6 of 6 4 of 6 6 of 6 6 of 6 6 of 6
The calculation of the concentrations of DMTP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure 3.7),
resulted in the values for the calibration standards and quality control standards as indicated in
tables 3.13 and 3.14 respectively.
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Figure 3.7 Calibration curve constructed by analysis of the STDs in validation batch 1,
indicating the DMTP concentration in each.
Table 3.13 Summary of the performance of the calibration standards of DMTP of validation
batch 1
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 1.02 1.86 4.16 8.52 15.15 32.3
Standard Deviation N/A 0.024 0.270 0.474 0.938 3.13
% CV N/A 1.3 6.5 5.6 6.2 9.7
% Accuracy 101.6 93.1 104.0 106.5 94.6 101.0
N 1 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
Table 3.14 Summary of the accuracy and precision of the quality control standards of DMTP
of validation batch 1
Nominal
Concentrations (ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 1.01 1.93 3.46 12.3 24.0
Standard Deviation 0.140 0.179 0.346 0.856 1.09
% CV 13.9 9.3 10.0 7.0 4.6
% Accuracy 101.0 96.6 98.2 98.1 96.0
N 5 of 6 4 of 6 6 of 6 6 of 6 6 of 6
14July15_OP curve.rdb (DMTP-1): "Quadratic" Regression ("1 / x" weighting): y = -0.000113 x 2^ + 0.0203 x + 0.00604 (r = 0.9995)
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The calculation of the concentrations of DEP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure 3.8),
resulted in the values for the calibration standards and quality control standards as indicated in
tables 3.15 and 3.16 respectively.
Figure 3.8 Calibration curve constructed by analysis of the STDs in validation batch 1,
indicating the DEP concentration in each
Table 3.15 Summary of the performance of the calibration standards of DEP of validation
batch 1
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 1.04 1.93 4.02 7.74 16.4 31.8
Standard Deviation 0.917 0.050 0.359 0.371 0.816 1.23
% CV 8.8 2.6 8.9 4.8 5.0 3.9
% Accuracy 104.4 96.2 100.4 96.8 102.7 99.5
N 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
14July15_OP curve.rdb (DEP-1): "Quadratic" Regression ("1 / x" weighting): y = -0.00165 x 2^ + 0.274 x + 0.0833 (r = 0.9988)
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Table 3.16 Summary of the accuracy and precision of the quality control standards of DEP of
validation batch 1
Nominal
Concentrations (ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 0.965 2.07 3.73 12.6 23.8
Standard Deviation 0.087 0.091 0.216 0.880 1.79
% CV 9.1 4.4 5.8 7.0 7.5
% Accuracy 96.5 103.5 106.5 100.4 95.3
N 6 of 6 6 of 6 4 of 6 6 of 6 6 of 6
3.4.1.1.2 Validation batch 2
The calculation of the concentrations of DMP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure 3.9),
resulted in the values for the calibration standards and quality control standards as indicated in
tables 3.17 and 3.18 respectively.
Figure 3.9 Calibration curve constructed by analysis of the STDs in validation batch 2,
indicating the DMP concentration in each.
17July15_curve&QC's.rdb (DMP-1): "Quadratic" Regression ("1 / x" weighting): y = -0.000266 x 2^ + 0.0657 x + 0.124 (r = 0.9963)
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Table 3.17 Summary of the performance of the calibration standards of DMP of validation
batch 2
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 0.952 1.95 4.28 8.47 14.9 32.5
Standard Deviation 0.010 0.116 0.119 0.361 0.033 2.25
% CV 1.1 6.0 2.8 4.3 0.2 6.9
% Accuracy 95.2 97.3 107.1 105.9 93.2 101.5
N 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
Table 3.18 Summary of the accuracy and precision of the quality control standards of DMP
of validation batch 2
Nominal
Concentrations
(ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration
(ng/ml)
1.06 1.99 3.60 12.7 25.9
Standard Deviation 0.099 0.164 0.182 0.731 0.742
% CV 9.4 8.3 5.1 5.8 2.9
% Accuracy 106.2 99.4 102.9 101.7 103.8
N 5 of 6 6 of 6 6 of 6 6 of 6 6 of 6
The calculation of the concentrations of DMTP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure
3.10), resulted in the values for the calibration standards and quality control standards as indicated
in tables 3.19 and 3.20 respectively.
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Figure 3.10 Calibration curve constructed by analysis of the STD’s in validation batch 2,
indicating the DMTP concentration in each.
Table 3.19 Summary of the performance of the calibration standards of DMTP of validation
batch 2
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 1.01 2.07 3.84 7.78 16.5 31.8
Standard Deviation 0.052 0.143 0.136 0.45 1.32 1.50
% CV 5.2 6.9 3.6 5.8 8.0 4.7
% Accuracy 100.8 103.4 96.0 97.2 103.3 99.3
N 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
Table 3.20 Summary of the accuracy and precision of the quality control standards of DMTP
of validation batch 2
Nominal
Concentrations
(ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration
(ng/ml)
1.00 2.06 3.59 12.4 24.3
Standard Deviation 0.115 0.191 0.258 0.718 0.560
% CV 11.5 9.3 7.2 5.8 2.3
% Accuracy 100.5 102.8 102.5 99.3 97.0
N 6 of 6 5 of 6 6 of 6 6 of 6 6 of 6
17July15_curve&QC's.rdb (DMTP-1): "Quadratic" Regression ("1 / x" weighting): y = -7.6e-005 x 2^ + 0.0181 x + 0.000475 (r = 0.9950)
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The calculation of the concentrations of DEP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure
3.11), resulted in the values for the calibration standards and quality control standards as indicated
in tables 3.21 and 3.22 respectively.
Figure 3.11 Calibration curve constructed by analysis of the STDs in validation batch 2,
indicating the DEP concentration in each.
Table 3.21 Summary of the performance of the calibration standards of DEP of validation
batch 2
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 0.983 1.99 3.94 8.54 15.3 32.2
Standard Deviation 0.053 0.089 0.245 0.048 0.0235 1.22
% CV 5.4 4.5 6.2 0.6 0.2 3.8
% Accuracy 98.3 99.9 98.6 106.8 95.7 100.7
N 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
17July15_curve&QC's.rdb (DEP-1): "Quadratic" Regression ("1 / x" weighting): y = -0.000415 x 2^ + 0.232 x + 0.0865 (r = 0.9988)
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Table 3.22 Summary of the accuracy and precision of the quality control standards of DEP of
validation batch 2
Nominal
Concentrations (ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 1.01 2.13 3.77 12.9 24.9
Standard Deviation 0.091 0.076 0.183 0.313 1.08
% CV 9.1 3.6 4.9 2.4 4.3
% Accuracy 100.6 106.7 107.7 103.5 99.7
N 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6
3.4.1.1.3 Validation batch 3
The calculation of the concentrations of DMP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure
3.12), resulted in the values for the calibration standards and quality control standards as indicated
in tables 3.23 and 3.24 respectively.
Figure 3.12 Calibration curve constructed by analysis of the STDs in validation batch 3,
indicating the DMP concentration in each.
26Aug15_curve&QC's only.rdb (DMP-1): "Quadratic" Regression ("1 / x" weighting): y = -0.000139 x 2^ + 0.0703 x + 0.118 (r = 0.9984)
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Table 3.23 Summary of the performance of the calibration standards of DMP of validation
batch 3
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 0.996 1.91 4.21 8.14 15.6 32.2
Standard Deviation 0.061 0.054 0.039 0.116 0.773 0.374
% CV 6.1 2.9 0.9 1.4 5.0 1.2
% Accuracy 99.6 95.6 105.2 101.7 97.5 100.5
N 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
Table 3.24 Summary of the accuracy and precision of the quality control standards of DMP
of validation batch 3
Nominal
Concentrations (ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 1.02 2.01 3.61 12.8 26.9
Standard Deviation 0.100 0.190 0.234 0.789 0.759
% CV 9.8 9.5 6.5 6.2 2.8
% Accuracy 102.2 100.6 103.3 102.5 107.5
N 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6
The calculation of the concentrations of DMTP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure
3.13), resulted in the values for the calibration standards and quality control standards as indicated
in tables 3.25 and 3.26 respectively.
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Figure 3.13 Calibration curve constructed by analysis of the STDs in validation batch 3,
indicating the DMTP concentration in each.
Table 3.25 Summary of the performance of the calibration standards of DMTP of validation
batch 3
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 1.08 1.86 3.96 7.87 16.4 31.8
Standard Deviation 0.085 0.078 0.116 0.460 0.420 1.37
% CV 7.9 4.2 2.9 5.8 2.6 4.3
% Accuracy 107.6 93.1 98.9 98.4 102.6 99.5
N 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
Table 3.26 Summary of the accuracy and precision of the quality control standards of DMTP
of validation batch 3
Nominal
Concentrations (ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 1.00 2.06 3.63 12.8 26.1
Standard Deviation 0.095 0.090 0.198 0.505 1.66
% CV 9.9 4.3 5.5 3.9 6.3
% Accuracy 96.8 105.2 103.6 102.6 104.4
N 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6
26Aug15_curve&QC's only.rdb (DMTP-1): "Quadratic" Regression ("1 / x" weighting): y = -4.47e-005 x 2^ + 0.0266 x + 0.00396 (r = 0.9990)
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The calculation of the concentrations of DEP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure
3.14), resulted in the values for the calibration standards and quality control standards as indicated
in tables 3.27 and 3.28 respectively.
Figure 3.14 Calibration curve constructed by analysis of the STDs in validation batch 3,
indicating the DEP concentration in each
Table 3.27 Summary of the performance of the calibration standards of DEP of validation
batch 3
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 1.04 1.96 3.87 7.97 16.3 31.9
Standard Deviation 0.033 0.087 0.168 0.019 0.396 1.18
% CV 3.2 4.5 4.4 0.2 2.4 3.7
% Accuracy 104.4 98.0 96.7 99.7 101.7 99.6
N 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
26Aug15_curve&QC's only.rdb (DEP-1): "Quadratic" Regression ("1 / x" weighting): y = -1.82e-005 x 2^ + 0.265 x + 0.0947 (r = 0.9998)
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Table 3.28 Summary of the accuracy and precision of the quality control standards of DEP of
validation batch 3
Nominal
Concentrations (ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 0.976 2.13 3.64 12.9 26.5
Standard Deviation 0.074 0.083 0.119 0.373 0.988
% CV 7.6 3.9 3.3 2.9 3.7
% Accuracy 97.6 106.4 103.9 103.2 105.9
N 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6
3.4.1.1.4 Reinjection of validation batch 2
The calculation of the concentrations of DMP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure
3.15), resulted in the values for the calibration standards and quality control standards as indicated
in tables 3.29 and 3.30 respectively.
Figure 3.15 Calibration curve constructed by analysis of the STDs in the reinjection of
validation batch 2, indicating the DMP concentration in each
17July15_curve&QC's.rdb (DMP-2): "Quadratic" Regression ("1 / x" weighting): y = -2.85e-005 x 2^ + 0.0382 x + 0.0825 (r = 0.9943)
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Table 3.29 Summary of the performance of the calibration standards of DMP of reinjection
of validation batch 2
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 1.04 1.95 3.84 8.30 15.9 32.0
Standard Deviation 0.005 0.161 0.223 0.326 1.091 0.076
% CV 0.5 8.3 5.8 3.9 6.9 0.2
% Accuracy 103.6 97.6 96.0 103.7 99.1 100.1
N 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
Table 3.30 Summary of the accuracy and precision of the quality control standards of DMP
of reinjection of validation batch 2
Nominal
Concentrations (ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 1.03 2.26 3.69 12.8 27.0
Standard Deviation 0.103 0.110 0.239 0.621 0.929
% CV 10.1 4.9 6.5 4.9 3.4
% Accuracy 102.8 112.8 105.3 102.5 108.2
N 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6
The calculation of the concentrations of DMTP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure 3.16)
resulted in the values for the calibration standards and quality control standards as indicated in
tables 3.31 and 3.32 respectively.
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Figure 3.16 Calibration curve constructed by analysis of the STDs in the reinjection of
validation batch 2, indicating the DMTP concentration in each.
Table 3.31 Summary of the performance of the calibration standards of DMTP of reinjection
of validation batch 2)
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 1.02 1.91 3.99 8.15 15.9 32.1
Standard Deviation 0.112 N/A 0.215 0.202 1.372 0.173
% CV 11.1 N/A 5.4 2.5 8.7 0.5
% Accuracy 101.6 95.3 99.6 101.9 99.1 100.1
N 2 of 2 1 of 2 2 of 2 2 of 2 2 of 2 2 of 2
Table 3.32 Summary of the accuracy and precision of the quality control standards of DMTP
of reinjection of validation batch 2
Nominal
Concentrations (ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 1.08 2.20 3.81 12.4 24.2
Standard Deviation 0.062 0.142 0.143 0.580 0.920
% CV 5.8 6.5 3.8 4.7 3.8
% Accuracy 107.9 109.8 108.9 99.5 96.8
N 6 of 6 6 of 6 6 of 6 6 of 6 6 of 6
17July15_curve&QC's.rdb (DMTP-2): "Quadratic" Regression ("1 / x" weighting): y = -3.24e-006 x 2^ + 0.00331 x + -0.000135 (r = 0.9899)
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
Analyte Conc. / IS Conc.
0.000
5.000e-3
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
0.050
0.055
0.060
0.065
0.070
0.075
0.080
0.085
0.090
0.095
0.100
0.105
0.110
An
al
yt
e
Ar
ea
/I
S
Ar
ea
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
130
The calculation of the concentrations of DEP, using the analytical method and applying the
acquired peak area ratios (using the relevant internal standard) to the calibration curve (figure
3.17), resulted in the values for the calibration standards and quality control standards as indicated
in tables 3.33 and 3.34 respectively.
Figure 3.17 Calibration curve constructed by analysis of the STDs in the reinjection of
validation batch 2, indicating the DEP concentration in each
Table 3.33 Summary of the performance of the calibration standards of DEP of reinjection of
validation batch 2
Nominal
Concentrations (ng/ml)
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Mean Observed
Concentration (ng/ml) 1.00 1.99 3.92 8.28 15.7 32.1
Standard Deviation 0.092 0.047 0.260 0.123 1.40 1.56
% CV 9.3 2.4 6.6 1.5 8.9 4.8
% Accuracy 100.1 99.9 98.0 103.5 98.2 100.3
N 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2 2 of 2
17July15_curve&QC's.rdb (DEP-2): "Quadratic" Regression ("1 / x" weighting): y = -0.000255 x 2^ + 0.146 x + 0.035 (r = 0.9991)
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Table 3.34 Summary of the accuracy and precision of the quality control standards of DEP of
reinjection of validation batch 2
Nominal
Concentrations (ng/ml)
QC 6 (LLOQ)
1.00
QC 5 (L)
2.00
QC 4
3.50
QC 2 (M)
12.5
QC 1 (H)
25.0
Mean Observed
Concentration (ng/ml) 1.03 2.14 3.82 12.9 25.3
Standard Deviation 0.095 0.041 0.137 0.355 0.753
% CV 9.3 2.0 3.6 2.8 3.0
% Accuracy 102.8 106.9 109.1 102.9 101.4
N 6 of 6 4 of 6 6 of 6 6 of 6 6 of 6
The acceptance criteria for intra-batch accuracy and precision were met for all the compounds.
3.4.1.2 Inter-batch perfomance of the method
The inter-batch validation is a comparison of the values of the calibration standards, the quality
control standards and the parameters of the calibration curves of the three independent validation
batches.
For the analysis of DMP, the inter-batch comparison of the calibration curve parameters is depicted
in table 3.35.
Table 3.35 The inter-batch comparison of the calibration curve parameters of DMP
measured during the three validation batches
Validation batch
Calibration Curve Parameters (DMP)
A B C R-Squared (r2)
Validation 1 -0.000292 0.0663 0.126 0.9980
Validation 2 0.000283 0.0636 0.104 0.9978
Validation 3 -0.000927 0.0566 0.133 0.9994
Mean -0.000212 0.06216 0.121 0.9984
% CV -61.094 8.053 12.506 0.1
Note: Quadratic regression model, weighted by 1/concentration (Resp. = AX2 + BX + C)
Comparison of the values of the DMP calibration standards between the validation batches are
shown in table 3.36.
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Table 3.36 Back-calculated calibration standard concentrations of DMP in ng/ml for the
three validation batches
Validation
batch Replicates
STD 6
1.00
STD 5
2.00
STD 4
4.00
STD 3
8.00
STD 2
16.0
STD 1
32.0
Validation 1
1 1.05 2.09 4.41 8.58 16.7 31.4
2 0.88 *1.59 3.88 6.88 15.6 32.5
Validation 2
1 0.96 1.86 4.37 8.73 14.9 34.1
2 0.94 2.03 4.20 8.22 14.9 30.9
Validation 3
1 0.95 1.87 4.18 8.22 16.1 32.4
2 1.04 1.95 4.24 8.05 15.1 31.9
Mean 0.971 1.960 4.213 8.11 15.55 32.20
% CV 6.6 5.1 4.5 8.1 4.7 3.4
STDEV 0.064 0.100 0.187 0.655 0.731 1.110
%Accuracy 97.1 98.0 105.3 101.4 97.2 100.6
N 6 5 6 6 6 6
Code: * = Deactivated calibration standard (% Dev > 15%)
Comparison of the values of the DMP quality control samples between the validation batches are
shown in table 3.37.
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Table 3.37 Statistics of quality control samples of DMP for the three validation batches
concentration in ng/ml
Validation
batch Replicates
QC 6
LLOQ
1.00
QC 5
Low
2.00
QC 4
3.50
QC 2
Med
12.5
QC 1
High
25.0
Validation 1
1 0.902 2.01 3.41 13.5 25.2
2 0.99 #2.71 3.39 14.1 23.0
3 1.25 #1.55 3.81 11.8 25.1
4 0.997 1.68 3.30 12.1 23.7
5 0.848 1.86 3.48 11.3 24.0
6 0.965 2.00 3.08 13.1 22.3
Validation 2
1 0.909 2.08 3.56 12.2 25.1
2 1.10 2.02 3.93 13.1 26.2
3 1.13 1.78 3.56 13.1 26.8
4 1.15 1.79 3.44 13.2 26.7
5 1.02 2.07 3.67 11.5 25.6
6 #1.22 2.18 3.44 13.3 25.2
Validation 3
1 1.09 2.12 3.63 12.8 26.3
2 0.939 1.79 3.93 12.7 28.2
3 1.06 1.93 3.56 13.7 27.0
4 0.878 2.27 3.44 13.2 26.3
5 1.15 2.13 3.67 13.1 26.2
6 1.01 1.83 3.44 11.4 27.2
Mean 1.022 1.971 3.542 12.73 25.56
% CV 10.9 8.6 6.4 6.5 6.0
STDEV 0.111 0.168 0.228 0.826 1.539
Accuracy 102.3 98.6 101.2 101.9 102.2
N 17 16 18 18 18
Code: # = Deactivated quality control sample
For the analysis of DMTP, the inter-batch comparison of the calibration curve parameters are
depicted in table 3.38.
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Table 3.38 The inter-batch comparison of the calibration curve parameters of DMTP
measured during the three validation batches.
Validation batch
Calibration Curve Parameters (DMTP)
A B C R-Squared (r2)
Validation 1 -0.0000549 0.0172 0.00328 0.9968
Validation 2 -0.000163 0.0289 0.00235 0.9985
Validation 3 -0.0000796 0.0253 0.00745 0.9991
Mean -0.000099 0.0283 0.00436 0.99813
% CV -57.120 25.179 62.296 0.1
Note: Quadratic regression model, weighted by 1/concentration (Resp. = AX2 + BX + C)
Comparison of the values of the DMTP calibration standards between the validation batches are
shown in table 3.39
Table 3.39 Back-calculated calibration standard concentrations of DMTP in ng/ml for the
three validation batches
Validation
batch Replicates
STD 6 STD 5 STD 4 STD 3 STD 2 STD 1
1.00 2.00 4.00 8.00 16.0 32.0
Validation 1
1 *0.584 1.88 4.35 8.18 14.5 30.1
2 1.02 1.85 3.97 8.85 15.8 34.5
Validation 2
1 1.04 1.97 3.74 8.09 15.6 30.7
2 0.97 2.17 3.94 7.46 17.5 32.8
Validation 3
1 1.14 1.92 3.87 7.55 16.7 30.9
2 1.02 1.81 4.04 8.20 16.1 32.8
Mean 1.04 1.93 3.99 8.06 16.0 32.0
% CV 6.0 6.6 5.2 6.3 6.4 5.2
STDEV 0.062 0.128 0.205 0.505 1.02 1.68
%Accuracy 103.8 96.7 99.6 100.7 100.2 99.9
N 5 6 6 6 6 6
Code: * = Deactivated calibration standard (% Dev > 15%)
Comparison of the values of the DMTP quality control standards between the validation batches
are shown in table 3.40
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Table 3.40 Statistics of quality control samples of DMTP for the three validation batches
concentration in ng/ml
Validation
batch Replicates
QC 6
LLOQ
1.00
QC 5
Low
2.00
QC 4
3.50
QC 2
Med
12.5
QC 1
High
25.0
Validation 1
1 1.10 1.75 3.09 10.9 23.3
2 #0.766 1.82 3.45 13.5 23.0
3 0.807 #1.54 3.06 12.2 23.8
4 1.07 2.01 3.52 12.6 23.4
5 0.925 2.14 3.65 12.0 24.6
6 1.15 #2.64 3.98 12.4 25.9
Validation 2
1 0.854 #1.65 3.35 12.2 23.9
2 0.925 1.86 3.42 11.8 24.0
3 0.929 1.86 3.31 12.5 24.0
4 1.09 2.08 3.77 11.8 24.7
5 1.13 2.20 3.93 12.5 25.2
6 1.09 2.28 3.74 13.7 23.7
Validation 3
1 0.955 2.14 3.64 12.8 25.5
2 0.854 2.21 3.42 12.5 26.7
3 0.935 1.98 3.49 12.4 23.5
4 0.925 2.02 3.47 12.8 27.0
5 1.00 2.09 3.86 13.8 25.5
6 1.14 2.19 3.87 12.7 28.4
Mean 0.992 2.04 3.56 12.5 24.8
% CV 11.2 7.9 7.6 5.6 6.0
STDEV 0.111 0.160 0.269 0.700 1.48
Accuracy 99.3 102.1 101.6 100.0 99.1
N 17 15 18 18 18
Code: # = Deactivated quality control sample
For the analysis of DEP, the inter-batch comparison of the calibration curve parameters are
depicted in table 3.41
Table 3.41 The inter-batch comparison of the calibration curve parameters of DEP
measured during the three validation batches
Validation batch
Calibration Curve Parameters (DEP)
A B C R-Squared (r2)
Validation 1 -0.000447 0.233 0.0807 0.9989
Validation 2 0.000118 0.237 0.111 0.9989
Validation 3 -0.000341 0.239 0.0875 0.9995
Mean -0.000302 0.236 0.0930 0.9991
% CV -55.602 1.293 17.083 0.1
Note: Quadratic regression model, weighted by 1/concentration (Resp. = AX2 + BX + C)
Comparison of the values of the DEP calibration standards between the validation batches are
shown in table 3.42
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Table 3.42 Back-calculated calibration standard concentrations of DEP in ng/ml for the three
validation batches
Validation
batch Replicates
STD 6 STD 5 STD 4 STD 3 STD 2 STD 1
1.00 2.00 4.00 8.00 16.0 32.0
Validation 1
1 0.979 1.96 3.76 7.48 15.9 31.0
2 1.11 1.89 4.27 8.00 17.0 32.7
Validation 2
1 1.02 2.06 4.12 8.58 15.3 31.4
2 0.945 1.94 3.77 8.51 15.3 33.1
Validation 3
1 1.07 1.90 3.99 7.99 16.6 32.7
2 1.02 2.02 3.75 7.96 16.0 31.1
Mean 1.02 1.96 3.943 8.09 16.0 32.0
% CV 5.8 3.4 5.6 5.0 4.3 2.9
STDEV 0.059 0.067 0.219 0.405 0.685 0.933
%Accuracy 102.4 98.1 98.6 101.1 100.1 100.0
N 6 6 6 6 6 6
Comparison of the values of the DEP quality control standards between the validation batches are
shown in table 3.43
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Table 3.43 Statistics of quality control samples of DEP for the three validation batches
concentration in ng/ml
Validation
batch Replicates
QC 6
LLOQ
QC 5
Low QC 4
QC 2
Med
QC 1
High
1.00 2.00 3.50 12.50 25.0
Validation 1
1 0.835 1.91 3.44 11.5 23.4
2 0.902 2.04 3.70 12.2 21.6
3 0.944 2.13 #4.12 12.2 26.6
4 1.00 2.14 3.95 12.7 23.0
5 1.05 2.15 3.81 12.7 25.3
6 1.06 2.04 #4.15 14.1 23.1
Validation 2
1 0.874 2.13 3.43 12.4 25.0
2 0.940 2.26 3.95 12.8 24.7
3 1.11 2.07 3.87 13.3 25.5
4 1.01 2.04 3.81 12.9 25.6
5 0.999 2.14 3.86 13.1 25.9
6 1.1 2.15 3.70 13.1 22.9
Validation 3
1 0.865 2.11 3.70 13.2 26.8
2 0.933 2.02 3.50 12.5 27.7
3 0.996 2.16 3.59 12.5 26.5
4 0.991 2.06 3.52 13.4 24.9
5 1.04 2.20 3.80 13.1 27.1
6 1.07 2.24 3.71 12.7 25.9
Mean 0.982 2.11 3.71 12.8 25.1
% CV 8.3 4.0 4.6 4.5 6.7
STDEV 0.081 0.084 0.170 0.569 1.68
Accuracy 98.2 105.5 106.0 102.4 100.3
N 18 18 16 18 18
Code: # = Deactivated quality control sample
The acceptance criteria for accuracy and precision were met for the inter-batch validation.
3.4.2 Stability assessments
3.4.2.1 On-Instrument stability
Six individual aliquots of the stability samples at high and low concentration levels (estimated
QClow at 2-3 times that of the LLOQ and estimated QChigh at about 80% of the ULOQ) were
extracted according to the sample preparation method. These were immediately injected and the
peak area ratios calculated. The extracted samples were then left for a period of 24 hours in the
auto sampler at 5°C and then re-analyzed and the peak area ratios then compared to those of the
first injection series.
The results, expressed as the area ratios, are depicted for DMP, DMTP and DEP in tables 3.44 to
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3.46
Table 3.44 Results for the assessment of on-instrument stability of DMP following extraction
from stripped urine
Sample
High Concentration (25 ng/ml) Low Concentration (2 ng/ml)
First Injection Peak
Area Ratio
Second injection
Peak Area Ratio
First injection Peak
Area Ratio
Second injection
Peak Area Ratio
1 1.52 1.59 0.2352 0.241
2 1.56 1.63 0.2320 0.259
3 1.61 1.62 0.2163 0.242
4 1.60 1.64 0.2175 0.237
5 1.55 1.61 0.2343 0.253
6 1.53 1.51 0.2414 0.260
Average 1.56 1.60 0.2295 0.249
STDEV 0 0.047 0.01021 0.009
% CV 2.4 2.9 4.4 4.0
% Difference - 2.6 - 8.6
Table 3.45 Results for the assessment of on-instrument stability of DMTP following
extraction from stripped urine
Sample
High Concentration (25 ng/ml) Low Concentration (2 ng/ml)
First Injection
Peak Area Ratio
Second injection
Peak Area Ratio
First injection
Peak Area Ratio
Second injection
Peak Area Ratio
1 0.60 0.62 0.0495 0.066
2 0.60 0.63 0.0554 0.058
3 0.60 0.66 0.0553 0.066
4 0.61 0.66 0.0617 0.061
5 0.62 0.66 0.0649 0.067
6 0.60 0.61 0.0670 0.068
Average 0.61 0.64 0.0590 0.064
STDEV 0 0.022 0.00668 0.004
% CV 1.7 3.4 11.3 6.2
% Difference - 5.8 - 6.8
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Table 3.46 Results for the assessment of on-instrument stability of DEP following extraction
from stripped urine
Sample
High Concentration (25 ng/ml) Low Concentration (2 ng/ml)
First Injection
Peak Area Ratio
Second injection
Peak Area Ratio
First injection
Peak Area Ratio
Second injection
Peak Area Ratio
1 5.96 5.84 0.6149 0.636
2 5.90 6.07 0.6460 0.629
3 6.07 5.98 0.6012 0.643
4 6.08 5.98 0.5944 0.620
5 6.16 6.05 0.6171 0.680
6 5.47 5.65 0.6205 0.686
Average 5.94 5.93 0.6157 0.649
STDEV 0 0.159 0.01793 0.027
% CV 4.2 2.7 2.9 4.2
% Difference - -0.2 - 5.5
The results obtained from the on-instrument stability assessment met the required acceptance
criteria of % Dev < 15% as well as a % CV < 15% for the analytes and indicated stability for at least
24 hours.
This stability assessment also proves on-instrument stability of the internal standards since these
were included in the sample preparation method.
3.4.2.2 Freeze-thaw stability
Six samples prepared in stripped urine at a concentration of 25 ng/ml of all three analytes, were
stored at -80°C for 12 hours. The samples were then left at room temperature to thaw unassisted.
After complete thawing, the samples were refrozen for 12 hours and the process repeated twice.
Following the third thawing cycle, the samples were analyzed together with a similar set of six
quality control samples at the same concentration of the analytes. Comparison of the two sets of
data will indicate the stability of the analytes during three freeze-thaw cycles.
Table 3.47 – 3.49 indicates the values obtained during this comparative analysis for each of the
analytes.
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Table 3.47 Results for the freeze-thaw stability of DMP
Peak area
Freeze-thaw stability (DMP)
Fresh (Reference) Control (~ -80 °C Freeze Thaw)
1 295000 295000
2 283000 290000
3 274000 299000
4 284000 299000
5 266000 299000
6 273000 293000
Average 279167 295833
STDEV 10265 3817
% CV 3.7 0.3
% Difference N/A 6.0
Table 3.48 Results for the freeze-thaw stability of DMTP
Peak area
Freeze-thaw stability (DMTP)
Fresh (Reference) Control (~ -80 °C Freeze Thaw)
1 128000 103000
2 134000 101000
3 134000 100000
4 137000 101000
5 130000 111000
6 131000 100000
Average 132333 102667
STDEV 3266 4227
% CV 2.5 4.1
% Difference N/A -22.4
Table 3.49 Results for the freeze-thaw stability of DEP
Peak area
Freeze-thaw stability (DEP)
Fresh (Reference) Control (~ -80 °C Freeze Thaw)
1 625000 593000
2 644000 583000
3 640000 556000
4 631000 586000
5 628000 622000
6 670000 592000
Average 639667 588667
STDEV 16525 21201
% CV 2.6 3.6
% Difference N/A 6.0
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The data indicate that DMP and DEP are stable during three freeze thaw cycles. DMTP is however
unstable under these conditions and consequently samples were not subjected to three freeze thaw
cycles.
3.4.3 Stability of stock solutions
Separate stock solutions of DMP, DMTP and DEP were prepared in methanol. Aliquots of each
solution were kept at room temperature and at approximately - 20ºC and - 80ºC for at least 8 hours
(test solutions). The test solutions were then prepared for analysis. Similar reference solutions were
prepared from fresh stock solutions. Analytical comparison was then made between the reference
solutions and the test solutions. The results for the three analytes are shown in tables 3.50 to 3.52.
Table 3.50 Results for the stock solution stability of DMP. Results in peak areas are shown.
Replicate
Stock Solution Peak Area (DMP)
Fresh (Reference) Control~ -20 °C Control~ -80 °C
1 295000 285000 312000
2 283000 294000 290000
3 274000 276000 289000
4 284000 292000 299000
5 266000 291000 309000
6 273000 292000 313000
Average 279167 288333 302000
STDEV 10265 6772 10881
% CV 3.7 2.3 3.6
% Difference N/A 3.3 8.2
Table 3.51 Results for the stock solution stability of DMTP. Results in peak areas are shown.
Replicate
Stock Solution Peak Area (DMTP)
Fresh (Reference) Control~ -20 °C Control~ -80 °C
1 128000 103000 116000
2 134000 111000 112000
3 134000 109000 104000
4 137000 100000 110000
5 130000 111000 104000
6 131000 112000 107000
Average 132333 107667 108833
STDEV 3266 4967 4750
% CV 2.5 4.6 4.4
% Difference N/A -18.6 -17.8
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Table 3.52 Results for the stock solution stability of DEP. Results in peak areas are shown.
Replicate
Stock Solution Peak Area (DEP)
Fresh (Reference) Control~ -20 °C Control~ -80 °C
1 625000 554000 558000
2 644000 578000 601000
3 640000 555000 576000
4 631000 543000 564000
5 628000 594000 585000
6 670000 581000 608000
Average 639667 567500 582000
STDEV 16525 19665 19910
% CV 2.6 3.5 3.4
% Difference N/A 3.3 8.2
The results indicate that DMP and DEP are stable in methanol for 8 days, when stored at room
temperature and at ~ -20ºC and -80ºC. DMTP however proofed to be unstable when stored at -
20°C and -80°C and consequently stock solutions were freshly prepared when used. No
assessments were performed on the stability of stock solutions of the internal standards.
3.5 RECOVERY
The extraction recovery pertains to the extraction efficiency of the analytical process within the
limits of variability. It is determined by comparing the analytical response of blank matrix spiked
with the analyte and extracted with the response of the blank matrix first extracted and then spiked
with analyte (theoretical, represents 100% recovery).
No recovery of the ISTD was calculated.
Extracted (test) samples: A minimum of six QCs at each concentration level (low, medium and
high) are extracted as per the analytical method.
Theoretical samples: Samples are spiked at each concentration level (relative to the final
concentration of the corresponding extracted QC’s level) in three fold using extracted blank matrix.
The analyte peak areas found after extraction are compared to the theoretical peak area expressed
as a percentage recovery.
The mean recovery of a quantitative drug assay should be consistent and the precision of the
measured recovery expressed as percentage coefficient of variation should not exceed 15 % for any
particular concentration of the analyte at which it is determined.
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Table 3.53 Recovery of DMP
Sample No.
High Concentration
(25 ng/ml)
Medium Concentration
(12.5 ng/ml)
Low Concentration
(2 ng/ml)
Corrected
Reference
Peak Area
Test Peak
Area
Corrected
Reference
Peak Area
Test Peak
Area
Corrected
Reference
Peak Area
Test Peak
Area
Sample 1 473000 158000 249000 84100 44200 24700
Sample 2 476000 175000 245000 89400 45200 23900
Sample 3 450000 164000 251000 88700 49000 22500
Sample 4 - 173000 - 90400 - 22400
Sample 5 - 158000 - 79100 - 25300
Sample 6 - 156000 - 84600 - 22400
Average 466333 164000 248333 86050 46133 23533
STDEV 14224 8622 3055 2879 2532 1114
% CV 3.1 5.3 1.2 3.3 5.5 4.7
% Recovery 35.2 34.7 51.0
%Average Recovery 40.3
STDEV 9.3
% CV 23.1
Table 3.54 Recovery of DMTP
Sample No.
High Concentration
(25 ng/ml)
Medium Concentration
(12.5 ng/ml)
Low Concentration
(2 ng/ml)
Corrected
Reference
Peak Area
Test Peak
Area
Corrected
Reference
Peak Area
Test Peak
Area
Corrected
Reference Peak
Area
Test Peak
Area
Sample 1 188000 175000 96300 88300 13400 13800
Sample 2 189000 187000 97800 96000 15000 16300
Sample 3 190000 177000 103000 94800 15000 15600
Sample 4 - 183000 - 101000 - 17100
Sample 5 - 179000 - 101000 - 16100
Sample 6 - 175000 - 96600 - 15200
Average 189000 179333 99033 96283 14467 15683
STDEV 1000 6429 3516 4143 924 1290
% CV 0.5 3.6 3.6 4.3 6.4 8.2
% Recovery 94.9 97.2 108.4
%Average Recovery 100.2
STDEV 7.2
% CV 7.2
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Table 3.55 Recovery of DEP
Sample No.
High Concentration
(25 ng/ml)
Medium Concentration
(12.5 ng/ml)
Low Concentration
(2 ng/ml)
Corrected
Reference
Peak Area
Test Peak
Area
Corrected
Reference
Peak Area
Test Peak
Area
Corrected
Reference Peak
Area
Test Peak
Area
Sample 1 4140000 2040000 2230000 999000 274000 214000
Sample 2 4170000 2230000 2180000 1150000 329000 219000
Sample 3 4250000 2190000 2170000 1080000 349000 208000
Sample 4 - 2250000 - 1130000 - 214000
Sample 5 - 2150000 - 1060000 - 224000
Sample 6 - 1990000 - 1100000 - 206000
Average 4186667 2141667 2193333 1086500 317333 214167
STDEV 56862 100167 32146 75567 38837 5508
% CV 1.4 4.7 1.5 7.0 12.2 2.6
% Recovery 51.2 49.5 67.5
%Average Recovery 56.1
STDEV 9.9
% CV 17.7
The results indicate reproducible extraction efficiency for DMP, DMTP and DEP at high, medium
and low concentrations.
3.6 APPLICATION OF THE ANALYTICAL METHOD
Urine samples originating from agricultural workers thought to be exposed to organophophate
pesticides were collected and stored at ~ -20°C until analysis. The validated method described in
this study was used to assess the presence of the DAP metabolites, DMP, DMTP and DEP in the
urine samples as markers to such exposure.
3.6.1 The performance of the analytical method
A total of 187 subject urine samples were prepared according to the validated method and were
analyzed in three separate production batches, each including a full set of calibration standards and
six quality control standards at each concentration level as used during the validations.
Representative calibration curves for DMP, DMTP and DEP are presented in figures 3.18 to 3.20,
respectively, as well as the results obtained from the STDs and QCs of each of the three individual
production batches are displayed in tables 3.56 to 3.61
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Figure 3.18 Calibration curve for the determination of DMP in subject samples. An
unweighted quadratic calibration curve was selected with the coefficient of determination (r2)
= 0.9990.
Table 3.56 Back-calculated calibration standard concentrations of DMP in ng/ml for the
three production batches
Production
batch Replicates
STD B STD C STD D STD E STD F STD G STD H STD I
0.780 1.56 3.13 6.25 12.5 25.0 50.0 100
Production 1
1 0.726 1.63 3.07 6.29 12.1 25.7 50.2 99.9
2 0.833 1.49 3.28 6.16 12.4 24.7 49.9 100
Production 2
1 0.722 1.48 3.38 6.27 12.1 25.3 49.4 103
2 0.865 1.45 2.98 6.45 13.2 25.6 48.6 98.0
Production 3
1 0.837 1.48 3.50 6.69 12.7 25.6 49.2 *
2 0.658 1.59 3.00 5.9 12.7 24.5 49.3 101
Mean 0.773 1.52 3.20 6.29 12.5 25.2 49.4 100
% CV 10.69 4.74 6.75 4.23 3.37 2.03 1.13 1.81
% Bias -0.833 -2.56 2.29 0.693 0.266 0.933 -1.133 0.380
N 6 6 6 6 6 6 6 5
Code: * = Deactivated calibration standard (% Dev > 15%)
Line.rdb (DMP): "Quadratic" Regression ("1 / x" weighting): y = -0.000422 x^2 + 0.243 x + 0.115 (r = 0.9990)
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Table 3.57 Statistics for the DMP contents of quality control samples for the three production
batches (concentration is in ng/ml)
Production
batch Replicates
QC A QC B QC C QC D QC E
2.00 4.00 12.0 30.0 80.0
Production 1
1 2.03 4.28 11.8 29.0 79.5
2 2.22 3.91 11.4 29.4 79.0
Production 2
1 2.27 3.88 11.6 29.3 78.5
2 2.06 4.31 11.7 29.1 76.7
Production 3
1 2.18 4.2 12.4 29.2 77.6
2 2.01 3.71 12.6 29.2 78.3
Mean 2.12 4.04 11.9 29.2 78.3
% CV 5.12 6.12 3.98 0.484 1.27
% Bias 6.4 1.2 -0.694 -2.66 -2.16
N 6 6 6 6 6
Figure 3.19 Calibration curve for the determination of DMTP in subject samples. An
unweighted Quadratic calibration curve was selected with the coefficient of determination
(r2) = 0.9976.
Line.rdb (DMTP): "Quadratic" Regression ("1 / x" weighting): y = -0.000235 x^2 + 0.0823 x + -0.0028 (r = 0.9976)
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Table 3.58 Back-calculated calibration standard concentrations of DMTP in ng/ml for the
three production batches
Production
batch Replicates
STD B STD C STD D STD E STD F STD G STD H STD I
0.780 1.56 3.13 6.25 12.5 25.0 50.0 100
Production 1
1 0.792 1.56 3.14 6.11 12.7 25.4 49.9 102
2 0.700 1.59 3.38 6.32 12.4 24.0 50.5 97.9
Production 2
1 0.666 1.45 3.2 6.3 12.4 24.7 49.6 103
2 0.719 1.65 3.33 7.31 12.9 24.2 49 97.6
Production 3
1 0.652 1.88 3.44 6.28 12.3 25.5 49.7 *
2 0.726 1.34 3.39 6.24 12.5 24.9 48.8 101
Mean 0.709 1.57 3.31 6.42 12.5 24.8 49.6 100
% CV 7.03 11.67 3.55 6.83 1.79 2.46 1.24 2.42
% Bias -9.08 1.17 5.85 2.82 0.266 -0.866 -0.833 0.3
N 6 6 6 6 6 6 6 5
Code: * = Deactivated calibration standard (% Dev > 15%)
Table 3.59 Statistics for the DMTP contents of quality control samples for the three
production batches (concentration is in ng/ml)
Production
Replicates
QC A QC B QC C QC D QC E
batch 2.00 4.00 12.0 30.0 80.0
Production 1
1 2.05 3.89 11.4 30.2 77.9
2 1.92 3.93 11.5 28.1 76.1
Production 2
1 1.79 3.47 12.3 28.9 75.0
2 1.97 3.79 13.1 30.1 78.1
Production 3
1 1.87 3.65 12.0 29.1 82.7
2 1.74 3.55 12.7 28.1 78.8
Mean 1.89 3.71 12.16 29.08 78.1
% CV 6.06 5.02 5.49 3.16 3.40
% Bias -5.5 -7.16 1.38 -3.05 -2.37
N 6 6 6 6 6
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Figure 3.20 Calibration curve for the determination of DMP in subject samples. An
unweighted quadratic calibration curve was selected with the coefficient of determination (r2)
= 0.9986.
Line.rdb (DEP): "Quadratic" Regression ("1 / x" weighting): y = -0.00231 x^2 + 0.4 x + 0.00888 (r = 0.9986)
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Table 3.60 Back-calculated calibration standard concentrations of DEP in ng/ml for the three
production batches
Production
batch Replicates
STD B STD C STD D STD E STD F STD G STD H STD I
0.780 1.56 3.13 6.25 12.5 25.0 50.0 100
Production 1
1 0.711 1.48 3.16 6.38 23.3 24.7 49.9 100
2 0.762 1.69 3.39 6.09 13.0 24.1 51.0 99.7
Production 2
1 0.550 1.57 3.39 6..19 12.9 25.1 48.6 105
2 0.793 1.69 3.19 6.70 13.1 24.2 49.5 96.0
Production 3
1 0.626 1.69 3.63 6.59 12.8 24.6 48.7 *
2 0.633 1.68 3.21 6.38 12.4 24.7 49.9 101
Mean 0.679 1.63 3.32 6.48 14.58 24.56 49.6 100
% CV 13.6 5.43 5.37 3.64 29.3 1.49 1.79 3.21
% Bias -12.92 4.70 6.33 2.84 16.66 -1.73 -0.8 0.34
N 6 6 6 6 6 6 6 5
Code: * = Deactivated calibration standard (% Dev > 15%)
Table 3.61 Statistics for the DEP contents of quality control samples for the three production
batches (concentration is in ng/ml)
Production
Replicates
QC A QC B QC C QC D QC E
batch 2.00 4.00 12.0 30.0 80.0
Production 1
1 2.06 4.10 11.6 28.8 76.7
2 2.06 3.94 12.7 28.1 74.7
Production 2
1 1.99 3.91 13.1 30.6 76.6
2 2.16 4.03 12.2 28.4 75.7
Production 3
1 2.0 4.14 12.1 28.1 80.3
2 2.15 3.88 13.9 28.9 76.1
Mean 2.07 4.00 12.6 28.8 76.7
% CV 3.48 2.65 6.50 3.25 2.49
% Bias 3.5 0 5 -3.94 -4.14
N 6 6 6 6 6
The results obtained from the analysis of the quality control samples met the acceptance criteria for
accuracy and precision proving the validity of the results and therefore the acceptance of the
production batch.
Blank samples included following high concentration calibration controls and quality control
samples indicated the specificity regarding the internal standards and that no carry over was
observed.
Each production batch contained ten System Suitability Samples (SYS) to evaluate the instrument
response during the production batch. No upwards or downward trends were noticed in each of the
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production batches.
3.6.2 Test samples results
The analytical results obtained from the analysis of the subject samples are indicated in tables 3.62,
3.63 and 3.64.
Table 3.62 Results summary of production batch 1 for DMP, DMTP and DEP
DAP-II batch 1-290116 DAP-II batch 1-290116
Sample
Name
Calc. Conc. (ng/mL) Sample
Name
Calc. Conc. (ng/mL)
DMP DMTP DEP DMP DMTP DEP
RED 002 3.99 47.1 87.4 RED 056 9.39 43.8 34.5
RED 003 8.37 71.4 47.2 RED 057 3.40 55.9 56.2
RED 004 4.02 37.3 30.4 RED 059 1.05 23.8 22.5
RED 005 4.79 104* 147 RED 060 17.2 355* 167
RED 008 8.45 17.7 10.7 RED 061 23.2 195* 113
RED 009 32.8 321* 126* RED 062 14.9 308* 34.8
RED 011 16.0 354* 202* RED 064 5.60 23.1 8.01
RED 013 2.16 179* 233* RED 065 1.34 8.83 3.83
RED 015 21.0 136* 181* RED 067 2.11 17.4 3.38
RED 016 42.4 327* 365* RED 068 13.9 13.7 14.3
RED 020 5.49 24.2 13.2 RED 069 9.77 44.7 15.5
RED 023 1.48 15.9 9.93 RED 070 2.52 13.0 12.4
BLUE 025 4.20 9.97 10.6 RED 071 5.83 144* 16.2
BLUE 027 BLQ 5.71 5.59 RED 072 11.8 47.1 30.8
BLUE 028 2.84 63.5 60.6 RED 073 3.94 8.77 4.09
BLUE 029 8.63 30.0 17.9 RED 075 5.54 40.9 15.4
RED 031 16.7 31.5 12.3 RED 076 22.2 25.4 30.8
BLUE 033 4.28 13.2 15.3 RED 078 1.82 45.5 21.0
RED 034 BLQ BLQ 3.62 RED 079 6.70 8.58 3.93
BLUE 035 BLQ BLQ 6.42 RED 080 18.8 4.13 5.11
RED 039 5.74 35.8 31.0 RED 081 23.3 29.1 6.78
RED 041 2.59 13.4 14.2 RED 083 BLQ 6.38 6.20
RED 042 10.7 90.5 48.3 RED 084 4.56 41.8 18.8
RED 043 4.98 62.8 92.5 RED 085 1.42 16.0 5.30
RED 044 13.5 157 288 RED 086 7.53 31.6 11.0
RED 045 4.81 11.0 30.3 RED 088 22.1 49.6 58.6
RED 046 BLQ 3.14 1.93 RED 089 244* 62.8 16.0
RED 046 BLQ 3.14 1.93 RED 091 7.51 40.4 13.1
RED 052 2.09 11.6 10.5 RED 092 8.51 29.5 15.2
RED 053 18.5 54.8 129 RED 093 3.17 27.6 18.0
RED 054 8.03 87.3 104 RED 094 6.55 57.0 39.3
RED 055 55.7 27.6 61.4
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Table 3.63 Results summary of production batch 2 for DMP, DMTP and DEP
DAP-II batch 2-290116 DAP-II batch 2-290116
Sample Name
Calc. Conc. (ng/mL)
Sample Name
Calc. Conc. (ng/mL
DMP DMTP DEP DMP) DMTP DEP
RED 095 13.3 9.47 7.58 RED 134 2.24 17.9 15.3
RED 097 5.26 73.9 40.2 RED 136 6.13 12.6 13.4
RED 098 5.34 75.5 25.0 RED 137 22.6 26.8 16.7
RED099(A) 4.50 21.3 30.7 RED 138 9.14 44.7 74.3
RED099(B) 0.642 11.2 14.6 RED 139 2.74 7.05 7.13
RED 100 15.1 104* 43.9 RED 140 6.34 67.5 20.3
RED 101 2.45 38.3 6.56 RED 141 3.07 32.4 42.3
RED 102 2.78 131 30.3 RED 142 8.60 29.3 14.7
RED 103 0.664 7.91 8.05 RED 143 6.74 63.6 32.7
RED 104 40.4 30.6 8.23 RED 144 199* 37.7 13.1
RED 106 5.83 323* 45.4 RED 145 16.0 9.38 14.5
RED 107 5.03 85.5 24.5 BLUE 147 BLQ 1.65 BLQ
RED 109 7.14 125* 43.4 BLUE 148 30.4 28.4 44.2
RED 110 6.15 170* 31.2 BLUE 149 1.01 4.72 6.89
RED 111 7.31 120* 40.2 BLUE 151 11.2 35.7 36.4
RED 113 BLQ 17.1 4.93 BLUE 154 1.05 11.2 4.15
RED 114 7.92 76.3 45.3 BLUE 155 2.10 14.9 9.88
RED 115 7.81 124* 58.9 BLUE 156 3.93 5.62 3.45
RED 116 7.29 406* 48.9 BLUE 157 4.97 35.7 16.7
RED 117 6.10 21.8 9.46 BLUE 158 2.84 1.41 3.25
RED 118 13.6 55.6 7.88 BLUE 159 7.86 24.5 8.63
RED 119 1.23 60.3 5.50 BLUE 160 4.18 52.1 60.9
RED 121 BLQ 4.90 4.86 BLUE 161 BLQ 6.00 10.9
RED 122 2.13 58.4 16.4 BLUE 163 14.9 17.2 10.3
RED 124 1.87 19.7 19.7 BLUE 165 2.22 4.42 5.38
RED 125 1.8 7.29 2.20 BLUE 166 3.27 52.3 56.3
RED 127 1.62 69.5 7.15 BLUE 167 1.96 29.3 41.1
RED 128 2.44 61.4 12.5 BLUE 168 10.9 73.7 3.99
RED 129 2.19 6.09 1.98 BLUE 169 BLQ 1.34 1.88
RED 130 2.29 6.46 5.90 BLUE 170 4.67 29.5 23.4
RED 131 BLQ 40.7 9.72 BLUE 171 BLQ 5.98 8.82
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Table 3.64 Results summary of production batch 3 for DMP, DMTP and DEP
DAP-II batch 3-290116 DAP-II batch 3-290116
Sample
Name
Calc. Conc. (ng/mL) Sample
Name
Calc. Conc. (ng/mL)
DMP DMTP DEP DMP DMTP DEP
BLUE 172 28.8 51.2 33.6 BLUE 206 5.90 44.2 60.3
BLUE 173 1.73 7.19 1.55 BLUE 207 14.7 31.9 40.3
BLUE 174 BLQ 6.46 6.61 BLUE 208 48.7 236* 56.8
BLUE 176 BLQ 10.8 5.32 BLUE 209 67.8 55.2 28.4
BLUE 177 BLQ BLQ BLQ BLUE 210 47.5 44.6 43.4
BLUE 178 BLQ 8.95 12.1 BLUE 211 20.2 8.45 14.9
BLUE 179 BLQ 18.2 16.1 RED 216 20.7 23.8 29.4
BLUE 180 BLQ BLQ 1.38 RED 217 11.1 18.7 9.29
BLUE 181 3.53 9.18 7.18 BLUE 220 15.3 42.0 82.8
BLUE 182 12.4 245* 221* RED221 7.99 15.7 27.7
BLUE 183 19.8 58.3 48.4 RED 222 4.82 7.42 6.44
BLUE 184 4.53 34.1 47.8 RED 223 13.8 68.7 29.3
BLUE 185 BLQ 32.6 65.3 RED 224 5.69 66.3 24.9
BLUE 186 1.24 10.2 4.96 RED 225 BLQ 5.89 3.07
BLUE 187 17.8 13.8 12.2 RED 226 17.5 93.4 38.3
BLUE 188 8.34 37.8 43.9 RED 228 8.33 20.6 14.4
BLUE 189 25.5 60.0 35.6 RED 229 9.33 26.1 26.2
BLUE 191 3.14 17.6 7.27 RED 230 2.60 3.57 8.31
BLUE 192 2.61 97.7 2.07 RED 231 10.8 45.5 38.4
BLUE 193 3.93 27.5 23.0 RED 232 BLQ 76.2 2.79
BLUE 194 2.49 1.23 1.86 RED 233 3.86 59.0 24.5
BLUE 195 19.2 70.0 120 RED 235 15.1 48.9 13.9
BLUE 196 2.04 7.50 4.15 RED 236 1.82 39.5 20.2
BLUE 198 4.76 101* 104* RED 237 29.0 47.6 29.8
BLUE 199 11.6 116* 94.8 RED 238 21.4 125* 113
BLUE 200 36.6 80.0 64.4 RED 239 21.4 280* 36.8
BLUE 201 54.0 58.1 55.9 RED 240 BLQ 5.78 6.00
BLUE 202 1.67 26.7 26.0 RED 247 10.7 48.2 35.8
BLUE 203 1.12 62.6 66.8 RED 248 3.36 16.6 9.34
BLUE 204 14.1 117* 70.0 RED 257 2.56 12.3 7.19
BLUE 205 114* 61.7 BLQ
Code: * = Values > 100 ng/ml as per dilution procedure
Although some samples were diluted four times according to the validated dilution procedure,
these still had values above 100 ng/ml for some of the analytes, especially for DMTP and DEP.
Such samples were labeled with * following the estimated concentrations.
There are also some samples with concentration values for the analytes below the lower limit of
quantifications. Such samples were labeled BLQ.
According to the results obtained from the subject samples, exposure to organophosphate
pesticides can be inferred for all subjects tested.
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3.7 CONCLUSION
An LC-MS/MS method was developed and partially validated in the laboratory of Clinical
Pharmacology at the University of Cape Town and this method was used in this study to evaluate
the levels of three dialkylphosphate (DAP) metabolites of organophosphates in urine samples of
agricultural workers reported to have been exposed to organophosphate pesticides during normal
working conditions. The detection and quantification of DMP, DMTP and DEP can be used as
markers to indicate organophosphate exposure and the fact that all samples but one, contained at
least one of the three metabolites, indicates that the sensitivity of the method is sufficient for this
purpose.
DuLaurent et al [36] reported a LC-MS/MS method for quantification of DAP metabolites in urine
with a lower limit of quantification (LLOQ) of 2 ng/ml, while Sinha et al [37] developed a LC-
MS/MS method with a LLOQ of 0.028 ng/ml. Although quantification of such low levels of the
DAP metabolites can thus be achieved using LC-MS/MS, the LLOQ obtained in this study was
regarded as suitable for the quantification of the DAP metabolites in the urine samples collected
during the clinical trial as very few of these samples had concentrations below the lower limit of
quantification (BLQ).
The reported presence of the three metabolites in most of the samples is evidence of definite
exposure to the pesticides and such values were also reported in the literature from similarly
exposed persons (Ueyama et al [78] Dulaurent et al [36]). These studies could however not
make distinctions between persons being exposed to normal house-hold levels and those
exposed in the work-place. Comparison between the statistical evaluation reported in
literature and similar evaluation of the results reported in this present study (see Table
3.65) can also not unequivocally proof the nature of the exposure.
Table 3.65 Statistical evaluation of the values of DMP, DMTP and DEP in urine samples
from 187 subjects supposedly exposed to organophosphates
Diakylphospahtes Detected (%) Geometric mean(ng/ml)
Median
(ng/ml)
95th percentile
(ng/ml)
DMP 88 (96*/84**)) 6.45(17*) 6.14(17.7*/20.1**) 32.99(117.4*/50**)
DMTP 97(78*/79**)) 23.01(1.3*) 28.75(1.1*/4.6**) 76.86(83.3*/139.2**)
DEP 98(80*/100**)) 16.99(0.7*) 76.86(0.4*/4.5**) 93.08(14.7*/85.4**)
Comparisons are made between values reported in this study and similar values reported
by Ueyama et al [78] * and DuLaurent et al [36]**.
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Ueyama et al [78] reported urinary concentration levels of DAP metabolites using 23
healthy volunteers (controls) and 25 exposed operators (sprayers). Urinary concentration
levels from the control and exposed group did not show a significant difference.
The values reported by DuLaurent et al [36] were compiled during a study using 19 non-
occasional exposed volunteers and some of the values, especially those representing
maximum levels of DMTP and DEP (95th percentile) are even higher than values obtained
from definite reported exposure.
The obvious uncertainty about baseline levels of organophosphate metabolites and the
relevance thereof to pesticide exposure, compounds the difficulty to use data such as this
reported by the present study to make conclusions regarding exposure. Well controlled
studies are needed which imply difficult ethical decisions regarding the use of study
subjects.
This study however focused mainly on the technical aspects regarding the development of
analytical methods and has proven that LC-MS/MS can successfully be used to detect and
quantify the relevant compounds in a biological matrix.
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CHAPTER 4
SUMMARY
The aim of the development and validation for the quantitative determination of endosulfan in
serum was to obtain data that would correlate exposure and possible levels in the biological matrix
and to compare this to published results.
Similarly, the use of the validated method obtained from UCT to study levels of organophosphate
metabolites in urine of exposed subjects provided data that can be used to monitor such exposure
and correlate it with similar data in the literature.
The OCPs assay was used for the simultaneous quantification of β-endosulfan and one of its main 
metabolites, endosulfan sulfate, in human serum as markers for endosulfan exposure to farm
workers. An AB Sciex API 4000 mass spectrometer at unit resolution in the multiple reaction
monitoring (MRM) mode, using electrospray ionization (ESI) in negative ionization mode was
used to monitor the transitions of the deprotonated precursor ions m/z 405.0 and 421.0 to the
product ions m/z 305.0 and m/z 97.0 for β-endosulfan and the metabolite endosulfan sulfate, 
respectively.
Sample preparation was performed using liquid-liquid extraction (LLE). The analytes were
extracted from serum, adjusted to pH 9, using a solvent mixture of hexane and dichloromethane
(60:40, v/v). The absolute recovery at high, medium and low concentrations of β-endosulfan and 
endosulfan sulfate varied between 93% and 104% with the coefficient of variation within a batch
and between batches, varying from 3% to 14%.
The dried extracts were reconstituted in a mixture of methanol and water (80:20, v/v) and injected
onto the analytical column. Chromatographic separation was achieved on a Supelco® Discovery®
C18 (2.1 mm x 150 mm, 5 μm) analytical column using a mobile phase of acetonitrile, methanol
and water in the ratio 80:80:40, v/v/v at a flow-rate of 200 µl/ml.
The calibration ranges for β-endosulfan and endosulfan sulfate were 0.8 ng/ml to 200 ng/ml and 
0.117 ng/ml to 30 ng/ml, respectively. The accuracy and precision of the method over these
calibration ranges were demonstrated by performing three independent validation batches. A linear
regression model, weighted by1/concentration2 was used to describe the concentration-response
relationship for the analyte and metabolite. A coefficient of determination (r2) of not less than
0.990 was achieved in each validation batch using this regression model throughout the validations
for each batch. Precision and accuracy conformed to the acceptance criteria through the complete
concentration ranges.
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The analytes were proven to be stable in serum when left on-bench at room temperature for 8 hours
and when left overnight as an extract in the auto sampler at 5°C. Freeze-thaw stability was proven
for three cycles. Long term stability of the analytes, stored at the same temperature as subject
samples, could not be proven for the complete storage period but was proven to be stable under
these conditions for at least one month.
The quantification of the analytes was not significantly influenced by co-extracted matrix
components. Haemolysis which can result in high concentrations of red blood cell components in
the serum was shown not to influence the analytical process. However, highly lipemic serum
negatively influenced analysis, most probably due to the fact that ionization was in the negative
mode and the presence of high concentrations of phospholipids in lipemic serum would then have
an effect.
The quantification of β-endosulfan and endosulfan sulfate in this study was performed without the 
inclusion of internal standards. The endosulfans contain six chlorine atoms resulting in extensive
and complicated isotope patterns. Stable isotope labelled congeners of these molecules, containing
either deuterium or carbon-13, would not be specific enough to act as internal standards, since the
resultant isotope patterns of labelled molecules will still coincide with isotope mass-peaks of
unlabelled molecules. Such stable isotope labelled isomers of β-endosulfan and endosulfan sulfate 
could also not be sourced commercially. Other molecules known to ionize well in the negative
mode, and to also contain chlorine atoms such as diclofenac were tested, but found not to
compensate well as internal standards for the endosulfans. Similar chlorinated pesticide molecules
tested were dieldrin and dichlorodiphenyltrichloroethane (DDT), but they could not be used due to
their lack of functional groups ionisable by electrospray. It was therefore decided to perform the
quantifications without internal standard. No adverse effect due to this omission was evident and
since the retention times of both analytes were well separated from the ion front, compensation due
to ionic effects was not deemed necessary.
The validated method was used to analyze 219 serum samples of agricultural workers thought to
have been exposed in their working environment to endosulfan pesticides. No indication of the
analyte and metabolite could be found in any of the serum samples. The reasons for the negative
results may reside in seasonal variation in the application of pesticides used for pest control. This
possibility can be explored by correlating the pesticide products used during or before the period of
sampling.
The second analytical method was used to quantitatively measure urinary dialkylphosphate (DAP)
metabolites as markers to indicated exposure of farm workers to organophosphorus pesticides. The
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developed method was used to determine three DAP metabolites, namely dimethyl phosphate
(DMP), dimethyl thiophosphate (DMTP) and diethyl phosphate (DEP).
The method was used to quantitatively analyze 187 urine samples from agricultural workers
suspected of being exposed to organophosphate pesticides in their working environment.
Different concentrations of the three DAP metabolites could be found in all the samples tested
from agricultural workers from the Hex River Valley where grape farming is practiced, Grabouw
where pome fruit farming is predominant and Piketberg where wheat and fruit farming is practiced.
These OP’s are considered by the World Health Organization [79] as highly hazardous (Class I-b)
and moderate hazardous (Class II), respectively. In the present study, DAP metabolites were
indicated in 100% of the samples with (DMP) in 88%, (DMTP) in 97% and (DEP) in 98% of the
samples tested. Comparatively, in other studies, the frequencies of detection of OPs found in urine
of farm workers were as follows: 96% and 94% for DMP and DEP [80] and 51% and 68% for
DMP and DEP [81], respectively. The results should however be stratified to indicate results from
the control group to determine the level of environmental exposure, as this can also be a source of
DAB metabolites in urine [82].
Some samples contained concentrations much higher than the upper limit of quantification and
even though dilution integrity was proven for concentrations as high as 100 ng/ml, higher levels
will have to be validated to determine the full range of concentrations. On average, the metabolite
found at the highest concentrations was DMTP, followed by DEP and DMT.
Keywords: analytical method, validated, liquid chromatography, multiple reaction monitoring,
electrospray ionization, β-endosulfan, endosulfan sulfate, chromatographic separation, 
calibration range, sample preparation, recovery, mass spectrometry, serum, urine,
dialkylphosphate.
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APPENDIX A: CERTIFICATES OF ANALYSIS
A1. α-Endosulfan 
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A2. β-Endosulfan 
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A3. Endosulfan sulfate
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A4 Endosulfan ether
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A5. Endosulfan lactone
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A6. O,O-Dimethylphosphorothioate (DMTP), potassium salt
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A7. Diethyl hydrogen phosphate (DEP)
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A8. O,O-Diethyl hydrogen thiophosphate (DETP), potassium salt
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A9. Dimethyl phosphate-d6 (d6-DMP), sodium salt (Internal Standard)
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A10. O,O-Dimethyl phosphorothionate-d6 (d6-DMTP), ammonium salt (Internal standard)
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A11. O,O-Di(ethyl-d5) phospate (d5-DEP), sodium salt (Internal Standard)
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APPENDIX B: CALIBRATION CERTIFICATES OF EQUIPMENT
B1. Mass Spectrometer Calibration
Q1 Positive
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Q3 Positive
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Q1 Negative
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Q3 Negative
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B2. Micro balance
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B3. Top loader balance
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B4. Pipette Calibration
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APPENDIX C: MNR-ESD OUTLIER TEST
C1. Analytical Performance of QC level D after Exclusion of Statistical Outliers (β-
Endosulfan)
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C2. MNR-ESD Outlier Test of QC level D (β-Endosulfan) 
The determination of β-endosulfan and endosulfan sulfate in human serum with dialkylphosphate metabolites as urinary 
markers using LC-MS/MS electrospray ionization
187
C3. Analytical Performance of QC level D after Exclusion of Statistical Outliers (Endosulfan-
sulfate)
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C4. MNR-ESD Outlier Test of QC level D (Endosulfan- sulfate)
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APPENDIX D: ADDITIONAL INFORMATION
D1. Examples of a sequence file setup
Validation batch sequence
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On-Bench Stability, Freeze-thaw Stability and Long-term Stability in Matrix
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On- instrument stability
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Production batch
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